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Abstract
Mounting effective adaptive immune responses requires a large naive T-cell population with
a wide diversity of target specificity. Naive CD8' T-cells depend on T-Cell Receptor (TCR)
and ye cytokine signals for their homeostatic survival and proliferation, but differences in
sensitivity to these homeostatic signals among T-cell clones have been generally attributed to
differences in TCR specificity. This thesis describes the novel identification and
characterization of intrinsic heterogeneity in the TCR-independent abilities of CD8' T-cells
to respond to homeostatic ye cytokines, and survive in their absence. These differences were
predictably marked by expression of CD5, a surrogate marker of TCR:spMHC binding
avidity. In vitro, CD5I T-cells proliferate more robustly to saturating levels of the y,
interleukin (IL) cytokines IL-7, IL-2 and IL-15, while CD5" cells have prolonged survival in
the absence of dedicated homeostatic cues. IL-7 is the most critical cytokine for naive T-cell
homeostasis, and a detailed analysis of IL-7 signaling revealed that IL-7 responsiveness is
primarily determined by IL-7 receptor (IL-7R) expression, which is correlated with CD5
expression. While T-cells share common relationships between IL-7-induced signaling and
responses, the signaling network encodes distinct signaling requirements for survival,
proliferation and CD8a induction responses. As a result, all T-cells survive when treated
with high doses of IL-7, but only cells with a critically high level of IL-7R expression can
induce sufficient signaling to proliferate. IL-7 depletion also scales with IL-7R expression,
and the 'overconsumption' of IL-7 by CD5hiIL-7Rh T-cells can compromise their prolonged
survival. In vivo, lymphoreplete mice preserve the homeostatic diversity of CD5 expression
by maintaining physiological IL-7 levels that promote neither preferential proliferation nor
survival of CD5hiIL-7Rh' and CD5'"IL-7R'" T-cells. However, elevated IL-7 levels in
lymphopenic mice or lymphoreplete mice administered with exogenous IL-7 yield
preferential expansion of CD5hiIL-7Rh T-cell subsets, elevating the mean CD5 expression of
the T-cell repertoire. This demonstration of functional intrinsic heterogeneities in IL-7R
expression between CD8' T-cells supports a previously under-appreciated role for IL-7 in
maintaining not only the size but also the diversity of the T-cell repertoire. Furthermore, the
exemplified potential for preferential expansion of more auto-reactive CD5"I T-cells subsets
has important implications for the design of cytokine therapies.
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Chapter 1 Highlights of This Thesis
The human adaptive immune system has been evolved to enable specific responses to a wide
array of foreign pathogens. A major component of our adaptive immune system are T-cells,
each of which is capable of detecting a different set of foreign antigens comprised of
peptides bound to major histocompatability complexes (pMHC) via their unique T-cell
receptor (TCR). T-cells are continually produced in the thymus where they obtain their
unique specificity and are selected for tolerance to binding to self-pMHC (spMHC).
Functional mature T-cells are then exported into peripheral tissues where they survey for
infection. In order to exploit our immune capacity, our bodies must therefore strive to
maintain a peripheral T-cell repertoire of maximum size and functional diversity of TCR
specificity within a defined physical space and with limited chemical resources. It is well
established that the critical chemical factors regulating peripheral homeostasis are spMHC
and interleukin-7 (IL-7) [1]. However, relatively little is known about the independent
abilities of these homeostatic cues to stimulate survival and proliferation across the T-cell
repertoire and how they coordinate to control homeostatic population size and diversity.
This thesis undertakes a detailed analysis of CD8' T-cell homeostasis, with a particular focus
on the role of cytokine signaling. It characterizes novel functional differences among CD8'
T-cells in their intrinsic cytokine responsiveness and survival capacities in the absence of
homeostatic stimuli. This work reveals an important role for IL-7R expression in regulating
the ability of T-cells to respond to and manipulate their cytokine environment. These
findings have critical implications for our understanding of the maintenance of T-cell
homeostasis and how the T-cell repertoire might be altered by cytokine therapies.
1.1 Homeostasis of T-Cell Population Size and Diversity: Open
Questions
The size of the T-cell pool remains stable throughout most of life [1]. This occurs despite
changes in the rate of naive T-cell production as we age, periodic bouts of infection invoking
massive effector T-cell proliferation and subsequent population contraction, and accruement
of memory T-cells. Maintaining the T-cell population size therefore requires a careful
dynamic balance of generation, survival, proliferation and differentiation. In addition to
regulating population size, maintaining the homeostasis of functional diversity of the naive
T-cell repertoire also requires balancing these effects across TCR specificities. The
maintenance of T-cell homeostasis is believed to occur via competition for homeostatic
survival factors in the form of IL-7 and spMHC. The presiding model is that competition
for a diverse pool of cognate spMHCs maintains the diversity in the T-cell repertoire [1-3],
while IL-7 availability regulates the overall size of the naive T-cell population [4, 5].
However, exclusive attribution of the control of T-cell diversity to TCR interactions requires
two critical assumptions. The first maintains that T-cells with different TCR specificities
have equal responses to available cytokines. The second is that all T-cells have equivalent
requirement for survival signals, meaning they survive equally well in the absence of
homeostatic stimulation. However, neither of these assumptions has been explicitly tested.
Despite the stringency for thymic selection, the naive T-cell repertoire comprises a
distribution of TCR:spMHC interaction strengths which are reflected in their level of TCR
signaling-induced CD5 expression [6-9]. Studies have suggested that CD5"' T-cells have a
competitive advantage as a result of their stronger avidity TCR:spMHC interactions [10, 11].
This poses a potential challenge for the homeostasis of T-cell diversity. As described by the
'competition-diversity paradox', this should result in a narrowing of diversity favoring
stronger avidity spMHC interactions [12, 13]. Interestingly, this narrowing is not observed in
normal T-cell replete mice, but enhanced proliferation of CD5hi T-cells can be observed in
lymphopenic environments with depleted T-cell pools [10, 11]. While differences had
heretofore been attributed solely to differences in spMHC availability, IL-7 levels also differ
between normal and lymphopenic environments. This offers prospect that IL-7 signaling
may contribute to the observed differences both between different environments and
amongst T-cells with varying avidity for spMHC. However, the ability for variations in IL-7
availability to influence the survival and proliferation of T-cells with different TCR avidities
has not been characterized.
This thesis aimed to address the aforementioned gaps in our understanding of the regulation
of T-cell homeostasis by carefully examining the role of cytokine signaling in promoting
survival and proliferation of CD8* T-cells of varying TCR specificity.
1.2 Heterogeneity in T-Cell Cytokine Responsiveness and Turnover
Previous studies have attributed all variations in the responses of T-cells to homeostatic cues
to differences in their TCR specificity. However, this thesis identifies novel heterogeneities
among mature CD8' T-cells in their functional responsiveness to IL-7 in the absence of
TCR stimulation. We find that differences in IL-7 induced survival, proliferation at CD8a
inductions between CD8' T-cells are predictably marked by their relative CD5 expression,
whose levels are independent of IL-7 stimulation and maintained in the absence of spMHC.
Only T-cells with high levels of CD5 are able to proliferate under IL-7 stimulation.
Conversely, while all T-cells can survive at high IL-7 doses, CD5'" T-cells have prolonged
survival when deprived of IL-7R and TCR stimuli. The IL-7 environment can therefore be
varied to favor CD5I or CD5" T-cells at high or low IL-7 doses respectively. Differences in
IL-7 dependent responses and CD5 expression were present even within monoclonal TCR-
transgenic populations, and were maintained following priming/differentiation, suggesting
these properties are intrinsic to an individual T-cell. CD5hI T-cells also had enhanced
responses to the related cytokines IL-2 and IL-15, indicating potential globally enhanced
cytokine responsiveness.
Our data suggest the mature T-cell pool is comprised of populations that differ not only in
their TCR sensitivity, but also in their intrinsic cytokine sensitivity. Furthermore, co-variation
of responses with TCR:spMHC avidity suggests an unappreciated role for IL-7 signaling in
previously observed heterogeneous T-cell responses. Whereas the enhanced LIP of CD5 T-
cell clones in IL-7 rich lymphopenic environments had been attributed to their greater
avidity for spMHC [10, 11], our data suggests enhanced IL-7 signaling may also potentiate
proliferation. IL-7 signaling may thereby play a role in shaping both the size and the
diversity/composition of the T-cell pool.
1.3 IL-7R as a Critical Controller of IL-7 Responsiveness
While many of the critical signaling pathways induced by IL-7 have been identified, few
studies have quantitatively characterized IL-7 signaling across T-cell specificities in the
absence of spMHC stimulation. To determine the signaling network basis of heterogeneous
IL-7-induced responses among T-cells, we therefore undertook a detailed analysis of IL-7
signaling in CD5"' and CD5" T-cells. Intriguingly, our data suggests that high IL-7R
expression on CD5"' T-cells is the primary determinant of their enhanced IL-7
responsiveness. While proximal signaling capacity scaled directly with IL-7R expression, T-
cells shared common relationships between their cytokine-induced signaling and responses,
including survival, proliferation and CD8a induction. However, the signaling network
encodes distinct signaling requirements for each response, such that all cells induced
sufficient signaling to survive, but only cells with critically high IL-7R expression could
initiate proliferation. This sharp signaling threshold is thereby responsible for generating
large differences in functional cytokine responses from a comparably narrow distribution of
IL-7R expression across the T-cell repertoire. Thus, while different IL-7 dose requirements
for survival versus proliferation had been suggested [14], our data suggest both the IL-7
environment and IL-7R expression determine an individual cell's response.
1.4 IL-7R as Regulator of the IL-7 Environment
Tight control over IL-7R expression is thought to be critical for regulating competition for
limiting pools of IL-7 amongst T-cells [5]. In the altruistic model of IL-7 regulation, negative
feedback to IL-7R expression maximizes the naive T-cell population size via scaling receptor
expression with the need for IL-7 signaling amongst naive T-cells cycling in and out of IL-7
rich lymphoid organs [5, 15]. However, this model makes assumptions of equal basal IL-7R
expression and requirements for survival signaling that our data shows to be invalid. We
therefore sought to characterize the ability of cells with heterogeneous IL-7R expression to
deplete their IL-7 environment and survive in limiting IL-7 conditions. We demonstrate that
the cellular consumption of IL-7 scales directly with IL-7R expression. However, depletion
of IL-7 doesn't necessarily scale with persistence, as IL-7Rhi cells can 'overconsume' IL-7
early in culture, compromising their later survival. This suggests that the population size may
not necessarily be maximized with available IL-7. Furthermore, while IL-7 levels in vi'o were
thought to scale inversely with total cell numbers [4], our data suggests possible cytokine
scaling inversely with total IL-7R expressed amongst those T-cells. Interestingly, we found
that T-cells require periodic contact with IL-7 on timescales that match their proposed
cycling times through IL-7 rich lymphoid organs [16, 17]. As IL-7 signaling is known to
induce expression of key trafficking molecules [2, 18], heterogeneous IL-7R expression may
therefore be converted to heterogeneous trafficking patterns.
1.5 IL-7 As Controller of the Homeostasis of CD5 Expression In Vivo
While our data revealed TCR-independent heterogeneities in IL-7 signaling between T-cells,
in zivo encounters with cytokine occur in the presence of spMHC stimulation. To determine
the physiological consequences of cytokine-dependent heterogeneities amongst T-cells, we
therefore examined the relative capacity of CDSI and CD5'" T-cells to survive and
proliferate in both normal mice and when IL-7 is elevated during lymphopenia or IL-7
therapy. Intriguingly, normal lymphoreplete mice were found to maintain a homeostatic
balanced between CD5I and CD5" subsets. At first this is somewhat perplexing, as co-
variation of cytokine responsiveness with TCR:spMHC avidity could be expected to
accentuate the problem posed by competition/diversity paradox, and favor population
dominance by CD5hIL-7Rhi T-cells. However, an in vivo bioassay indicated that
lymphoreplete mice maintain IL-7 concentrations that favor neither selective persistence nor
survival CD5" or CD5"I T-cells. However, when IL-7 levels become increased during
lymphopenic IL-7 treatment, CD5 h T-cells have a proliferation advantage, and the resulting
T-cell repertoire shifts towards higher CD5 expression.
Our data indicates that IL-7 is not only a regulator of the size of the T-cell population, but
also significantly impacts the diversity of TCR avidities in vivo, reflected in the distribution of
CD5 expression across the repertoire. Expansion of more self-reactive clones has been
linked to autoimmune progression [19, 20], and enhanced IL-7 signaling has been proposed
as a contributing factor in leukemia [21]. Therefore while the therapeutic use of IL-7 may
expand overall T-cell numbers, it may have the unintended consequence of preferentially
expanding undesirable T-cell populations. Given the increasing interest in IL-7 based
therapies, further investigation of the intrinsic differences in the signaling networks across T-
cell populations will help us understand the clinical impact of skewing the T-cell repertoire
toward a CD5"IL-7R"' or CD5"IL-7R(" phenotype.
1.6 Integrated Quantitative Systems Analysis of T-Cell Homeostasis
While many of the critical mediators of spMHC -and cytokine- induced signaling have been
identified, there is relatively little know about how these signals integrate collectively control
T-cell responses [1]. While IL-7 induced signals are the most critical for naive T-cell
homeostasis, related cytokines, such as IL-2 and IL-15, have partially overlapping functions
mediated by shared receptor components and downstream signaling pathways [22]. TCR-
mediated signaling cross-talk with cytokine-induced signaling has also been proposed to yield
both synergistic [23] and inhibitory [24] responses. Moreover, there exist multiple modes of
feedback regulating cell responses, encoded both within cell-intrinsic signaling networks, and
between networks of cells in their coordinated regulation of production, consumption and
access to homeostatic spMHC and cytokine resources. Understanding the often non-
intuitive behavior resulting from these complex interactions begs for an integrated
quantitative systems approach. Using mathematical modeling to interpret and inform the
design of experiments measuring quantitative and dynamic signaling and responses has
proven to be a powerful method for deconvoluting key regulatory relationships from
complex network behavior [25]. This thesis begins by undertaking a theoretical examination
of the properties of the IL-7R signaling network architecture that may contribute to
regulatory control under stimulation with IL-7 alone or in the context of other TCR and
cytokine cues. Although the remainder of this thesis is devoted to the experimental
characterization of T-cell behavior, its design is motivated by this quantitative approach, and
opportunities to use data to inform quantitative models that may extend our understanding
of the system behavior is highlighted throughout. In particular, we describe how the data
presented here, combined with mathematical modeling, can be potentially used to inform the
improved design of cytokine therapies.
1.7 Outline of Chapters
Chapter 2 reviews IL-7R and TCR signaling and current models for their regulation of the
homeostasis of T-cell population size and diversity.
Chapter 3 undertakes a theoretical examination of the properties of the IL-7 signaling
network architecture contributing to signaling control under stimulation with IL-7 alone or
in the context of other TCR and cytokine cues.
Chapter 4 presents novel experimental findings supporting heterogeneous intrinsic cytokine
responsiveness among T-cells in the absence of TCR stimulation that correlates with CD5
expression. Also demonstrated are previously unappreciated differences in the survival of T-
cells in the absence of homeostatic stimulation.
Chapter 5 delves into a quantitative signaling analysis of IL-7-induced responses that reveals
IL-7R expression as the dominant controller of cytokine responsiveness. While T-cells are
shown to share common signal-response relationships, the IL-7 signaling network is revealed
to encode distinct IL-7R signaling requirements for survival versus proliferation.
Chapter 6 determines how observed in vitro variations in IL-7 sensitivity and turnover
translate to the in vivo environment, specifically examining how IL-7 levels in vivo maintain
homeostasis and the effects of IL-7 therapy on the composition of the T-cell pool. Observed
variations in IL-7 levels are used to re-interpret previous data in support of TCR-mediated
variations between T-cells from different TCR-transgenic mice.
Chapter 7 ascertains the relative ability of T-cells with heterogeneous IL-7R expression to
deplete their IL-7 environment, and examined the consequences of consumption on cell
persistence and maintenance of population size.
Chapter 8 discusses in detail the implications of heterogeneity in IL-7R expression, cytokine
responsiveness and turnover amongst T-cells, and proposes revised models for the
regulation of population size and diversity with particular regard to the application of IL-7
therapies.
Chapter 9 proposes future studies in which experimental and computational approaches are
used to clarify how signaling originating from TCR and other cytokine receptors interacts
with IL-7, and design optimal therapeutic IL-7 dosing strategies.
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Chapter 2 Signaling Control of T-Cell Homeostasis
2.1 Homeostasis of T-Cell Population Size & Diversity
2.1.1 T-Cell Development and Function
T-cells function to specifically recognize foreign pathogens during infection. Critical to this
function is the expression of a unique T-cell receptor (TCR) by individual T-cells. Through
genetic recombination of TCR genes during early development, upwards of 10"5 TCR
variants can be expressed [3]. In the thymus, a small fraction of T-cells are selected for the
ability for their TCR to weakly recognize endogenous peptide fragments bound to major
histocompatibility complex (MHC) molecules on the surface of antigen presenting cells
(APCs). In this process - termed positive selection - those T-cells that don't recognize self
peptide-MHC (spMHC) die by neglect. Potentially autoreactive TCRs that bind spMHC
ligands strongly are eliminated by a negative selection process. During thymic maturation, T-
cells also acquire one of two TCR co-receptors, CD4 or CD8, the latter of which is of
interest to the studies discussed in this thesis. These fully mature 'naive' T-cells leave the
thymus and enter the peripheral lymphoid organs, tissues and circulation.
In the periphery, naive T-cells must remain tolerant of weak interactions with self-peptides.
While selection eliminates T-cells bearing TCRs that interact with spMHC too strongly or
too weakly, there remains a distribution of different TCR:spMHC avidities over which
tolerance is maintained. During infection, T-cells encounter foreign or 'agonist' peptide-
MHC (pMHC) ligands not present during thymic development, and those T-cells capable of
binding strongly to agonist MHC are activated by strong signaling through their TCR. These
cells undergo clonal expansion and differentiation to produce a large number of 'effector' T-
cells which perform functions specific to pathogen clearance. After clearance, the majority of
effector cells die in a contraction phase. However, a small population of 'memory' T-cells
remain which are able to mount a quicker immune response upon reencounter with the same
foreign peptide than their naive counterparts.
2.1.2 T-Cell Homeostasis
Maintaining an extensive diversity of TCR expression is critical to ensuring the presence of
T-cells in the periphery that are strongly reactive to any particular foreign peptide, but not to
self peptides. This diversity is strongly connected to overall size of the T-cell repertoire [3].
The objective of immune system homeostasis at its simplest can therefore be summarized as
how to maintain the maximum number of tolerant T-cells within a defined physical space
with limited chemical resources. T-cells are maintained in the periphery at very stable
numbers over most of an animal's lifetime [26, 27]. A careful balance of T-cell generation,
survival, death, proliferation and differentiation shapes the naive T-cell repertoire (Fig 2.1).
Export of newly developed naive T-cells from the thymus continually replenishes the T-cell
pool, while naive T-cell loss occurs via activation and differentiation into memory cells, as
well as death during normal T-cell turnover.
Naive T-cells in 'lymphoreplete' hosts - those with a full T-cell compartment - are normally
quiescent and only proliferate only when encountering a foreign antigen [1, 2]. However, T-
cell proliferation can occur in T-cell-deficient - or 'lymphopenic' - hosts, termed
'homeostatic' proliferation or 'lymphopenia-induced' proliferation (LIP), which results in
partial restoration of T-cell population sizes [2, 28]. Regulation of T-cell numbers is
therefore frequently studied by adoptively transferring T-cells into lymphopenic recipients.
There is considerable debate over the relevance of LIP to T-cell maintenance in normal T-
cell replete hosts [2, 29, 30], but there are arguably common mechanisms controlling cell
viability and turnover [1, 2, 31]. Furthermore, LIP likely also contributes significantly to
recovery of T-cell counts where the hematopoeitic system is severely compromised, such as
arising from whole body irradiation, chemotherapy or viral immunodeficiency [32, 33].
Lymphopenia also occurs in both early and late stages of life where thymic output is
insufficient to fill the T-cell pool, and its study is therefore relevant to understanding how T-
cell numbers and diversity are initially established and are impacted by ageing.
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Figure 2.1. Dynamic Regulation of T-Cell Homeostasis
A schematic diagram of the dynamic balance of inputs and outputs required to maintain homeostasis
of the naive T-cell repertoire. New naive T-cell cells are continually exported from the periphery.
Mature cells then rely on signaling from limited amounts of survival 'resources' in the form of
cytokines and peptides released by and presented on stromal cells. While naive T-cells are normally
quiescent, under conditions where resources are in excess, cells can undergo limited division, termed
lymphopenia-induced proliferation (LIP). Cells exit the naive T-cell pool when they become activated
via contact with foreign antigens. These cells clonally expand and differentiate into effector cells.
Most cells are clonally deleted after the infection is cleared, but a fraction persists as memory cells.
Direct exist of T-cells from the naive T-cell repertoire also occurs via normal T-cell turnover when
faced with resource limitations. Lastly, this system must also respond when faced with acute system
perturbations such as cell or cytokine therapies, or severe T-cell depletion after chemotherapy or viral
attack.
One interesting feature of LIP is that proliferating cells acquire phenotypic and functional
similarity to memory T-cells [2, 28, 33, 34]. Naive T-cells undergoing division in
lymphopenic hosts upregulate the memory cell markers CD44, CD122 (IL-2RS) and
lymphocyte 6 complex (Ly6C) [35]. When activated with an agonist, they also acquire the
ability to make IFN-y, upreglate CD69 and downregulate TCR quicker than their naive
predecessors [35]. The lack of both effector cell formation and CD28 and IL-2 signaling
requirements during memory T-cell generation by LIP distinguishes it from antigen-induced
memory cell production [28]. However, both processes share common features including
TCR ligation and cell division [28, 36], and the resulting expression profiles are closely
matched [31].
2.1.3 Homeostatic Signals Regulating T-Cell Population Size and Diversity
Once naive T-cells have exited the thymus, they persist for at least several weeks in the
periphery [2]. Their turnover is not regulated by an intrinsic survival clock, but rather by
competition for limiting amounts of 'resources' required for their continued persistence. The
two most critical homeostatic signals regulating both the survival and proliferation of T-cells
have been identified as T-cell receptor (TCR) binding to self-peptide MHC (spMHC) and
interleukin 7 binding to the IL-7 receptor (IL-7R) [1, 2] (Fig. 2.2). Competition for these
limiting resources - also referred to as 'space' - determines both the size and the diversity
(or composition) of the T-cell repertoire. The presiding model is that the diversity of the T-
cell repertoire is determined primarily via competition for a diverse pool of cognate
spMHCs. In contrast, IL-7 availability is thought to regulate the overall size of the naive T-
cell population, with each T-cell responding equally to IL-7. However, there is increasing
evidence that a model supposing distinct roles for IL-7R and TCR signaling may be too
simplified. Recent studies have suggested that IL-7R signaling in T-cells may vary with the
strength of their spMHC signaling as a result of cross-talk between the TCR and IL-7R
signaling pathways [24]. Yet these studies still imply that differences in TCR specificity
underlie heterogeneities in ability of T-cells to respond to homeostatic cues. One particularly
important point of contention with this model is that assumptions of equal reliance on and
responses to cytokines amongst T-cells of different TCR specificities have not been
rigorously tested. Potential heterogeneities in IL-7-induced proliferation and survival
responses amongst naive T-cells with different specificities would call for a re-examination
of the classical roles of TCR and IL-7R signaling in the homeostasis of T-cell population size
and diversity.
Figure 2.2. T-Cell Homeostatic Cues
Naive T-cell survival and proliferation are dependent upon TCR binding to self peptides (sp) found
to major histcompatibility complex (MHC) presented on antigen presenting cells (APCs) as well as
soluble interleukin-7 (IL-7) secreted by stromal epithelia, which binds to the heterodimeric IL-7
receptor (IL-7R) composed of IL-7Ra (CD127) and the common gamma chain (yc/CD132).
In the following sections we discuss the evidence supporting the importance of TCR and IL-
7R signaling in the regulation of homeostatic naive T-cell survival and proliferation. We
discuss both initial experiments supporting their distinct roles in the control of T-cell
population size and diversity and new data that challenges this simplified model. We
highlight unaddressed questions regarding the homeostasis of the T-cell repertoire, with a
particular focus on those relating to the role of cytokine signaling that this thesis aims to
address.
2.2 Role of TCR in T-Cell Homeostasis
2.2.1 Requirement for spMHC:TCR Engagement for Survival/Proliferation
Although strongly self-reactive cells are eliminated during selection, positive selection
requires some reactivity with self [37]. Several experiments have demonstrated the continued
requirement for weak spMHC-induced TCR signaling for mature T-cell survival,
proliferation and maintenance of function in the periphery [2]. Transfer of T-cells into hosts
lacking relevant MHC ligands leads to their death [38-401, as does the inducible loss of TCR
expression [41] or the Src kinases Lck and Fyn required for TCR signaling [42]. While these
studies all involved lymphopenic hosts, a recent study has demonstrated a requirement for
TCR:spMHC engagement within normal replete hosts [43]. Microscopy reveals that in the
absence of infection, naive T-cells are continually establishing transient contacts with
spMHC within lymph nodes [44]. These low-affinity interactions upregulate CD3
phosphorylation that is abrogated upon loss of contact [42, 45]. However, it is controversial
whether this signaling is functional or whether TCR:spMHC engagement elicits other signals
or guides cell localization to receive additional stimulation, such as IL-7. Each T-cell receptor
is able to bind to a variety of different peptides, albeit with differing affinity [3, 46, 47]. It is
generally thought that the same self-peptides mediating positive selection in the thymus are
responsible for maintaining survival and inducing proliferation in the periphery [34, 38, 40,
48, 49].
2.2.2 Mechanisms for TCR-Mediated Control of Diversity
Although it is the general consensus that diversity in the T-cell repertoire is maintained via a
requirement for TCR:spMHC engagement, there is some controversy over the mechanism
[1, 2]. Some studies suggest that there is intraclonal competition between cells of the same
specificity, but not between cells of different specificity [50-52] (Figure 2.3a). As such, the
expression and access to cognate spMHC expression limits the diversity of the T-cell
repertoire. This model for competition is supported by recent work looking at clonal
abundance (-20-200 for each epitope) [53], and the selective survival/proliferation of T-cell
clones when their numbers are shifted above or below this apparent steady state [54]. Other
work suggests there is a hierarchy between T-cells of different specificity in their capacity to
compete for spMHC [10, 11, 55, 56]. There are two proposed models for a hierarchy in
competitiveness [2]. The first suggests that TCR promiscuity, or the diversity of cognate
spMHC that a T-cell can engage, determines competitiveness [56] (Figure 2.3b). The second
suggests that not all interactions with spMHC are equal, and that stronger and/or more
frequent interactions directly provide stronger survival signals [10, 11] or allow cells
enhanced ability to compete for other survival factors [55] (Figure 2.3c).
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Figure 2.3. Models of T-Cell Competition
Schematic of proposed models for the mechanisms of homeostatic competition regulation the size
and diversity of the T-cell repertoire. (a) In the 'interclonal competition' model, T-cell diversity is
maintained strictly via competition between T-cells of a given specificity for the available number of
spMHC. T-cells of one specificity die or proliferate independently of another specificity to use all
available resources. (b) In the 'interclonal dominance through promiscuity' model T-cells with the
broadest array of spMHC specificity have enhanced capacity to compete for limited spMHC. (c) In
the 'interclonal dominance through fitness' model T-cells with a greater ability to compete for
homeostatic factors, either directly via higher avidity specific TCRspMHC interactions, or resulting
increased access to cytokine resources, are able to dominate the population. Adapted from Takada K
and SC Jameson, 2009 [2].
2.2.3 Role of TCR Affinity in Regulating Homeostasis
Several studies examining competition between T-cells have suggested an important role for
the affinity of TCR-spMHC interactions in regulating T-cell homeostasis [10, 11, 57]. When
TCR-transgenic (TCRtg) T-cells of different TCR specificity were adoptively transferred into
lymphopenic hosts, their relative ability to survive and proliferate strongly correlates with
CD5 expression [10, 11, 57]. In particular, donor T-cells were only able to expand upon
adoptive transfer into TCRtg hosts when the recipient CD5 expressing was less than that of
the donor [10]. CD5 is a putative negative regulator of TCR signaling [58] that is up-
regulated upon spMHC engagement [7]. Thus, CD5 expression levels are thought to reflect
the strength of TCR-spMHC interactions [6-9] (Figure 2.4). As such, CD5' T-cells are
thought to have increased homeostatic survival and proliferation properties as a result of
greater ability to compete for spMHC. One proposed implication of selective expansion of
higher avidity T-cells is that LIP may skew the T-cell repertoire toward greater self-reactivity
[59]. Although, as noted by Takeda & Jameson [2], even cells with the greatest ability to
compete will still reach some maximum number limited by cognate spMHC expression and
other survival resources.
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Figure 2.4. CD5 as an Indicator of TCR:spMHC Signal Strength
CD5 expression is increased as a result of spMHC interactions, and CD5 is therefore often used as a
proxy for TCR avidity for spMHC. Here, we show a panel of TCR-transgenic T-cells which vary in
their CD5 expression in the order F5<2C<OT1, and this hierarchy is reflected in their capacity to
proliferate under lymphopenia (Ge, Bai et al. 2004).
2.2.4 TCR Signaling in Naive T-Cell Survival and Proliferation
Aside from knowledge of some downstream TCR signaling activity following spMHC
binding (evidenced by zeta chain phosphorylation), the exact signaling pathways critical for
spMHC dependent survival and proliferation are not well characterized. For cells undergoing
slow proliferation in lymphopenic hosts, microarray analysis suggests that signaling activity
resembles that typical of IL-7 and TCR under activating stimuli, though at much lower levels
[31]. Potentially critical to the regulation of spMHC signaling is feedback control to TCR
signaling. As highlighted above, TCR signaling is believed to induce negative feedback to its
own signaling via upregulating expression of CD5, a scavenger receptor whose intracellular
tail binds phosphotases that inhibit TCR signaling [6]. TCR:spMHC signaling is also
proposed to modulate expression of the CD8 coreceptor, which promotes binding to MHC
[24]. TCR signaling is therefore believed to tune its relative activation thresholds via
balancing feedback to CD5 and CD8O expression, though the mechanisms regulating this
feedback, and whether they equalize signaling activity across different affinity TCRs, remain
unknown.
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2.2.5 Summary: TCR Signaling Control of T-Cell Homeostasis
In summary, it is clear that contact with spMHC is essential for regulating T-cell survival and
function in vivo. Current studies suggest that the diversity of spMHC presentation determines
the diversity of TCR expression of the T-cell repertoire, though there is some debate over
whether there is a hierarchy in competitiveness between T-cells for overlapping spMHC
specificity or access to spMHC and/or other resources.
2.3 Role of Cytokine Signaling in T-Cell Homeostasis
2.3.1 Homeostatic Requirement for IL-7 & Regulation of Population Size
Many experiments have demonstrated the requirement of IL-7 in both naive and memory T-
cell survival and proliferation [60-62]. IL-7Ra( and IL-7 mice are lymphopenic because
IL-7 is critical to normal thymic development [63, 64]. The first demonstrations that IL-7
was involved in T-cell maintenance were therefore performed by treating thymectomized
mice with anti-IL-7 antibodies, which resulted in severe T-cell depletion [65]. Similar results
were seen upon transfer of naive T-cells into IL-7 / hosts [64]. Conversely, transgenic
expression of IL-7 or exogenous IL-7 treatment results in increased T-cell expansion [66-68].
This lead to the suggestion that IL-7 might act as a limiting factor for the size of the T-cell
pool [4, 5].
Other interleukin cytokines may also play a role in naive T-cell survival. For instance, IL-15
can often substitute for IL-7, though it appears to more critical for memory cell maintenance
[69, 70]. Similarly, IL-2 can also provide some survival signaling to naive T-cells, though its
presence in vivo is usually restricted to periods of production by effector T-cells following
their activation, and these cells are much more sensitive to and reliant on IL-2 than naive T-
cells. There is some evidence that naive T-cells in titro are also maintained by IL-4, IL-6 and
TSLP [71-73]. However, in viio IL-7 appears to be the most important and other interleukin
family cytokines are either not required or delivering redundant signals [62, 64, 74].
IL-7 is not produced by T-cells themselves, but is rather produced primarily by fibroblastic
reticular cells in the T-cell zones of secondary lymphoid organs (SLOs) [75]. IL-7
concentrations in the serum have been estimated to be at or below the current limit of
detection of approximate -1 pg/mL [76], However, IL-7 is believed to remain highly
localized at its sites of production by virtue of binding to the extracellular matrix following
secretion, as has been shown for other related cytokines [77]. While recent studies suggest
some potential mechanisms for feedback to IL-7 production by dendritic cells following
binding of displayed spMHC by CD4' T-cells [76], for the most part IL-7 is thought to be
produced at relatively constitutive rates [1]. The balance of constitutive production and cell-
mediated consumption and degradation is therefore thought to regulate IL-7 concentrations
in vivo, such that that there is a linear inverse scaling of population size with in vimo IL-7 levels
[4].
In accordance with its purported role as a limiting factor for population size, cell-mediated
consumption of IL-7 levels is thought to drive cytokine to very low levels barely sufficient to
support T-cell survival [2]. However, in lymphopenic hosts, the rise in IL-7 levels resulting
from reduced cellular consumption are believed to play an important role alongside spMHC
in potentiating LIP [2]. Proliferation would thereby continue until IL-7 and/or spMHC
resources are depleted. In addition to regulating survival and proliferation responses, IL-7
signaling is thought to be critical for maintaining cell function [1]. In particular, IL-7
signaling may act to prime cells, lowering their TCR signaling threshold for activation [78].
2.3.2 IL-7R Signaling Control of T-Cell Survival and Proliferation
IL-7 binds to a dimeric receptor composed of the IL-7RaX chain (CD127) which is specific
to IL-7 binding, and the common gamma chain ye (CD132) which is a shared component of
the multimeric receptors of several related cytokines including IL-2, IL-4, IL-9, IL-15 and
IL-21 [22, 70]. These cytokines are often referred to as IL-2 family or ye cytokines. As 7, is
expressed ubiquitously on the cell surface, responsiveness to IL-7 at the receptor level is
controlled primarily by IL-7RX abundance. IL-7 binding to IL-7R is thought to regulate T-
cell responses primarily via activation of two signaling pathways which are important across
multiple 7c cytokines: Jak-Stat and PI3K/Akt [1, 2, 22] (Figure 2.5).
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Figure 2.5. Interleukin-7 Signaling Network
Interleukin-7 is thought to regulate T-cell responses primarily via activation of the Jak/Stat and
PI3K/Akt pathways. Shown are the major pathways controlling cell survival, proliferation,
migration/trafficking and metabolism. While Jak/Stat and PI3K/Akt have been shown to be
independently important in each of these responses, it is clear that there is some degree of signaling
pathway crosstalk. Adapted from Takada and Jameson (2009) [2].
Jak-Stat Signaling
The primary signaling pathway initiated by IL-7 is Jak-Stat activation. IL-7 binds to IL-7Ra
with high affinity, mediating recruitment of the y chain. This leads to reciprocal tyrosine
phosphorylation of Janus kinases Oaks) which are constitutively associated with the
cytoplasmic tails of the receptor chains: Jak1 and Jak3 with the a and y chains respectively.
Activated Jaks phosphorylate tyrosine residues on the cytoplasmic tails of the opposing
receptor chain. These serve as docking sites for the SH2 domain of the Signal Transducer
and Activator of Transcription (Stat) proteins 1, 2, 3 and 5. Stat5 appears to be the most
critical for IL-7 signaling, though it is activated by many other ye cytokines, notably IL-15
and IL-2 [79]. Jak-mediated Stat5 phosphorylation leads to Stat5 dimerization. Dimerized
Stats then translocate to the nucleus where they regulate transcription of many genes,
including ye cytokines [80]. Stat5 - mice have decreased T-cell numbers [81-83], while
overexpression enhances peripheral expansion of T-cells [84], suggesting a critical role for
Stat5 in peripheral T-cell homeostasis. Jak-Stat signaling also induces negative feedback
through transcriptional upregulation of CIS and Socsl [85]. Socsl binds to Jak kinases,
inhibiting their activity, whereas CIS inhibits Stat recruitment to the cytokine receptors [85].
PI3K/Akt signaling
IL-7 binding also induces the activation of P13K and one of its key downstream targets, Akt.
P13K and Akt are critically implicated in many cytokine survival signals and can also induce
cell cycling and gene transcription [22, 86, 87]. However, what little is known about their
mechanisms of action is largely derived from studies of other IL-2 family cytokines and the
relevance to IL-7 signaling is often uncertain. The activation of P13K is linked to receptor
signaling by the activity of the Jak kinases, which phosphorylate P13K upon recruitment via
its SH2 binding domain [88].
Survival Signaling
The major mechanism by which IL-7 is thought promote cell survival is by altering the
balance between pro- and anti-apoptotic factors of the Bcl-2 family, which regulate the
intrinsic mitochondrial cell death pathway [2, 89]. IL-7 induces the anti-apoptotic proteins
Bcl-2 and Mcl-1 [90], and inhibits pro-apoptotic proteins Bax [91], Bad [92], and Bim [93].
Both Jak-Stat and PI3K-Akt signaling are thought to contribute to this mechanism of pro-
survival signaling [2]. However, overexpression of Bcl-2 or Bim gene knockouts only
partially rescues T-cell survival in IL-7R deficient mice [94, 95], suggesting other IL-7-
induced signaling pathways contribute to survival. P13K-mediated activation of mTOR [72]
and upregulation of the glucose transporter Glut1 [96] are thought to be critical for
preventing cell atrophy upon cytokine removal [97]. IL-7-induced PI3K-Akt signaling can
also affect rates of T-cell trafficking to sites of IL-7 production at SLO via Foxol inhibition
[98], as Foxol upregulates important homing molecules such as CCR7 and CD62L (L-
selectin) [18].
Proliferation Signaling
Comparably less is known about signaling implicated in IL-7-mediated proliferation
responses than its regulation of survival. Studies in IL-7-dependent T-cell lines have
demonstrated mechanisms by which IL-7 may directly control proliferation. Li et al. show
that IL-7 withdrawal leads to post-transcriptional upregulation of the Cdk2 inhibitor p27P'
leading to G1 cell arrest, while cytokine re-addition lead to PKC -mediated p27 Kil
degradation and S phase entry [99]. The same group also found that IL-7 stimulates the
phosphatase Cdc25a to remove an inhibitory phosphate on Cdk2 [100]. Akt modulates
PKCO activity, suggesting a potential role for the PI3K-Akt pathway in mediating
proliferation responses. Akt-mediated Foxol inhibition may also be involved in IL-7-
mediated proliferation, as Foxol also inhibits P271P1 [97, 99]. Thus while mechanisms for
IL-7 induced proliferation have for the most part not been shown directly in primary cells,
these studies suggest a role for IL-7 signaling beyond simply mediating T-cell survival.
2.3.3 Regulation of IL-7R Expression
As y is expressed ubiquitously on the surface of almost all hematopoietic cells and is shared
amongst multiple cytokine receptors, responsiveness to IL-7 at the cell surface is controlled
primarily via IL-7Ra expression [5]. Multiple signals regulate IL-7Ra expression, including
TCR signaling, other cytokines, and IL-7 itself [5, 15, 22, 101]. In addition to surface
receptor loss due to internalization following IL-7 binding [102], IL-7R signaling leads to
transcriptional downregulation of IL-7Ra expression [15]. Receptor downregulation occurs
via induction of the transcriptional repressor GFI1, a mechanism common to multiple
cytokines regulating IL-7R expression [15].
Negative feedback to IL-7R expression is thought to be a critical mechanism for rationing
limited IL-7 resources amongst naive T-cells to allow support for the maximum T-cell
population size [5, 15]. The notion that IL-7R levels are optimally tuned via feedback control
to maximize the population size under limited IL-7 conditions originated in studies of
enforced IL-7R expression on mature T-cells [15]. In contrast to the expected increase in
total population size from increased survival signaling, there was a paradoxical decrease in
the peripheral T-cell population. This unexpected decrease was attributed to increased
consumption of limiting IL-7 beyond an individual cell's survival requirements. The
'altruistic' model of IL-7R regulation therefore proposes that cells that have recently received
survival signals downregulate IL-7R in order to not compete with cells that have sustained
longer cytokine deprivation (Figure 2.6). This is thought to be particularly important in the
context of cells cycling in and out of IL-7-rich SLOs, a notion further supported by the
modulation of homing molecules by IL-7 signaling (Figure 2.6a). The broad distribution of
IL-7R expression observed among naive T-cells in tivo is therefore attributed largely to
spatiotemporal variations in their contact with IL-7 as they move throughout the body [5,
15].
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Figure 2.6. 'Altruistic' Model for Interleukin-7 Regulation
Schematic representation of the 'altruistic' model of IL-7 regulation, both within naive T-cell
populations, and between naive and rapidly expanding effector T-cell populations. (a) In the absence
of antigen stimulation, the periphery is occupied by the maximum number of T-cells that can be
supported by the limiting amount of IL-7 in vivo. As T-cells enter IL-7-rich lymphoid organs, they
bind IL-7, receive survival signals and downregulate their receptor so as not to compete with other
cells entering these region which still require survival signaling. When cells leave the periphery,
survival signals dissipate and receptor is re-expressed. This allows for T-cells to maintain clonal
diversity and optimally allocate cytokine survival resources. (b) When T-cells encounter a specific
activating antigen, they begin to secrete their own survival cytokines, in this case, IL-2. The rapidly
expanding population becomes dependent on these self-produced cytokines, and downregulates IL-
7R so as not to compete for survival resources with the naive T-cell population. In this way, antigen-
induced proliferation can occur independent of the naive T-cell pool and not inflict clonal loss.
Adapted from Park et al (2004) [15].
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Strict regulation of IL-7R expression is also thought to be critical for mediating competition
between different T-cell populations. In both immature and mature cells, IL-7R expression
is downregulated on rapidly expanding populations (Figure 2.6b). Downregulation of IL-7R
by DN cells as they proliferate and differentiate into DP cells during thymic selection is
thought to prevent them from competing with less abundant DN and SP cells [5].
Consistent with this idea, enforced expression of IL-7R throughout development results in
an increase in DN cell death [103]. A similar mechanism is employed by activated cells,
which lose IL-7R expression and become dependent on IL-2, thereby preventing their rapid
expansion from affecting the naive T-cell pool [15].
2.3.4 Summary: IL-7R Signaling Control of T-Cell Homeostasis
In summary, IL-7 induces Jak-Stat and PI3K-Akt mediated signaling critical to T-cell
survival, proliferation and function. Strict control of IL-7Ra expression is critical for
regulating sensitivity to cytokines, and mediating competition both within and between T-
cell populations to maximize population size. IL-7 production is largely constitutive, and its
availability is believed to limit the total T-cell population with the assumption that T-cells
have equal cytokine requirements and sensitivity. While IL-7 levels in replete hosts are barely
sufficient for survival, elevated IL-7 levels during lymphopenia are thought to be important
for potentiating proliferation. IL-7 is therefore believed to control naive T-cell population
size, but not its composition.
2.4 Interaction Between TCR and IL-7R
While the studies discussed in the previous sections strongly indicate that TCR and IL-7R
signals each influence both T-cell survival and proliferation, the mechanisms by which they
interact in vivo to regulate overall T-cell homeostasis remain unclear. Several studies have
suggested positive interactions between TCR and IL-7R signaling. In one model, stronger
TCR:spMHC interactions promote more frequent and/or sustained access to IL-7 produced
by APCs and/or bound to their surrounding ECM [55]. Similarly, higher TCR interactions
have been suggested to sensitize cells to IL-7 signaling [11, 78], and vice versa [104].
Interestingly, many IL-7 target genes are overlapping with genes induced by TCR activation
[22, 105], leading to suggestions that these two signaling pathways may cooperate to enhance
each others signal strength or duration at the transcriptional level [22]. Experiments using T-
cells lacking Lck, a kinase required for homeostasis signaling through the TCR, suggested
that both TCR and IL-7R signals operate independently to promote lymphopenia-induced
expansion, however in combination they synergize to give overall greater proliferative
capacity [23]. One interesting potential result of proposed synergies in TCR and IL-7R
signals is further reinforcement of what has been referred to as the 'competition-diversity'
paradox [12, 13]. According to this model, the T-cell population should be dominated by
those cells with the greatest ability to compete for survival/proliferation stimuli. Cells with
both increased TCR and IL-7R signaling could therefore theoretically overrun the T-cell
population to the extent that spMHC/IL-7 becomes limiting.
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Figure 2.7. Co-Receptor Tuning Model
(a) Schematic illustration of the co-receptor tuning model for balancing IL-7R and TCR mediated
homeostatic signaling among T-cells of different TCR:spMHC avidity [24]. In this model, mutual
feedback between IL-7R and TCR results in 'tuning' of CD8a co-receptor expression inversely with
the TCR avidity of the T-cell clone. IL-7 signaling upregulates CD8a expression, but TCR signaling
then feeds back to inhibit IL-7R signaling, which is reflected by less efficient IL-7R suppression. (b)
This model is supported by an inverse correlation of CD8ct expression with both CD5 and IL-7R
expression for a panel of freshly isolated TCR-tg CD8+ T-cell clones.
In contrast to suggested synergistic interactions of TCR and IL-7R signals, Park et al (2007)
[24] have proposed a model whereby signaling crosstalk between the two receptors acts to
balance net homeostatic signaling. In what they have termed the 'co-receptor tuning' model,
CD8aX expression is regulated by mutual feedback between the IL-7Rx and TCR signaling
pathways: IL-7Ra signaling induces the transcription of CD8x to increase TCR signaling,
which negatively feeds back to reduce IL-7 signaling (Figure 2.7a). Reduced CD8a co-
receptor expression on CD5 h T-cells is then proposed to 'tune down' excessive spMHC-
induced TCR signaling. In support of this model, freshly isolated CD5hi male HY TCR-tg
CD8' T-cells lack the ability to phosphorylate Stat5 in response to IL-7. Also observed in
support of their model is a positive correlation of IL-7Ra, and inverse correlation of CD8a,
with CD5 expression for a panel of freshly isolated TCR-tg cells (Figure 2.7b). However,
the observation that LIP of TCRtg T-cells varies with their TCR avidity for spMHC as
reflected by their CD5 expression [10, 11] suggests that TCR and IL-7R signals are not fully
balanced in some environments.
Thus, while it is increasingly evident that TCR and IL-7R signals interact to control T-cell
responses, the specific mechanisms of interaction, and whether they reinforce or counteract
the effects of varying TCR:spMHC affinity, are largely unknown.
2.5 IL-7 & IL-7 Therapies in Health & Disease
Because of its diverse roles in promoting T-cell development and function, there is much
interest in the therapeutic manipulation of IL-7 levels in the treatment of multiple
pathologies. IL-7 therapy has been shown to expand T-cell populations in normal mice by
both thymic-dependent and independent mechanisms [106-108]. Under conditions of
lymphopenia, such as following chemotherapy of whole-body irraditation, IL-7 addition also
accelerates lymphoid regeneration [109-111]. IL-7 also has prospective uses as a vaccine
adjuvant. When administered in combination with immunization, IL-7 enhanced T-cell
responses to subdominant antigens and promoted the formation of long-lived memory cells
[112, 113]. This has made IL-7 therapy attractive for use in cancer immunotherapies, as
tumor antigens are typically weak self-antigens with low immunogenicity. A recent study
demonstrated that IL-7 enhances tumor specific immunity by multiple mechanisms, though
it is inefficient in the absence of vaccination [113]. IL-7 may also find use in enhancing the
ex-vivo expansion of patient cells for adoptive immunotherapy [114] and prolonging the
survival of those cells in vit'o after transfer.
IL-7 is also being explored in the treatment of HIV. Naive T-cell proliferation under IL-7
therapy may be able to counteract the reduction in regeneration of lost CD4' T-cells during
HIV infection [115-117]. IL-7 may also help restore HIV-specific T-cells that are normally
lost early in infection [114, 118, 119]. Despite its potential therapeutic uses, deregulation of
IL-7 signaling has been implicated in HIV progression. IL-7 levels rise as T-cell numbers
decrease, and increased IL-7 has been shown to increase HIV replication [120] and cell entry
[121] and may predispose T-cells to Fas-mediated death [122].
Deregulation of IL-7 signaling has also been implicated in other disease pathologies. Patients
with single nucleotide polymorphisms (SNPs) in IL-7, IL-7Ra and SOCS1 genes also have
much higher risk for multiple sclerosis (MS), suggesting deregulated IL-7 signaling may be
connected to the disease pathology [123-125]. Whilst IL-7 is being investigated for use in
cancer immunotherapy, enhanced IL-7R signaling has been proposed to contribute to T-cell
leukemogenesis [21]. Selective expansion of more self-reactive clones in response to
increased IL-7 has also been proposed to contribute to development and progression of
autoimmune disorders [19, 20]. Thus while IL-7 therapies may expand overall T-cell
numbers, they may have the unintended consequence of preferentially expanding undesirable
T-cell population subsets.
Two rhIL-7 phase I clinical trials have recently been completed in adult patients with
refractory cancer [126, 127]. In both trials, CD8' and CD4' T-cells showed an IL-7 dose-
dependent increase in population size, but no accompanying anti-tumor activity.
Interestingly, authors saw a concomitant increase in the diversity of TCR VP usage amongst
T-cells, which they attributed to predominant expansion of the more 'diverse' recent thymic
emigrant (RTE) population [127]. The resulting TCR repertoire usage resembled that of
healthy young adults, suggesting therapeutic use of IL-7 in rejuvenating the T-cell repertoire
of elderly or lymphopenic patients whose restricted repertoire may limit their immune
competence [128]. However, significant questions remain as to how this increase in diversity
of TCR VP segment usage translates to functional diversity, as contrary to increased thymic
export, division of mature cells does not expand the number of unique TCRs in the
periphery and may not translate to increase ability to respond to new antigenic challenges.
While the therapeutic potential of cytokines has been recognized for decades, there has been
mixed success in their application. Early clinical trials of cytokine therapies were conducted
prior to a good understanding of cytokine biology, particularly regarding the diversity of
different responsive cell types and the subtleties involved in predicting their responses and
half-lives upon systemic delivery [129]. Administration of high doses cytokines was found in
some cases to invoke severe immunotoxicity [129-131]. These early failed attempts stalled
the rapid development of related therapies, but nevertheless many successful applications for
multiple cytokines, including IL-2, have been approved and/or are in clinical trials [129].
Given the diversity of different disease contexts for which IL-7 is being considered
therapeutically relevant, and the number of IL-7 clinical trials already underway, a careful
study into the consequences of IL-7 therapies and how they might be optimized is timely
and critical to their successful development.
2.6 Unaddressed Aspects of Homeostasis Signaling Control & Aims of
This Thesis
There is ample evidence supporting critical roles for both IL-7R and TCR signaling in
regulating survival and proliferation responses. However, the mechanisms by which these
signals integrate to regulate the homeostasis of the T-cell repertoire remain unclear. The
presiding model is that competition for TCR engagement with spMHC maintains diversity in
the T-cell pool [1-3] while IL-7 availability regulates the overall size of the naive T-cell
population but not its composition [4, 5]. This simplified model assumes that all variations in
the homeostatic capacity of T-cells arise from the strength and/or frequency of engagement
of their specific TCR with spMHC. It also implies that IL-7R signaling is uniform amongst
all T-cell populations, and that T-cells survive equally well in the absence of homeostatic
stimuli. However, few studies have rigorously tested these assumptions. Recent studies
suggest IL-7R signaling in T-cells may vary with the strength of their spMHC signaling as a
result of TCR and IL-7R crosstalk [241, but these again imply that differences in TCR
signaling underlie heterogeneities in the response to homeostatic cues. One potential
problem with studies in support of distinct role for spMHC and IL-7 signaling is that in
most cases responses induced by either TCR or IL-7R stimulation have not been examined
independently of potentially heterogeneous signaling via the other receptor. This greatly
confuses the ability to attribute variations in individual responses across T-cells to
differences in either TCR or IL-7R signaling alone.
There are many instances in which the source of variations in T-cell responses to
homeostatic signals may be arguable. For example, variation in the rates of LIP of naive T-
cell clones has been attributed solely to their strength of TCR signaling, indicated by their
CD5 expression level [10, 11]. However, whether IL-7R signaling also varies with TCR
specificity and potentiates proliferation responses and has not been examined. Expression
levels of key homeostatic signaling components, including IL-7R [5] and CD5 [8], are known
to vary among naive CD8' T-cell clones. While these differences in expression have been
attributed to the interaction of T-cells with heterogeneous IL-7 and spMHC environments
[7, 15, 24], they could also reflect stable cell-intrinsic differences in signaling pathways
among mature T-cells. The potential misattribution of heterogeneous T-cell responses to
variations in TCR signaling and/or the local environment calls for a carefully controlled re-
examination of T-cell responses to individual homeostatic stimuli.
The general aim of this thesis is therefore to specifically examine the role of cytokine
signaling in the regulation of CD8' T-cell homeostasis. We first undertake a theoretical
examination of the properties of the IL-7 signaling network that contribute to signaling
control in the context of TCR and other cytokines. Prior assumptions regarding equal
cytokine responsiveness and turnover across T-cells of different specificities are then
experimentally tested in the absence of TCR stimulation. Taking a rigorous quantitative
signaling analysis approach, we determine relationships between receptor expression and
signaling activity to cytokine-induced survival and proliferation responses. In vivo
examinations of T-cell survival and proliferation in zilo are then used to determine how IL-7
signaling contributes to homeostatic control of population size and diversity, and examine
the potential of cytokine therapies to alter the T-cell repertoire. Turning the tables, we then
determine the capacity for the T-cell repertoire to alter their cytokine environment. This
detailed analysis of cytokine signaling control is used to re-interpret previous models for the
control of T-cell population size and diversity in both normal and disease contexts. By these
means, we aim to clarify the role of cytokine signaling in the control of T-cell homeostasis.
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Chapter 3 Perspectives on the Integrated Systems
Analysis of IL-7 Receptor Signaling
In recent years, the analysis of cell signaling networks using quantitative systems biology
approaches has revealed emergent phenomena that are not obvious based on the study of
the individual network components [132]. Further, it has yielded a molecular understanding
of previously observed phenomena at the level of the cell, such as cellular responses
occurring only over a narrow range of ligand stimulation, and at the level of the entire
organism, such as tissue homeostasis. Of particular relevance to the biology of IL-7 are
lymphocyte differentiation checkpoints at various stages of development and the regulation
of lymphocyte population size at the level of the organism. It is becoming increasingly clear
that the IL-7R signaling network is regulated at multiple hierarchical levels in the signaling
pathways. What is unclear is the relative contribution of the various arms of the IL-7R
regulatory network in controlling IL-7R signaling efficacy and the IL-7R signaling network
behavior as a whole in stimulating survival, proliferation and differentiation throughout
lymphocyte development.
In this chapter, we present an analysis of the IL-7R signaling network and network behavior
from an integrated systems perspective. A scheme of the IL-7R signaling network and its
connectivity with other signaling networks in T-cells is depicted in Figure 3.1. We have
highlighted the occurrence of the following mechanisms of signaling control: shared
receptor components, signaling pathway crosstalk, common interaction domains, feedback
regulation, integrated gene regulatory control, multimerization and ligand competition. In
subsequent figures (Figures 3.2-3.8), we have illustrated the potential of each 'network
motif' to affect the properties of the IL-7R signaling network including the strength and
duration of IL-7R signaling. Because the quantitative properties of many of the system
interactions are poorly characterized at present, we employ idealized models with assumed
parameters in presenting these illustrations. We find that the interacting network
components have the potential to affect the biology of the IL-7R signaling network in
important but non-intuitive ways. We discuss the implications of these IL-7R signaling
'network motifs' on lymphocyte biology in health and disease. Since we have used idealized
models, the predictions presented in this review are best viewed as hypothetical system
properties that will require confirmation using quantitative experimental and analytical
approaches. Model details associated with each figure are outlined in the Appendix.
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Figure 3.1. Control Mechanisms in the IL-7R Signaling Network
A schematic diagram of the IL-7R signaling network and its connectivity with interacting signaling
networks, including TSLP, IL-15 and the TCR, is depicted. Important 'network motifs' of signal
control are labeled with circled numbers.
3.1 Shared Receptor Components
Several cytokine receptors are multimeric complexes made up of two or more different
component proteins, which are often shared between multiple cytokine receptors. This can
impact the relative availability of each receptor component, thereby limiting the extent of
cytokine receptor signaling. Common examples of shared cytokine receptor components
include sharing of the common gamma chain (yc) between the receptors for IL-2, -4, -7, -9, -
15 and -21, the sharing of a common B chain between the receptors for IL-3, IL-5 and GM-
CSF [133], and the sharing of the B chain between IL-2 and IL-15 receptor complexes [134].
In the case of the IL-7R complex, both receptor subunits are components of other
receptors. As discussed in chapter 2, the ye chain is shared with five other cytokine
receptors, all of which regulate T-cell growth and differentiation. As signaling specificity
through the ye cytokine receptors is largely controlled by expression of the cytokine-specific
a chains (as well as the $ chain for IL-2 and IL-15), these subunits are kept under tight
transcriptional control throughout development. The IL-7RX chain can also form a
heterodimeric receptor complex on binding to the TSLPR, which is homologous to the ye
chain [135]. IL-7Ra and TSLPR are co-expressed on T-cells, pre-B cells and dendritic cells
(DCs) [136]. The ligand for the IL-7Ra:TSLPR complex is TSLP, which is a cytokine that is
homologous to IL-7, and is produced by cells of epithelial origin in the thymus, lung, gut and
skin [137]. The presence of shared receptor components among cytokines can result in
competition for the shared components among their respective ligands.
The association between the ye chain and IL-7Rx is required for the generation of a
functional receptor complex and is mediated either by the binding of IL-7 or the activation
status of T-cells [138]. The presence of competing cytokines can sequester IL-7 receptor
components and adversely impact the ability to form functional IL-7R signaling complexes.
For instance, IL-7 and TSLP can compete for IL-7RX. Similarly, IL-7 and IL-15 compete
for the y, chain (Fig 3.2a). One potential repercussion of shared receptor components
among cytokines is an upper limit on the total amount of cytokine-specific signaling that a
cell can receive in response to multiple cytokines. For instance, IL-15 can compete for the
shared ye component when its expression is limiting [139]. An example of the quantitative
effects of this sharing is shown in (Fig 3.2b), which illustrates how the number of IL-7:IL-
7R complexes may decrease on exposure to increasing levels of IL-15 in the presence of a
constant level of IL-7. However, the net signal strength down any given pathway may
depend on the extent to which the y, chain is complexed with IL-7Ra or IL-15Ra. The use
of shared receptor components also partly helps explain the overlap in many cytokine
receptor signaling pathways. As discussed in subsequent sections, this pleiotropy can also
lead to competition for intracellular binding partners and downstream signaling effectors
that can affect the propagation of signals from a particular receptor when multiple cytokines
are present.
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Figure 3.2. Influence of Shared Receptor Components on Signaling
(a) Receptor component chains shared among IL-7R, IL-15R and TSLPR complexes. IL-7R and
TSLPR share the IL-7Ra chain, while IL-15R and IL-7R share the common yc. (b) Example of
competition between IL-7 and IL-15 for the yc, assuming limiting levels of yc chain and that IL-7
binds with 10-fold greater affinity than IL-15 to its respective receptor. Even at constant levels of IL-
7, the number of signaling competent IL-7:IL-7Ra complexes decreases with increasing levels of IL-
15 as IL-1 5:IL-1 5Ra sequesters available yc.
Aberrant receptor competition may be related to pathological outcomes. For instance,
atopic dermatitis and asthma involves pathological Th2 differentiation induced by dendritic
cells primed with TSLP [140]. The effects of TSLP on T-cells are largely mediated by
modulating the function of DCs [141]. IL-7 can also modulate DC function. For example,
IL-7 is produced by inflamed synoviocytes in rheumatoid arthritis and it induces cell contact-
dependent Th1 cytokine production in cocultures of synovial T-cells and monocytes [142].
Interestingly, skin keratinocytes have been shown to produce both IL-7 and TSLP, especially
on exposure to certain pathogens [143]. The competing effects of TSLP and IL-7 on
dendritic cells may therefore influence their ability to bias Th2 cell differentiation of CD4'
T-cells that they activate. Further, we speculate that the possible ability of IL-7 to modulate
the effects of TSLP by ligand competition may open new therapeutic avenues for asthma or
atopic dermatitis.
3.2 Shared Downstream Signaling Components
Many of the main signaling components of the IL-7R signaling pathway, including both
positive and negative regulators of cell proliferation and survival, are shared with other
cytokine receptors. During such an interconnected signaling network response, multiple
input cues work together through a small set of signaling network effectors that propagate
down and spread to a number of downstream targets. Competition for shared signaling
mediators can result in a hierarchy of responses controlled at the level of abundance and
relative binding affinities to upstream regulators of the response.
The cross-specificity in Jak and Stat activation is one of the major nodes of cytokine
signaling crosstalk. The Jak kinase family is comprised of four members: Jak1, Jak2, Jak3 and
Tyk2, each of which is found to be associated with multiple cytokine receptors [144]. For
instance, Jak1 is associated with the X subunits of y, cytokines such as IL-7Rx and IL-4Ra.
Jak3 is associated with the ye chain [145, 146]. Cytokine binding stimulates the trans-
phosphorylation of receptor associated Jak kinases, which in turn phosphorylate tyrosine
residues on the receptors themselves. The receptor phosphotyrosines serve as docking sites
for SH2 domain proteins including the Stat family of transcription factors which are
activated by Jak-mediated phosphorylation. Signaling crosstalk due to shared Jak kinases
likely underlies many of the redundant signaling activities observed among interleukin family
pro-survival cytokines. Cytokines, as well as many other growth factors, activate overlapping
subsets of the seven Stat family members (Statl, 2, 3, 4, 5a, 5b, and 6) [144]. Thus,
phosphorylation of multiple Stats by the Jak kinases also results in considerable crosstalk
[831. Yet another point of crosstalk exists in the induction of suppressor of cytokine
signaling (SOCS) family members. The SOCS proteins include eight family members (SOCS
1-7 and CIS), each of which can inhibit signaling induced by multiple cytokines and growth
factors by several mechanisms, including binding the Jak catalytic site, occupying the
receptor Stat docking site, and targeting signaling proteins for degradation [147]. SOCS1 is
the major SOCS family protein involved in IL-7R signaling regulation and is induced by
other cytokines, especially IFNy. Another major point of signaling crosstalk with the IL-7R
signaling network is the PI3K-Akt pathway which is involved in a number of signal
transduction networks that regulate cell survival [148]. Each level of cross-specificity in these
pathways, at the level of Jaks, Stats, SOCSs and PI3K-Akt targets, makes it harder to assign
protein-specific effects and to deconvolve multi-cytokine responses.
a b
- 8 W ItL-15 + Ll-7
8I04
L 5
.02
0 10 20 30 40 50 60G - Time (min)
Figure 3.3. Influence of Pathway Crosstalk on Signaling
(a) Signaling through the common Jak-Stat pathway downstream of IL-7Ra and IL-15R. (b)
Example of the anticipated kinetics of Stat5 phosphorylation after stimulation with either IL-7 or IL-
15. Here we assume equal IL-7 and IL-15 receptor numbers and ligand concentration but that IL-7
binds to its receptor with 10-fold greater affinity than IL-15, as well as first order Stat
dephosphorylation. In this case, the combined IL-7 and IL-15 signal give more rapid Stat5
phosphorylation than each of the cytokines alone, but a less than additive level of phosphorylation
due to limiting amounts of Stat5. The combined signaling would approach the predicted additive
signal upon increasing downstream Stat5 target expression.
Currently little is known about how pathways signaled by IL-7 are quantitatively regulated,
especially in the context of concurrent signals derived from other cytokines or the T-cell
receptor (TCR). When signaling originates from multiple cytokines, it is likely that limiting
amounts of common downstream targets can result in less than additive activation profiles.
This phenomenon is illustrated in Figure 3.3, which examines the combined activation of
the Jakl-Stat5 pathway by IL-15 and IL-7 in the presence of limiting Stat5. When both
cytokine receptors are simultaneously ligated, the combined cytokine signals results in an
increase in the rate of the response but little increase in the magnitude of the response over
individual cytokine treatments. For simplicity, we have treated IL-15 as a soluble ligand like
IL-7 in this example. However, it is now established that IL-15 is primarily bound to IL-
15Ra by IL-15 producing cells in vivo [149]. This is reminiscent of the biological activities of
surface-tethered growth factors such as EGF, which induce sustained signals as they prevent
the internalization of the receptor complex [1501. The effects of possible differences in
receptor internalization rates of cytokines like IL-7, which is soluble, and IL-15, which is
presented by IL-15Ra, have not been investigated. These differences could impact the
dynamics of downstream signal competition. Well-designed quantitative experiments at the
network level will be required to develop strategies for therapeutic manipulation of the
network due to complex interconnected effects of multiple pathway activation.
3.3 Common Interaction Domains
The vast inter-connectivity of signaling networks is largely a result of overlapping binding
specificities of multiple proteins for the same target motif, which often occurs in several
distinct signaling proteins. Thus, many kinases have numerous substrates, and signaling
scaffold proteins can recruit several different signaling mediators to the same domain. Yet,
cytokines often predominantly activate only a small subset of these signaling mediators.
Simultaneous stimulation with multiple cytokines which share overlapping downstream
partners can also influence the strength and dynamics of the signal. Multiple cytokines can
compete for the same binding site on a limiting number of receptors. Alternatively, the
presence of the same signaling domain on multiple receptors can lead to competition for
limiting downstream signaling mediators. Response specificity, timing and prioritization for
pathway activation is thus dictated by the relative abundance and binding strength of
interacting signaling proteins.
Several conserved interaction domains are found in the intracellular domain of the IL-7Ra
chain. The cytoplasmic tail of IL-7Ra has two regions, Box1 and Y449, which are thought
to be of particular importance for signal propagation regulating survival, proliferation and
thymocyte development. Box1 is an eight amino acid membrane proximal motif that binds
Jak1 and is found in all type I cytokine receptors. Y449 is one of three tyrosines in IL-7Ra,
which is conserved between humans and mice, and recruits SH2 domain-containing Stat
family members when it is phosphorylated by receptor-associated Jak1. Although Stat5 is the
major Stat recruited to the Y449 site on IL-7R signaling, SH2 domain homology with other
Stat family members could lead to competition among the Stats for binding to the Y449 site
(Figure 3.4a). In particular, Stat1, 3 and 5 have been shown to be activated by IL-7R
signaling [83, 102]. However, a mutation at the Y449 site does not completely abrogate Stat1
and Stat3 signaling [102], suggesting additional routes for their activation by IL-7. Additional
phosphotyrosine binding proteins like the Shc adaptor protein and insulin receptor substrate
proteins may also compete with Stat5 for binding to the Y449 site [22]. Competition at the
Y449 site affecting Stat5 access could alter the timing and magnitude of Stat signaling. A
hypothetical example of such competition between Stat5 and Stat3 is shown in Figure 3.4b.
We have assumed that the Stat5:pY449 interaction is 10-fold stronger than the Stat3:pY449
binding and that the rates of Jak-mediated phosphorylation are equal for both Stats. The
resulting delay in the kinetics of Stat3 phosphorylation, given limiting amounts of pY449
binding sites, is illustrated. Conversely, the presence of phosphotyrosines on other proteins
that can also bind the SH2 domain of Stat5 could sequester Stat5 and hinder its binding to
IL-7Ra. It has also been proposed that a second survival signal originating from the Y449
site arises from the recruitment of P13K [88]. The difference in binding kinetics of P13K and
Stat5 to the Y449 site could regulate the extent and timing of the signal through these two
pathways, which may influence the downstream integration of survival signals. Quantitative
experiments of signal dynamics under varying IL-7Ra, P13K or Stat5 levels will be needed to
determine how competition for binding sites impacts propagation of survival signals.
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Figure 3.4 Influence of Conserved Binding Domain on Signaling
(a) Competition between the SH2 domains of Stat3 and Stat5 for binding the phosphorylated Y449
residue in the IL-7Ra chain. (b) Hypothetical differences in the kinetics of activation of Stat5 and
Stat3, which bind the same site (pY449) on the IL-7Ra receptor, with different affinities. Here we
assume that the affinity of the pY449 site on IL-7Ra for Stat5 is 10-fold higher than that for Stat3,
and that Stat3 and Stat5 phosphorylation rates by Jak1 are equal.
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3.4 Signaling Feedback Control
Feedback loops comprise key mechanisms by which signal inhibition and propagation is
controlled within cells. Signaling through a receptor may lead to signal inhibition via receptor
internalization, induction of inhibitory phosphatases or transcriptional changes in receptor
or regulator expression. Likewise, positive signaling feedback can be generated by inducing
transcription of the receptor or its positive regulators or by autocrine secretion of a
stimulatory ligand. Signaling feedback control is an important regulatory process in IL-7R
signaling that allows avoidance of pathway saturation, establishment of signaling thresholds
and fine-tuning of the signal at an optimal level for cell survival. Understanding the balance
of positive and negative feedback loops will be essential for a complete understanding of
cytokine responses.
Negative feedback loops are particularly important in the regulation of IL-7Ra expression.
Receptor ligation leads to endocytic loss of the receptor from the surface, contributing to
signal attenuation. In addition to receptor loss from internalization, several y cytokines,
including IL-7, activate both negative and positive feedback loops to modulate receptor
mRNA expression. In CD8' T-cells, downregulation is mediated by the transcriptional
repressor Gfil, which is upregulated upon IL-7R signaling, as well as signaling by other
interleukin family members [15]. A second transcriptionally mediated negative feedback loop
involves upregulation of Socsl expression upon cytokine signaling (Figure 3.5). Socsl can
directly inhibit Jaks by acting as a pseudosubstrate through its kinase inhibitory region, as
well as by ubiquitin-mediated degradation of the signaling complex itself [147]. In addition,
cytokine-independent regulation of SocsSl also plays critical roles in regulating signaling by
IL-7 and other ye cytokines throughout development. For example, Socsl is expressed at
high levels in DP cells during thymic development to prevent IL-7R signaling and possible
aberrant positive selection [151]. Socsl knockout mice show spontaneous activation of
lymphocytes even in a pathogen free environment [152]. A number of negative regulators of
the Stats have also been identified such as the PIAS family of proteins [153]. However, the
relative contribution of these mechanisms of signal feedback inhibition to the overall control
of IL-7R signal attenuation is yet to be elucidated.
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Figure 3.5. Influence of Feedback Control on Signaling
(a) Negative feedback in IL-7 mediated Jak-Stat signaling, wherein activated Stat5 induces
upregulation of SOCS1, which in turn inhibits Stat5 activation by Jak1. (b) Example of the kinetics
of Stat phosphorylation in the presence and absence of negative feedback via SOCS1 upregulation
and binding to activated Jak1, assuming first order Stat desphosphorylation. In the absence of
feedback, the signal perpetuates, whereas SOCS1 upregulation leads to signal dissipation.
IL-7R signaling also elicits positive feedback loops which contribute to signal amplification
and sharp response thresholds. In developing B cells, IL-7R signaling causes upregulation of
the transcription factors EBF and E2A, which in turn upregulate IL-7Ra, leading to a self-
sustaining positive feedback loop [154]. Feedback loops in IL-7R signaling play a critical role
in B cell development by maintaining B cell lineage commitment among differentiating
common lymphoid progenitors. In addition, sustained IL-7R signaling is necessary for
survival of pro-B cells [155]. EBF and E2A coordinately regulate the initiation of the B cell
gene expression program as well as rearrangement of the immunoglobulin heavy chain loci
[153]. The signal feedback loops between these proteins ensure normal development of B
cell precursors through various checkpoints in B cell development.
It was recently shown that in macrophages, Tat protein produced by the human
immunodeficiency virus (HIV) can cause upregulation of IL-7Ra and increase IL-7R
signaling. Increased signaling in turn promotes early infection events including viral entry,
and ultimately efficient viral production [156]. Interestingly, the effect of HIV Tat protein on
CD8' T-cells was the opposite of that seen in macrophages, where it instead decreased IL-
7Ra expression, inhibiting cell survival signaling [157]. A detailed analysis of the complex,
cell-specific feedback mechanisms will help better understand how the IL-7R signaling
network is exploited by pathogens.
3.5 Integrated Gene Regulatory Control
Interaction between signaling pathways at the gene regulatory level gives rise to a
coordinated response and synergy in outcomes. Survival, activation and proliferation
programs that are driven by antigen-receptor signaling and various y cytokines are
characteristic of lymphocytes. Microarray profiling has allowed for the high-throughput
querying of gene expression programs regulated by cytokine and TCR signaling and their
relationships with a variety of biological processes. High levels of overlap have been
observed amongst the several hundred genes regulated by IL-2, IL-7 and IL-15. However,
approximately 73% of these genes are also regulated by TCR signaling, and less than 20% of
genes are unique to cytokine stimulation [105, 158]. Socsl and Gfil are genes that are known
to be transcriptionally induced during T-cell activation as well as by pro-survival cytokine
signaling. Socsl and Gfil inhibit the IL-7R signaling pathway at the post-translational and
transcriptional levels respectively. IL-7Ra itself is transcriptionally downregulated by
antigen-receptor signaling. In fact, it has been suggested that there is a greater overlap among
TCR and interleukin-induced genes than amongst the genes induced by interleukin family
members themselves [105]. This strongly suggests that gaining a complete understanding of
IL-7 induced signaling will require consideration of how related cytokines and TCR signaling
influence the transcriptional network response.
As a specific example of the impact of interacting gene regulatory control, we have
illustrated the phenomenon of coreceptor tuning which is proposed to allow CD8' T-cells to
maintain their antigen-receptor signaling at levels just below the threshold of autoimmunity
(Figure 3.6a) [24]. The levels of CD8 are a critical determinant of the responsiveness of a T-
cell to self-peptide MHC (spMHC) as CD8 promotes the kinetics of binding of TCR to a
spMHC complex [159]. Interestingly, CD8u is transcriptionally induced by IL-7R signaling
while at the same time, IL-7R signals are inhibited by spMHC-induced TCR signal
transduction. This leads to a mutual feedback loop at the level of gene regulation which
results in co-regulation of T-cell survival and antigen responsiveness [24]. This allows CD8*
T-cells to adapt to the self-specificity of their unique TCRs so that they receive sufficient
survival signals without losing self-tolerance. Figure 3.6b illustrates how the combined TCR
and IL-7 survival signal would be expected to change as a function of the strength of
interaction between TCR and spMHC in the presence and absence of the coreceptor tuning
effect. In the absence of coreceptor tuning, cells with higher self-reactivity would receive
greater survival stimuli, making them potentially autoreactive. Coreceptor tuning may also
allow T-cells with a weak responsiveness to spMHC to better receive other pro-survival
signals from IL-7.
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Figure 3.6. Influence of Integrated Gene Regulatory Control on Signaling
(a) Co-regulation of TCR and IL-7R induced signaling according to the CD8 coreceptor tuning
model. IL-7 transcriptionally increases CD8a expression to promote TCR- self peptide-MHC
engagement, but TCR signaling impairs IL-7R signaling. (b) The predicted effects of coreceptor
tuning are shown by plotting how TCR and IL-7R signals would be expected to vary as a function of
TCR input signal strength ('affinity' for spMHC) with constant IL-7 input signal, either with or
without TCR mediated IL-7R signal inhibition as described by the coreceptor tuning model. In the
absence of tuning, TCR signaling is enhanced by IL-7 signaling and increases with the TCR input
strength, whereas negative feedback to IL-7 dampens the TCR signaling induced by high 'affinity'
ligands.
Studying the circuitry of gene regulatory programs may help bring important new insights
into the contribution of IL-7R signaling to autoimmunity and cancer. Exposure of CD8' T-
cells to low levels of IL-7 in vitro for a few hours can pre-dispose them to an enhanced
syngeneic mixed lymphocyte reaction with syngeneic dendritic cells [24]. This phenomenon
suggests that autoimmune phenotypes may involve deregulation of coreceptor tuning
machinery. It has also been suggested that elevated responses to pro-survival cytokines may
contribute to the ability to avoid death by lymphoblastic leukemia cells [21]. The altered
responses of these leukemic cells likely reflect critical changes in gene expression. Predicting
potential therapeutic targets in the IL-7R signaling pathway will therefore require a
comprehensive understanding of how normal control is achieved, and the transcriptional
processes contributing to its pathological deregulation.
3.6 Multimeric Signaling Complexes and Combinatorial Complexity
The Stat proteins are transcription factors involved in y, cytokine signaling that are expressed
constitutively at high levels in the cytosol of resting cells which facilitates their ability to
induce a rapid response on phosphorylation by Jak kinases [144]. Tyrosine phosphorylation
of Stats leads to their dimerization through their SH2 domain interactions. Both
homodimers (all Stats except Stat2) and heterodimers (Stat1 and Stat2, Stat1 and Stat3, and
Stat5a and Stat5b) are formed [22, 144]. Furthermore, tetramerization of Stats has been
shown to occur in the case of Stat3, Stat4 and Stat5. Such higher order complex formation is
mediated by the N-terminal domains of Stat proteins. The Stat dimers and corresponding
tetramers could have differences in their respective DNA binding specificities [1601.
The presence of several Stat protein multimerization states (monomer, dimer and tetramer)
simultaneously present in the cell, each with different cellular function, complicates the
ability to directly relate Stat phosphorylation state to activity and phenotypic outputs.
Multimerization kinetics can also cause higher order oligomerization states to be turned on
over narrower ranges of input signal (Figure 3.7). IL-7 has been shown to promote survival
versus proliferation at different concentrations (0.1 and 1ng/mL respectively) in recent
thymic emigrants, but the effect is not correlated with total Stat5 phosphorylation [161]. One
potential explanation could be that Stat dimers and tetramers could preferentially induce cell
survival or cell cycle entry respectively. As shown in Figure 3.7b, one possibility is that Stat5
dimers may be more abundant than tetramers upon weak IL-7 signals, with the opposite
effect being seen for high IL-7 signals.
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Figure 3.7. Influence of Component Multimerization on Signaling
(a) IL-7 induced formation of phosphorylated Stat5 dimers and tetramers, each with unique
influences on gene expression programs. (b) Potential Stat5 phosphorylation response showing
relative steady state levels of pStat5 monomers, dimers and tetramers with varying IL-7 stimulation
dose assuming equal rates of dimerization and tetramerization and first order Stat dephosphorylation.
There exist IL-7 concentrations at which dimer abundance is either greater or lesser than tetramer
abundance due to a sharper dose response with higher multimerization states.
Due to cooperative effects, Stat tetramers may selectively increase the activity of certain
promoters that have lower affinity binding sites for Stats. Indeed, mutational analysis of
Stat5a-binding DNA oligonucleotides has demonstrated that it is possible to introduce
specific mutations that virtually abolish Stat5a dimer binding without affecting binding as
tetramers. Increased promoter occupancy may change the threshold for transcriptional
activity while widening the gene transcription spectrum [160]. Some responses to cytokine
signaling may be explained by the presence of conditions that favor the generation of dimers
over tetramers or vice versa. In fact, the presence of high levels of Stat5 tetramers has been
consistently seen in some leukemias [161]. Furthermore, combinatorial complexity in the
dimerization of Stats can lead to additional diversity in the nature of signals transduced by
IL-7. Stat5a and Stat5b are two closely related Stats with subtle differences in their DNA
binding specificity. These differences are likely to be reflected in the DNA-binding
specificities of Stat5a/b homodimers and heterodimers and also in their higher order
complexes. Combinatorial complexity in these interactions can also arise from the
heterodimerization of other Stats (Stat1 /Stat3 or Stat1 /Stat2).
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3.7 Multicellular Ligand Competition
Lymphocyte homeostasis refers to the maintenance of the numbers and diversity of
lymphocytes through an organism's lifetime. The homeostasis of naive T-cells is maintained
by the competition for limiting amounts of pro-survival cytokines such as IL-7 and regular
contact with spMHC [155]. Despite stiff competition for pro-survival ligands among T-cells,
the homeostasis of T-cell numbers as well as diversity is maintained [3]. This can be better
explained by studying how features of the IL-7R signaling network affect the behavior of the
entire cell population.
T-cells have evolved strategies to maximize the efficiency of utilization of limiting amounts
of IL-7 to maintain homeostasis. IL-7Rx downregulation, which is induced by IL-7R
signaling, has been proposed to serve as a mechanism to maximize population size among
cells competing for limiting IL-7 by allowing the maximum possible number of cells to
receive pro-survival signals [15]. In this 'altruistic' model of IL-7R signaling, cells signaled by
IL-7 transiently downregulate surface expression of IL-7Ra and thus become unresponsive
to the continued presence of IL-7. The remaining IL-7 in the extracellular milieu can then
be used to signal as of yet unsignaled cells. Cells are hypothesized to indefinitely cycle
between signaled and unsignaled states with low and high receptor expression respectively
[5]. It is not known if such cycling occurs in vivo and if it does occur, what the time scales of
the cycling in receptor levels are. A further point of contention that remains unexplored is
whether 'altruistic' behavior must be realized by two populations of 'signaled' and
'unsignaled' cells in vivo, driven for example by their respective arrival at the IL-7 production
sites in the lymph node, or whether the entire population is maintained at constant receptor
levels in equilibrium with extracellular IL-7. Furthermore, it is possible that the
comparatively faster processes of IL-7Rax internalization are sufficient to regulate signal
strength and depletion. This 'altruistic' behavior has been extended to explain the need for
IL-7Ra downregulation upon T-cell activation (Figure 3.8) [15]. Activated T-cells undergo
rapid expansion and their numbers can occasionally reach almost half of the total number of
T-cells during some acute infections [162]. On activation, T-cells gain responsiveness to
other cytokines such as IL-2 and downregulate IL-7Ra and IL-7 consumption, presumably
in order to preserve the naYve repertoire that is critically dependent on IL-7. Figure 6.8b
shows the possible decrease in total naive T-cell population numbers that might be expected
in the absence of IL-7Ra downregulation in the activated pool as compared to what would
be seen for an 'altruistic' activated pool. A similar interaction is believed to exist between
double negative (DN) and double positive (DP) thymocytes. The DN population of
lymphocyte precursors in the thymus is critically dependent on IL-7 and gives rise to DP
cells that constitute a large fraction of the cells in the thymus. As forced expression of IL-
7Ra on DP thymocytes results in reduced numbers in the thymus, it has been suggested that
the physiological downregulation of IL-7Ra on DP cells results in sparing of the limiting IL-
7 resource for the DN population [103].
IL-7 has been tested as a therapy for lymphopenic disorders [126]. A population level model
of the IL-7R signaling network can be used to estimate optimal IL-7 therapeutic dosing
regimens that minimize simultaneous activation of negative feedback loops. This will
require careful determination of the effects of both receptor downregulation at increasing
doses in combination with consideration of the effects of multi-cellular competition.
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Figure 3.8. Influence of Multicellular Ligand Competition Effects on Signaling
(a) Competition between naive and activated cells in the presence or absence of 'altruistic' IL-7Ra
downregulation by activated cells. According to this model, downregulation of IL-7Ra prevents
depletion of available IL-7 by the expanding population of activated cells, which is required for naive
T-cell survival. (b) An example of how the abundance of naive and activated T-cells might be
expected to change once activated T-cells undergo rapid IL-7 independent expansion (days 2-7) and
either (i) downregulate their receptors ('altruism') or (ii) do not ('no altruism') according to the model
in (a). The naive T-cell population sizes decrease in the absence of altruism due to IL-7 ligand
consumption.
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3.8 Conclusions: An Integrated Systems Analysis of IL-7R Signaling
We have discussed several examples of pathological perturbations in the IL-7R signaling
network. However, the involvement of IL-7R signaling in many diseases is not completely
understood. For instance, a likely causal SNP (rs6897932) in the IL-7Rax gene, was recently
identified in a population of multiple sclerosis (NIS) patients [124]. This SNP results in
aberrant expression of a soluble isoform of the IL-7Ra by putatively disrupting an exonic
splicing silencer. Simultaneously, the level of the normal membrane-bound IL-7Rx is
reduced. This may have an impact on the pathogenesis of MS by altering the dynamics of the
IL-7 or TSLP signaling network in multiple cell types. Notably, TSLP-activated DCs are
involved in CD4* T-cell homeostasis [163] and T regulatory cell development in the thymus
[164]. In another recent development, a low level of IL-7Ra was shown to be an excellent
marker for human T regulatory cells and Foxp3 expression [165]. This further suggests that
there may be hitherto unrecognized roles for the IL-7R signaling network in human diseases.
The IL-7R signaling network provides a good example of the utility of a systems perspective
in examining how multiple levels and mechanisms of regulation interact to produce a
dynamic cellular response. A view of the pathway that is focused on single components
provides an incomplete picture of the regulatory network because IL-7R simultaneously
signals through multiple shared pathways and IL-7R signaling is modulated through multiple
concurrent mechanisms. We can reliably model the complex biology of IL-7R signaling only
by integrating what is known about all the factors involved in signal propagation, repression
and modulation. A comprehensive quantitative evaluation of the IL-7R signal network will
extend our understanding of complex relationships involved in lymphocyte development
and homeostasis. In addition, a detailed network analysis of IL-7R signaling may shed light
on other cytokine signaling networks as well because it shares many components with other
cytokine signaling networks. New technologies that allow quantitative network level
analysis of signaling will improve our understanding of the immunobiology of IL-7R
signaling.
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Chapter 4 Intrinsic Heterogeneity in Cytokine-
Dependent Naive T-Cell Survival and
Proliferation
The rates of LIP among different naive T-cell clones vary depending upon the specificity of
their TCRs, and correlate with their CD5 expression levels [10]. CD5 is a putative negative
regulator of TCR signaling [58] that is up-regulated upon spMHC engagement [7]. Thus,
CD5 expression levels are thought to reflect the strength of TCR-spMHC interactions [6-9].
Based on these data, variations in LIP have been attributed to differences in the avidity of T-
cells for cognate spMHC [10, 11], with the implicit assumption that naive T-cells bearing
different TCRs have equal cytokine signaling capacity. Examinations of the lifespan of naive
T-cells have also inherently assumed that T-cells survive equally well in the absence of
dedicated homeostatic cues [166-169]. Nonetheless, expression levels of key homeostatic
signaling components, including IL-7R [5] and CD5 [8], are known to vary among naive
CD8' T-cell clones. These differences in expression have been attributed to the interaction
of T-cells with heterogeneous IL-7 and spMHC environments [7, 15, 24], but could also
theoretically reflect stable cell-intrinsic differences in signaling pathways among mature T-
cells. To explore this possibility, we tested the assumption that cytokine responsiveness is
intrinsically uniform among distinct mature naive CD8' T-cell clones in the absence of
spMHC signals. Our focus was primarily on responses to IL-7, as it is considered to be the
most critical for naive T-cell responses [1, 2]. However, we also briefly examine responses to
the related gamma-chain cytokines IL-2 and IL-15, which have partially redundant roles in
supporting naive T-cell survival [1].
4.1 Heterogeneity in Cytokine-Induced Proliferation of CD8* T-Cells
4.1.1 Heterogeneity in IL-7-Induced Proliferation of CD8' TCR-tg T-cells
We sought to determine whether T-cells with a common genetic background but different
antigen specificities respond similarly to IL-7. We began by studying responses between
naive T-cells isolated from TCR-tg mice as a model system for identifying potential
variations across polyclonal T-cell repertoires. Naive CD8* T-cells isolated from OT1 and
F5 TCR-transgenic (TCR-tg) B6.Rag/ mice (hereafter referred to as OT1 or F5 cells) were
chosen for comparison as both cells are selected in the H-2b MHC background, but OT1
cells exhibit markedly greater LIP than F5 cells [10]. In support of studies linking LIP to
TCR sp-MHC avidity, OT1 cells also have higher CD5 expression than F5 T-cells.
Comparison of freshly isolated unpurified OT1 and F5 CD8* T-cells revealed a CD44i
population in OT1 cells that was not present in F5 populations (Figure 4.1a). To ensure we
were directly comparing naive T-cell populations, we therefore sorted OT1 and F5 cells on
their CD44' 'naive' fraction for all experiments. Freshly isolated OT1 cells had slightly
higher CD44, CD62L and TCR expression, and approximately equal CD8a expression,
compared to F5 cells (Figure 4.1b).
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Figure 4.1. Surface Expression Profiles of OT1 and F5 TCR-tg CD8+ T-Cells
(a) CD44 expression on freshly isolated unsorted OT1 and F5 TCR-tg naive CD8+ T-cells. (b)
CD44, CD62L, CD5, TCR and CD8a expression profiles of freshly isolated OT1 and F5 TCR-tg
naive (CD44Jo) CD8+ T-cells.
To compare the IL-7 proliferation responses of OT1 and F5 cells, we cultured CFSE-labeled
cells at low density in media containing 10 ng/mL IL-7 for seven days. We were surprised to
find that in vitro IL-7 stimulation alone had disparate effects on naive OT1 and F5 cells: a
fraction of the OT1 cells proliferated with 1-3 rounds of division while essentially none of
the F5 cells divided (Figure 4.2a).
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Figure 4.2. OT1 and F5 TCR-tg CD8+ T-Cells Differ in their Proliferation Responses to IL-7
(a) CD5 surface expression of freshly isolated OT1 and F5 TCR-tg naive (CD44Jo) CD8+ T-cells (top
panel) and their proliferation when cultured in vitro at low density (-2x10 5 cells/mL) with 10 ng/mL
of IL-7, as assayed by CFSE dilution after 7 days (middle panels), and quantified as the fraction of
cells divided (bottom panel). (b) As described in (a), except for OT1 and F5 TCR-tg CD8+ in titro
memory-like cells generated via activation of naive (CD44)o) OT1 and F5 TCR-tg CD8+ T-cells with
plate-coated aCD3 and 20 ng/mL IL-2 for 3 days, followed by incubation with 40 ng/mL IL-15 for
3 days and overnight rest in cytokine-free media prior to IL-7 stimulation.
We next sought to determine whether this difference in IL-7 sensitivity was maintained
between OT1 and F5 cells after activation and differentiation to memory-like cells. OT1 and
F5 memory-like cells were generated in vitro using minor modifications to a procedure
previously described [35]. Briefly, cells were activated on plate-coated anti-CD3 in the
presence of 20 ng/mL IL-2 for 3 days, differentiated in 40 ng/mL IL-15 for 3 days, and then
cultured overnight in the absence of cytokine. OT1 and F5 memory-like cells showed similar
differences in proliferation in response to IL-7 compared to the naive T-cells from which
they were derived: OT1 cells underwent several rounds of division, while F5 cells were
unable to proliferate (Figure 4.2b). These results suggested that T-cells of different TCR
specificities have intrinsically different capacities to proliferate in response to IL-7 that are
robustly heritable through several rounds of division.
4.1.2 Stability in the Relative CD5 Expression Between T-Cell Clones
In addition to maintaining their relative sensitivity to IL-7, OT1 and F5 cells maintained
their relative CD5 expression following priming/differentiation (Figure 4.3c-d). CD5 is
often used as a surrogate measure of the strength of spMHC-mediated signaling based on
the requirement for continuous TCR engagement with spMHC to maintain CD5 levels [7].
We also found that CD5 levels on OT1 and F5 cells decayed over time during in zitro culture,
independent of IL-7 stimulation (Figure 4.3a). However, naYve OT1 cells maintained their
approximately 3-fold higher level of CD5 at all time-points (Figure 4.3b). Relative CD5
expression between OT1 and F5 cells was also maintained during IL-7 culture for memory-
like cells (Figure 4.3c). This suggests that the basal CD5 expression is intrinsic to a
particular T-cell clone, independent of IL-7 levels and TCR engagement.
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Figure 4.3. Intrinsic Heterogeneity in IL-7-Independent Basal CD5 Expression
(a-b) Decay of CD5 surface expression of freshly isolated OT1 and F5 TCR-tg naive (CD4410) CD8+
T-cells cultured with 0, 0.1, 1 or 10 ng/mL IL-7, normalized to (a) initial expression for each cell
type or to (b) initial CD5 expression on OT1 cells. (c-d) CD5 expression profiles before and after
low density (-2x10 5 cells/mL) in vitro culture with 10 ng/mL for 7 days as flow cytometry histograms
(left two panels) and quantified relative to the CD5hi population for (c) OT1 and F5 TCR-tg naive
(CD44)o) CD8+ T-cells (d) OT1 and F5 TCR-tg CD8+ in vitro memory-like cells.
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4.1.3 CD5 Marks Heterogeneity in the IL-7-Induced Proliferation Capacity of
Polyclonal CD8* T-cells
Maintenance of relative CD5 expression levels led us to hypothesize that CD5 expression
might generally stratify T-cell populations with varying IL-7 sensitivity. To test this
hypothesis in polyclonal T-cell populations, we sorted polyclonal naive (CD44o) CD8+ T-
cells from B6 mice into fractions expressing the top and bottom ~2 0% CD5hi and CD5O
fractions. Similar to OT1 and F5 TCR-tg cells, polyclonal CD5hi CD8' T-cells had slightly
higher CD44 expression than CD5 cells (Figure 4.4). IL-7 sensitivity also showed similar
trends to TCR-tg cells: Culturing CFSE-labeled cells at low density with 10 ng/mL IL-7 for
7 days yielded greater proliferation for polyclonal CD5hi T-cells compared to CD5o cells
(Figure 4.5a). CD5hJ and CD5 cells also maintained their relative CD5 expression levels
following IL-7 treatment (Figure 4.5b). Similar differences in IL-7 responsiveness were
observed when TAP1 ' CD5h' and CD5O T-cells were compared (Figure 4.5c,d), suggesting
that the differential response to IL-7 is due to intrinsic differences in the ability of cells to
respond to IL-7 and not a result of differential interaction with spMHC complexes
presented on T-cells themselves. These data show that CD5 expression levels stratify the
polyclonal naive CD8* T-cell repertoire in terms of proliferation responses to the
homeostatic cytokine IL-7, with higher CD5 levels marking cells with more robust
proliferation.
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Figure 4.4. Surface Expression Profiles of Polyclonal B6 CD5hi and CD51o CD8+ Naive T-cells
CD44 and CD5 expression profiles of C57BL/6 naive (CD44o) CD8+ T-cells sorted into CD5hi and
CD5o expressing fractions compared to unsorted cells.
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Figure 4.5. CD5 Expression Levels Stratify a Hierarchy in the IL-7-Induced Proliferation
Capacities of Polyclonal CD8+ T-cells
(a) CD5 surface expression of freshly isolated C57BL/6 naive (CD44o) CD8+ T-cells sorted into
CD5hi and CD5o expressing fractions (top panel) and their proliferation when cultured in vitro at low
density (-2x10 5 cells/mL) with 10 ng/mL of IL-7, as assayed by CFSE dilution after 7 days (middle
panels), and quantified as the fraction of cells divided (bottom panel). (b) As described in (a), except
for freshly isolated TAP-/- C57BL/6 naive (CD44Jo) CD8+ T-cells sorted into CD5h and CD510
expressing fractions. (c-d) CD5 expression profiles before and in titro culture with 10 ng/mL for 7
days quantified relative to the CD5h population for C57BL/6 naive (CD44o) CD8+ T-cells from (c)
wild type, and (d) TAP-/- mice.
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4.1.4 Heterogeneity in IL-7-Induced Proliferation Marked by CD5 Expression
Even within a population of TCR-tg T-cells, CD5 expression levels are distributed with
some variance. We hypothesized that CD5 levels might also stratify monoclonal T-cell
populations in their responsiveness to IL-7. To test this idea, we sorted OT1 cells into CD5hi
and CD5 fractions (Figure 4.6a). Importantly, these cells express identical levels of TCR
(Figure 4.6b). Following 6 days in low-density culture with 10 ng/mL IL-7, OT1 CD5I cells
showed a modest but statistically significant increase in proliferation over CD5" cells
(Figure 4.6a). This indicates that CD5 levels are intrinsic to an individual T-cell, even
intraclonally and independent of TCR expression level, and can be used as a marker for the
proliferation capacity of naive CD8* T-cells.
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Figure 4.6. CD5 Expression Marks Intraclonal Differences in IL-7-Induced Proliferation
capacity of Naive CD8+ T-cells
(a) CD5 surface expression of OT1 TCR-tg naive (CD440) CD8+ T-cells sorted into CD5hi and
CD51O expressing fractions (top panel) and their proliferation when cultured in litro at low density
(-2x10 5 cells/mL) with 10 ng/mL of IL-7, as assayed by CFSE dilution after 7 days (middle panels),
and quantified as the fraction of cells divided (bottom panel).
4.1.5 CD5 Expression as a Global Marker of T-Cell Proliferation Capacity Across
Multiple y, Cytokines
We hypothesized that CD5 expression levels might also indicate responsiveness to other
related pro-survival cytokines. IL-2 and IL-15 are considered to be more critical for
supporting survival of effector and memory T-cells respectively compared to naive T-cells,
responses thought to be regulated via expression of the cognate receptor components and
local cytokine availability [1]. However, IL-2 and IL-15 have overlapping signaling pathways
with IL-7 (Chapter 3), and have been shown to partially compensate for IL-7 in supporting
peripheral naive T-cell survival in IL-7 depleted environments [69, 70]. Culturing CFSE-
labeled OT1 and F5 cells in saturating levels of IL-7, IL-2 and IL-15 for 7 days revealed even
more robust proliferation responses for OT1 cells in response to IL-2 and IL-15 compared
to IL-7 (Figure 4.7a,b). In contrast, F5 cells did not divide in any of the cytokine cultures.
Similar trends were seen between CD5I and CD5 sorted polyclonal CD8' T-cells (Figure
4.7c,d).
Examination of the surface expression profiles of proliferated OT1 cells indicated an
activated phenotype in IL-2 stimulated cells characterized by increases in CD44, CD25 and
CD69 expression and a decrease in CD62L expression (Figure 4.8). In contrast, IL-15 and
IL-7 induced a milder increase in CD44 expression, and both showed little or no change in
any other indicator of activation. Again, similar trends were observed for polyclonal CD5I
cells that had undergone cytokine-induced proliferation (Figure 4.9).
These data suggest that CD5hI T-cells may have globally enhanced responsiveness to related
homeostatic pro-survival gamma chain cytokines. However, high doses of these cytokines
may be sufficient to induce activated T-cell phenotypes. Despite IL-7 yielding weak
proliferation compared to IL-2 or IL-15, we focused for the remainder of this thesis on
characterizing IL-7 responses, as IL-7 is considered essential for naive T-cell survival, while
IL-2 and IL-15 provide only overlapping or partially redundant signals which may be
additionally restricted via production/localization [1].
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Figure 4.7. CD5 Expression Marks Differences in Proliferation Responses to Multiple Pro-
Survival Cytokines
(a-b) Proliferation of OT1 and F5 TCR-tg naive (CD4410) CD8+ T-cells when cultured in titro at low
density (-2x105 cells/mL) with either 10 ng/mL of IL-7 (top panels), 20 ng/mL IL-2 (middle panels)
or 40 ng/mL IL-15 (bottom panels), as assayed by (a) CFSE dilution after 7 days, and (b) quantified
as the fraction of cells divided (bottom panel). (c-d) As described in (a-b), except for C57BL/6
naive (CD440) CD8+ T-cells sorted into CD5hi and CD5o expressing fractions.
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Figure 4.8. Surface Expression Profiles of OT1 TCR-tg T-cells Proliferating in Response to
Pro-Survival Cytokines
CD44, CD25, CD5, CD62L, TCR, CD69 and CD122 surface expression versus CFSE dilution for
OT1 TCR-tg naive (CD441o) CD8+ T-cells following 7 day in vitro culture with either 10 ng/mL IL-7
(left column), 20 ng/mL IL-2 (middle column) or 40 ng/mL IL-1 5 (right column).
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Figure 4.9. Surface Expression Profiles of B6 CD5 CD8+ Naive T-cells Proliferating in
Response to Pro-Survival Cytokines
CD44, CD25, CD5, CD69 and CD62L surface expression versus CFSE dilution for CD5"h sorted
C57BL/6 naive (CD44o) CD8+ T-cells following 7 day in titro culture with either 10 ng/mL IL-7 (left
column), 20 ng/mL IL-2 (middle column) or 40 ng/mL IL-1 5 (right column).
4.1.6 Enhanced IL-7 Responsiveness of CD44 T-Cells
OT1 mice have a CD44' peripheral T-cell population in vivo (Figure 4.10a), and can exhibit
a mild increase in CD44 expression upon IL-7 treatment in vitm (Figure 4.8). We therefore
hypothesized that high CD44 expression might mark cells with greater cytokine sensitivity.
We therefore sorted OT1 cells into CD44' and CD44' fractions and examined their
proliferation in response to 1Ong/mL IL-7 for 7 days. While both CD44' and CD44
populations underwent division, CD44 T-cells had more robust proliferation (Figure
4.10b,c). CD44 cells also showed an increase in CD44 expression and a decrease in CD62L
expression indicative of conversion to a memory-like phenotype that was not observed in
the CD44" population (Figure 4.10b). These data suggest that the CD44 population
observed in OT1 mice may represent cells that have already undergone LIP and conversion
to a memory-like phenotype, and these cells are imparted with an enhanced sensitivity to IL-
7 compared to their CD44' counterparts. To facilitate direct comparison of the same T-cell
population across different TCR specificities, we focused on characterizing responses of the
CD441 'naive' T-cell population for the remainder of this thesis.
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Figure 4.10. OT1 CD44h CD8+ T-cells Have Enhanced IL-7-Induced Proliferation
(a) CD44, CD5 and CD8z expression profiles of OT1 TCR-tg CD8+ T-cells either freshly isolated
or sorted into CD4410 or CD44hi expressing populations. (b) Proliferation as assayed by CFSE
dilution for OT1 TCR-tg CD8+ T-cells sorted into CD44o or CD44hi expressing fractions when
cultured in titro at low density (-2x10 5 cells/mL) for 7 days with 10 ng/mL of IL-7. CFSE dilution
profiles are shown as histograms or against the expression of CD44, CD5 or CD62L. (c)
Quantification of proliferation as the fraction of cells divided for the conditions described in (b).
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4.2 Heterogeneity in the Cytokine-Deprived Survival Capacities of
CD8* Naive T-Cells
4.2.1 Prolonged Survival of CD5* T-Cells in the Absence of Homeostatic Signaling
Having observed difference in the IL-7-induced proliferation capacities of naive T-cells, we
next asked whether there were comparable differences in the ability of IL-7 to support
survival in CD5" and CD5 cells. We first examined survival responses of OT1 and F5 cells.
However, freshly isolated cells undergo an acute, IL-7 independent crash in survival in the
first 8-12 hours in culture (Figure 4.11) that is unpredictably variable depending on the age
and sex of the mouse and the isolation procedures used. Furthermore, residual signaling
from heterogeneous IL-7 and spMHC environments between TCR-tg mice could convolute
examination of responses directly following isolation. Therefore, for all experiments, we
cultured cells in cytokine-free media overnight (~16 hours) before stimulating with IL-7.
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Figure 4.11. Initial IL-7-Independent Acute Death Following Isolation of TCR-tg CD8+ T-
Cells
Viability of freshly isolated OT1 and F5 TCR-tg naive (CD44'o) CD8+ T-cells cultured at low density
(-2x10 5 cells/mL) in titro in media containing IL-7 at concentrations ranging from 0.001-10ng/mL at
varying time points over 24 hours showing an early IL-7 independent acute death immediately
following isolation.
To examine survival responses, overnight rested OT1 and F5 cells were cultured in IL-7-
supplemented or cytokine-free cultures. Both OT1 and F5 naive T-cells exhibited -100%
survival over three days in the presence of saturating doses of IL-7 (Figure 4.12a). However,
F5 cells survived better in vitro than OT1 cells in the absence of IL-7. Polyclonal CD5hi and
CD5 naive CD8' T-cells behaved similarly to their TCR-tg counterparts, with CD5" cells
surviving better in cytokine-deprived culture though differences were milder (Figure 4.12b).
Thus, while CD5h and CD5 CD8+ T-cells have different abilities to proliferate in response
to IL-7, they also have different abilities to survive in the absence of homeostatic stimuli.
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Figure 4.12. CD5lo Naive CD8+ T-cells Have Prolonged Cytokine- and TCR-Independent
Survival
(a-b) Viability over 3 days of (a) OT1 and F5 TCR-tg naive (CD44O) CD8+ T-cells, and (b) C57BL/6
naive (CD440) CD8+ T-cells sorted on CD5hi or CD51 expressing fractions, for cells rested
overnight (~16 hours) in cytokine-free media and then treated +/- 10 ng/mL IL-7 in titm in low
density (-2x10 5 cells/mL) culture (top panel), and mean half-lives of cytokine-deprived cells (bottom
panel).
4.2.2 Increased Glucose Uptake by CD51* T-Cells
IL-7 supports survival in part by increasing glucose uptake via up-regulation of the Glut1
glucose transporter [96]. Upon cytokine withdrawal, Glut1 is internalized and degraded, and
cells lose glucose uptake and atrophy. To determine whether OT1 and F5 cells differed in
glucose uptake, we measured their radioactive glucose incorporation following overnight
culture in the presence or absence of IL-7. While both cells increased glucose uptake with
IL-7 treatment, F5 cells had greater uptake than OT1 in both the presence and absence of
IL-7 (Figure 4.13). Greater glucose uptake in F5 cells may therefore support prolonged cell
survival in cytokine-depleted conditions, whereas in the presence of cytokine, both cells may
have sufficient glucose uptake.
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Figure 4.13. F5 T-cells Have Increased Glucose Uptake
Radioactive glucose uptake for OT1 and F5 TCR-tg naive (CD440) CD8+ T-cells cultured 16 hours
+/- 10 ng/mL IL-7, rested 30 minutes in serum- and glucose-free media, and then incubated for 45
minutes with 0.1mM 2-deoxy-D[1- 3H] glucose (4 gCi/mL).
4.2.3 Increased Sensitivity to P13K Inhibition of CD5" T-Cells
P13K is a critical mediator of IL-7-mediated glucose uptake [96]. We therefore hypothesized
that F5 cells might have increased P13K signaling activity compared to OT1 cells. Low Akt
phosphorylation levels in the absence of cytokine signaling prevented accurate quantification
of phospho-Akt as a proxy for signaling activity (data not shown). We therefore took an
alternative approach and determined the sensitivity of OT1 and F5 viability to P13K
inhibition. Inhibition of P13K by LY294002 did not significantly decrease OT1 or F5
survival over 24 hours in the presence 0.1 ng/mL IL-7 (Figure 4.14a). However, F5 cells
had lower sensitivity to P13K inhibition in the absence of cytokine, with an IC50 of 25uM
LY294002 compared to 10uM for OT1 cells (Figure 4.14b). Similar differences in sensitivity
were observed with a second P13K inhibitor, PI-103 (Figure 4.14c). This suggests that
greater baseline P13K activity in CD5o T-cells may support their prolonged survival in
cytokine-deprived conditions via P13K-dependent mechanisms, including glucose uptake.
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Figure 4.14. F5 T-Cells Have Decreased Sensitivity to P13K inhibition in the Absence of IL-7
(a-b) Sensitivity of viability to P13K inhibition for OT1 and F5 TCR-tg naive (CD4410) CD8+ T-cells
rested overnight (-16 hours) in cytokine-free media and then treated 24 hours with varying doses of
the P13K inhibitor LY294002 in (a) cultures containing 1Ong/mL IL-7, and in (b) cytokine-deprived
cultures, normalized to uninhibited viabilities. The LY294002 IC50 for the viability of OT1 and F5 T-
cells in the absence of cytokine is shown to be 10 pM and 25 gM respectively. (c) Same as (b), but
for P13K inhibition with 6.25uM PI-103.
4.2.4 Cell Size Variation with CD5 Expression
IL-7 is known to be an important regulator of cell size that is often linked to its ability to
support metabolism and cell survival via P13K-dependent pathways [72]. Despite the fact
that F5 cells appeared to have enhanced metabolic capacity in the absence of cytokine as
measured by prolonged survival and P13K activity, F5 cells have smaller cell size (as
measured by Forward Scatter in Flow Cytometry Measurements) than OTI cells (Figure
4.15a,c). This same trend is seen between CD5i and CD5'O polyclonal CD8' T-cells (Figure
4.15b,c). This suggests that cell size may be more closely linked to IL-7 responsiveness than
cell survival capacity in the absence of cytokine.
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Figure 4.15. CD5hi T-Cells Have Increased Cell Size
(a-c) Comparison of Forward Scatter by flow cytometry as an indication of relative cell size for (a)
OT1 and F5 TCR-tg naive (CD4430) CD8+ T-cells and (b) C57BL/6 naive (CD44o) CD8+ T-cells
sorted on CD5hi or CD5o expressing fractions. (c) Quantification of the mean forward scatter from
profiles shown (a-b).
4.3 Different IL-7 Dose Requirements for Survival and Proliferation
Our examinations of cytokine responses thus far had focused on saturating doses of IL-7
>lng/mL. However, IL-7 levels in vivo are thought be much lower [2, 76], and still support
cell survival. We therefore titrated the level of IL-7 in vitro and examined the 24 hour survival
and 5 day proliferation of OT1 and F5 cells (Figure 4.16). The fraction of cells expressing
the proliferation antigen Ki67 was used as a more sensitive readout of proliferation. IL-7
concentrations >= 0.1ng/mL were able to support complete survival of both OT1 and F5
cells (Figure 4.16a), while concentrations >=lng/mL were required to induce proliferation
in OT1 cells (Figure 4.16b). Different IL-7 dose requirements for survival and proliferation
have previously been identified for polyclonal recent thymic emigrant T-cell populations
[14]. However, our data suggests that the IL-7 requirements for survival are similar among
T-cell clones, and while greater IL-7 doses can support proliferation for some cells, the
extent of the response depends on the particular T-cell examined.
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Figure 4.16. Different IL-7 Dose Requirements for T-Cell Survival versus Proliferation
(a) 24 hours viability and (b) 5 day proliferation (as assessed by Ki67+ fraction) of OT1 and F5
TCR-tg naive (CD440) CD8+ T-cells rested overnight (-16 hours) in cytokine-free media and then
cultured in zitro at low density with IL-7 concentrations ranging from 0.0001-1 OOng/mL.
4.4 Summary: Heterogeneity in IL-7 Responsiveness and Turnover
Among the Naive T-Cell Repertoire
We have identified differential IL-7 responsiveness amongst mature TCR-tg and polyclonal
CD8* T-cell populations in the absence of TCR signaling that is correlated with CD5
expression. CD5 levels are IL-7-independent, and relative differences in basal CD5
expression are maintained in the absence of spMHC. At saturating doses of IL-7, all T-cells
survived efficiently, but only cells with high levels of CD5 were capable of proliferating.
Conversely, at low doses of IL-7, CD5O cells had prolonged survival, that was also reflected
in their P13K-dependent glucose uptake. Differences in IL-7 responses are presents even
intra-clonally within populations bearing the same TCR specificity, and persist through
several rounds of activation-induced proliferation. CD5hi populations also have increased
responsiveness to the related y, cytokines IL-2 and IL-15. This suggests that the T-cell
repertoire is comprised of populations with both intrinsic differences in TCR specificity and
cytokine responsiveness. Thus, while the enhanced LIP of CD5" T-cell clones has been
previously attributed to their greater avidity for spMHC [11], our data suggests differential
cytokine signaling may also potentiate proliferation.
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Chapter 5 Quantitative Signaling Analysis of IL-7
Responsiveness
In Chapter 4, we characterized heterogeneous abilities among naive T-cells to proliferate in
response to IL-7 stimulation that was predictably marked by their CD5 expression. We
hypothesized that differences in cellular responses to IL-7 would be encoded by IL-7-
dependent signaling pathway activation. Previous studies have identified differences in IL-7-
induced signaling and responses between T-cells, but these were attributed to different
strengths of TCR-mediated negative feedback to IL-7 signaling [24]. We therefore sought to
characterize potential differences in IL-7 induced signaling in CD5hi and CD5'") cells in the
absence of spMHC signaling, and determine how these give rise to heterogeneous IL-7
responses. While many of the signaling components critical for mediating IL-7-induced
responses in T-cells have been identified (Section 2.3.2, Figure 2.5), few studies have
quantitatively analyzed IL-7 signaling, particularly across T-cell populations of different TCR
specificity. In this chapter we undertake a detailed analysis of IL-7 signaling in CD5I and
CD5') T-cells that suggests IL-7R expression is a critical mediator of downstream responses.
Receptor expression limits the ability of cells to achieve distinct signaling requirement for
different downstream responses, including survival, proliferation and induction of the TCR
co-receptor CD8a.
5.1 Heterogeneity in IL-7R Expression Among CD8' T-Cells
5.1.1 Heterogeneous CD8* T-Cell IL-7R Expression Correlated With CD5 Levels
We first characterized IL-7Ra surface expression of OT1 and F5 cells. As IL-7 signaling
suppresses transcription of IL-7Ra [15] and in vivo IL-7 levels may differ between OT1 and
F5 mice, we compared IL-7Ra expression in both freshly isolated T-cells and cells placed in
cytokine-free culture for 16 hours (Figure 5.1a). Freshly isolated OT1 cells had
approximately 2-fold higher IL-7Rc expression than F5 cells, and this relative difference was
maintained following cytokine-free culture, exposing a higher 'basal' (i.e. uninhibited)
receptor expression in OT1 cells (Figure 5.1a). In contrast, culture of either OT1 or F5
cells for 16 hours with 10 ng/mL IL-7 completely suppressed surface IL-7Ra expression.
Polyclonal naive CD8+ CD5" and CD5"' T-cells also showed more modest but statistically
significant differences in IL-7Ra levels (Figure 5.1b), suggesting that CD5 levels mark
intrinsic differences in IL-7Ra expression. IL-7Ra surface expression differences between
OT1 and F5 cells were reflected in the IL-7Ra mRNA expression profiles (Figure 5.2),
though IL-7Rz was not completely suppressed in IL-7 culture, supporting the notion that
IL-7Ra expression is primarily, but not fully, controlled at the level of gene expression.
Naive CD8+ T-cell populations are therefore heterogeneous in their IL-7R expression, which
is correlated with CD5 expression, and regulated at the level of gene expression.
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Figure 5.1. CD5h Naive CD8+ T-cells have higher IL-7R expression
(a-b) Surface IL-7Ra expression of (a) OT1 and F5 TCR-tg naive (CD44o) CD8+ T-cells and (b)
C57BL/6 naive (CD441o) CD8+ T-cells sorted on CD5hi or CD5O expressing fractions, for cells
freshly isolated from lymph nodes or cells cultured overnight (16 hours) +/- 10 ng/mL IL-7.
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Figure 5.2. IL-7Ra Surface Expression Reflected by mRNA Expression
IL-7Ra mRNA expression of (a) OT1 and F5 TCR-tg naive (CD440o) CD8+ T-cells for cells freshly
isolated from lymph nodes or cells cultured overnight (16 hours) +/- 10 ng/mL IL-7.
5.1.2 IL-7 Dose Requirements for IL-7R Suppression
Negative feedback to IL-7Ra expression after IL-7 binding occurs via at least two
mechanisms: transcriptional suppression of IL-7Ra expression [15], and endocytic
internalization of ligand-bound receptors [170]. To determine whether differences in IL-7
responses may be reflected in negative feedback to IL-7Ra expression, we characterized the
IL-7 dose requirements for suppression of surface receptor expression in OT1 and F5 cells
(Figure 5.3). IL-7Ra expression 24 hours after treatment with varying concentrations of IL-
7 showed similar dose responses between OT1 and F5 cells, with complete receptor
suppression for IL-7 >0.lng/mL, no suppression at IL-7 <0.Olng/mL and partial
suppression at 0.01ng/mL. Notably, only at IL-7 doses leading to surface receptor
suppression do we observe support of cell survival and proliferation (Figure 4.16b),
supporting a strong relation between receptor levels and responses.
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Figure 5.3. IL-7 Dose Requirements for Receptor Downregulation
(a-b) Surface IL-7Ra expression for OT1 and F5 TCR-tg naive (CD44Jo) CD8+ T-cells rested
overnight (~16 hours) in cytokine-free media and then cultured in titro at low density with IL-7
concentrations ranging from 0.0001-10 ng/mL, normalized to (a) OT1 expression at 0 ng/mL IL-7
or (b) individual cell expression at 0 ng/mL IL-7.
Signaling arising from TCR binding to spMHC is also proposed to inhibit IL-7 signaling
mediated suppression of IL-7R expression [24, 171]. As an additional control to determine
whether T-cells were interacting with spMHC on their own surface and influencing
responses, OT1 cells were cultured for 24 hours with varying doses of IL-7 in the presence
of known positively selecting self-peptides of varying affinity for the OT1 TCR, or foreign
antigenic peptides (Figure 5.4). IL-7Ra expression, survival and CD8a expression were
unchanged in cultures with self-peptides compared to the no peptide control. However,
addition of antigenic peptide to cultures suppressed IL-7Rax expression and supported
partial viability, independent of -IL-7 dose. Conversely, IL-7 dose-dependent increases in
CD8a expression were conserved in cultures with antigen, but there was a large increase in
absolute CD8 levels. This provided further supporting evidence that the signaling and
response we were characterizing were specific to IL-7R and not being influenced by TCR
engagement with self-peptides under the examined culture conditions.
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Figure 5.4. IL-7R, Viability and CD8a Responses to IL-7 are Not Influenced by Self-
Peptides
(a-c) (a) Surface IL-7Ra expression, (b) viability and (c) CD8a of OT1 and F5 TCR-tg naive
(CD44O) CD8+ T-cells rested overnight (-16 hours) in cytokine-free media and then cultured in titro
at low density with IL-7 concentrations 0.001-10ng/mL and either no peptides, known positively
selecting self peptides (1 uM or 5uM ISFKFDHL or RTYTYEKL) or known antigenic peptides (1uM
SIINFEKL),
5.2 Enhanced IL-7 Signaling of CD5"' T-Cells Mediated by High IL-
7R Expression
5.2.1 Differential Dependence of Signaling and Responses on Jak and PI3K
Activation
IL-7 induces activation of the Jak/Stat and PI3K/Akt pathways [1, 2], however there is
some uncertainly as to the relative importance of these pathways in the control of
downstream responses and their potential points of crosstalk. We therefore examined
signaling and responses in OT1 cells in the presence and absence of IL-7 in the presence of
either the Jak family inhibitor Jak Inhibitor I, or the P13K inhibitors LY294002 or PI-103
(Figure 5.5). We also wished to identify a downstream proxy for P13K signaling activity, and
therefore examined phosphorylation of two kinases purportedly regulated by IL-7 dependent
P13K activation: GSK3 and Akt. Interestingly, we did not see any IL-7 dependent increases
in Akt phosphorylation, but total phosphorylation was decreased in both cytokine-
supplemented and cytokine-free cultures under either Jak or P13K inhibition (Figure 5.5a).
These same trends were observed when Akt phosphorylation was detected by SDS-PAGE,
and notably, pAkt was only expressed at very low levels near the limit of accurate
quantization (data not shown). Conversely, GSK3 phosphorylation exhibited a strong Jak
and P13K dependent increase with IL-7 treatment (Figure 5.5b). We therefore chose to use
GSK3 as a proxy for P13K and/or Jak activity in future assays. This data also suggests that
P13K dependent responses to IL-7 may not be primarily transduced via Akt, and rather,
through other downstream targets of P13K.
Our examination of cellular responses to IL-7 surprisingly revealed that IL-7-dependent
increases in viability were Jak- but not P13K-dependent, while only P13K inhibition
significantly decreased viability in cytokine-free cultures (Figure 5.5c). Decreases in viability
in the presence of IL-7 under Jak inhibition were reflected in the Bcl2 profiles, but not under
cytokine-free P13K inhibition (Figure 5.5d). This supports the notion that while Bcl2
induction is a critical mediator of the anti-apoptotic effects of Bcl2 inhibition, P13K activity
is essential for other mechanisms supporting cell survival. Suppression of IL-7R by IL-7 also
occurs via a Jak-dependent but P13K-independent pathway (Figure 5.5e). Conversely, basal
levels of CD8ax are not affected by inhibition of either pathway, and IL-7-induced increases
in CD8aX expression are both Jak- and P13K- dependent (Figure 5.5f). These data support a
network structure whereby all IL-7 dependent responses are Jak-dependent, and that Jak-
dependent P13K pathway activation is critical to some responses (CD8a induction) but not
others (Viability, Bcl2 induction, IL-7R suppression). Furthermore, P13K is essential for
basal cytokine-deprived survival.
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Figure 5.5. Different Dependence of IL-7 Responses on PI3K- and Jak-Mediated Signaling
(a-f) Influence of PI3K and Jak inhibition on cellular responses to IL-7. OT1 TCR-tg naive (CD441-)
CD8+ T-cells were rested overnight (~16 hours) in cytokine-free media and then cultured in itro at
for 24 hours at low density in media +/- 1 ng/mL IL-7 alone or in the presence of the Jak family
inhibitor Jak Inhibitor I (1 uM), the PI3K Inhibitors LY294003 (10 uM) or PI-103 (10 uMI), or a
DMSO vehicle control. After 24 hours in culture, (a) pAkt (S473), (b) pGSK3a/$, (c) Viability, (d)
Bcl2, (e) IL-7Ra surface expression, and (f) CD8a surface expression were assayed by flow
cytometry. (g) Putative signaling network connectivity map derived from signaling inhibition studies
shown in (a-f).
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5.2.2 Enhanced IL-7-Dependent Signaling Pathway Activation for CD5hi T-Cells
We sought to determine whether the modest differences in IL-7R expression between CD5"I
and CD5" T-cells elicits differential signaling pathway activation. To characterize both
Jak/Stat and P13K dependent signaling we measured levels of phosphorylated Stat5 and
GSK3 (pStat5 and pGSK3) and increases in Bcl2 and CD8a expression following IL-7
stimulation. T-cells were rested overnight before measuring signaling to eliminate the
potential effects of heterogeneous signaling received in ivo. OT1 cells treated with IL-7
showed higher pStat5 (at 20 minutes) and pGSK3 (at 24 hours) than F5 cells (Figure 5.6a),
which was independent of total Stat5 or GSK3 expression (Figure 5.6b). IL-7 also induced
a greater increase in CD8a expression at 24 hours in OT1 cells. While the fold induction of
Bcl2 at 24 hours was similar between the two cells, OT1 cells had higher basal and IL-7-
induced Bcl2 levels. Polyclonal naive CD8' CD5"' and CD5'" cells exhibited the same trends
as TCR-tg cells, although the differences were less pronounced, reflecting the smaller
differences in their initial IL-7Rax expression (Figure 5.6c). Differences in IL-7-induced
pStat5 between OT1 and F5 cells could also be seen immediately following isolation, when
IL-7Ra is partially suppressed (Figure 5.6d). These results demonstrate that even mild
differences in baseline IL-7R levels between CD5" and CD5'" cells are associated with
significant differences in IL-7-induced signaling pathway activation.
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Figure 5.6. CD5h Naive CD8+ T-cells Have Higher IL-7-Induced Signaling Capacity
(a) IL-7-induced signaling in OT1 and F5 TCR-tg naive (CD441o) CD8+ T-cells as assessed by Stat5
phosphorylation at 20 minutes, and GSK3a/S phosphorylation, Bcl2 and surface CD8a expression
at 24 hours, in cells rested overnight and then treated with +/- 10 ng/mL IL-7. All measurements
made by intracellular flow cytometry. (b) Total expression of Stat5, GSK3 and P-actin (loading
control) as assessed by SDS-PAGE (left panel) and quantified by densitometry (right panel) in OT1
and F5 TCR-tg naive (CD44o) CD8+ T-cells rested overnight in cytokine-free media. (c) As
described in (a), except for C57BL/6 naive (CD44o) CD8+ T-cells sorted on CD5M or CD5o
expressing fractions. (d) Stat5 phosphorylation at 20 minutes for freshly isolated OT1 and F5 TCR-
tg naive (CD441o) CD8+ T-cells treated with +/- 1Ong/mL IL-7.
5.2.3 Receptor-Proximal Signaling Capacity Directly Related to IL-7R Expression
It was not clear that higher IL-7-induced signaling in CD5h T-cells was due to greater IL-7R
expression alone. To elucidate the relationship between IL-7R expression and signaling, OT1
and F5 cells were treated with varying IL-7 doses and their pStat5 and IL-7Ra surface
expression dynamics measured over 6 hours (Figure 5.7a,b). Both OT1 and F5 cells
showed the same linear relationship between loss of surface IL-7Ra at 6 hours and the level
of Stat5 signaling induced (quantified either as the pStat5 level at 10 minutes or integrated
over 6 hours) (Figure 5.7c,d). This suggests equivalent proximal signaling per receptor
bound and internalized for OT1 and F5 cells, and that the enhanced signaling capacity of
OT1 cells is directly related to their higher IL-7R expression.
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Figure 5.7. Linear Correspondence Between IL-7Ra Expression and pStat5 Signaling
(a-b) Dynamics of (a) surface IL-7Ra expression and (b) Stat5 phosphorylation over 6 hours for
OT1 and F5 TCR-tg naive (CD441o) CD8+ T-cells rested overnight (16 hours) in cytokine-free media
and the treated with 0, 0,001, 0.01, 0.1, 1 or 10 ng/mL IL-7. (c-d) Linear correlation between loss of
surface IL-7Ra expression at 6 hours with (c) Stat5 phosphorylation integrated over 6 hours and (d)
Stat5 phosphorylation at 10 minutes for the signaling time courses described in (a-b).
5.3 CD8* T-Cells Share Common Signal-Response Relationships
5.3.1 Methodology for Signal-Response Analysis
We next asked whether OT1 and F5 cells translated a given amount of signaling into
equivalent functional responses. We compared two methods for quantitatively titrating the
level of receptor-proximal signaling (1) varying the IL-7 concentration, or (2) treating with a
saturating dose of IL-7 and varying amounts of a Jak family inhibitor (Figure 5.8a,b). There
is a strong linear correspondence between early (20minute) pStat5 and pGSK3 signaling and
agreement between varying IL-7 and varying inhibitor conditions for both OT1 and F5 cells
(Figure 5.8c). There also exists a strong linear relationship between (20 minute) and late (24
100
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hour) pGSK3 levels for cells with a varying inhibitor treatment, indicative of sustained
signaling. However, this relationship is lost for OT1 cells in the varying IL-7 treatment, with
low IL-7 doses showing decreased late signaling. Less sustained signaling resulted from
ligand depletion from the media (explored further in Chapter 7), whose effects are more
apparent for OT1 than F5 cells due to their higher IL-7R expression. The effects of ligand
depletion severely impact the interpretation of signal response relationships across different
timescales. For instance, in examining the relationship between early 20 minute pStat5
signaling and 24 hour viability, titrating signaling via different IL-7 concentration yields a
linear relationship between signaling and responses (Figure 5.8d). Only in eliminating the
effects of ligand depletion by titrating the inhibitor dose do we expose that viability actually
quickly saturates as a function of pStat5 signaling.
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Figure 5.8. Determination of Signal-Response Relationships Requires Signal Inhibition
Approach
(a) Comparison of strategies for examining the relationship between IL-7-induced signaling and
responses. IL-7 signaling can be modulated by either increasing IL-7 dose, or using a constant
saturating dose of IL-7 and varying the levels of a receptor proximal signaling inhibitor such as Jak
Inhibitor I. (b) 20 minute Stat5 phosphorylation for OT1 and F5 TCR-tg naive (CD441o) CD8+ T-
cells rested overnight (-16 hours) without cytokine and then subject to either the varying IL-7 dose
(left panel) or varying Jak inhibitor I with constant 1 ng/mL IL-7 dose (right panel) treatments for
titrating IL-7 signaling as described in (a). (c) Correspondence between 20 minute Stat5
phosphorylation and 20 minute GSK3 phosphorylation (left panel) and between 20 minutes and 24
hour GSK3 phosphorylation (right panel) for OT1 and F5 TCR-tg naive (CD44o) CD8+ T-cells
when IL-7-induced signaling is titrated by varying the IL-7 dose versus using a constant saturating
dose of IL-7 and varying inhibitor treatments as described in (a-b). (d) Relationship between 20
minute Stat5 phosphorylation and 24 hour viability for OT1 TCR-tg naive (CD441) CD8+ T-cells
under varying inhibitor of varying IL-7 dose treatments as described in (a). An arrow indicates the
effect of ligand depletion on the signal-response curve at low IL-7 doses.
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5.3.2 Common Relationships Between Signaling and Viability, CD8a Induction
Given a common relationship between receptor expression and proximal signaling, we asked
whether OT1 and F5 similarly translated a given amount of proximal signaling into
downstream proliferation responses or CD8a induction. To eliminate the effects of ligand
depletion, cells were treated with a high dose of IL-7 (1 ng/mL) and signaling was titrated by
varying the amount a Jak family inhibitor, Jak Inhibitor I. OT1 and F5 cells exhibited
common relationships between IL-7 signaling (20 minute pStat5 or 24 hour pGSK3) and
viability or CD8a expression at either 24 or 48 hours, but had different dynamic ranges
(Figure 5.9). Viability responses were nonlinear with IL-7 signaling and were readily
saturated, with ~100% cell survival induced by very low levels of IL-7 signaling (Figure
5.9a,b,e,g). A consequence of this sensitive viability response is that the uninhibited
signaling capacities of OT1 and F5 cells, though reaching different maxima, were each
sufficient to yield complete survival of either T-cell at high IL-7 doses. In contrast, while
OT1 and F5 cells also shared a common relationship between signaling and induction of
CD8L expression, this relationship was linear (Figure 5.9c,d,g,h). Thus the maximum
signaling capacity of F5 cells was insufficient to yield the maximum CD8a induction
achievable by OT1 cells. A naive T-cell's capacity to survive and induce CD8a in response
to IL-7 is therefore directly related to its IL-7R receptor expression, and in abundant
cytokine conditions, a mild decrease in receptor expression limits CD8a induction, but not
viability.
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Figure 5.9. IL-7R Expression Thresholds Naive CD8+ T-Cell Responses to IL-7
(a-d) Relationship of IL-7-induced signaling to (a-b) viability and (c-d) CD8a expression at (a,c) 24
hours and (b,d) 48 hours for 'early' signaling quantified as 20 minute Stat5 phosphorylation for OT1
and F5 TCR-tg naive (CD4410) CD8+ T-cells rested overnight (-16 hours) in cytokine-free media and
then treated with 1 ng/mL of IL-7 and varying concentrations of the Jak family inhibitor Jak
Inhibitor . (e-f) As described in (a-d) except for 'late' signaling quantified as GSK3 phosphorylation
at 24 hours.
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5.4 IL-7R Expression Limits Naive CD8* T-Cell Proliferation
Capacity
5.4.1 Attempts to Modulate IL-7R Expression of CD8* T-Cells
We hypothesized that similar to CD8a induction and viability, there may exist a threshold
level of IL-7 signaling required to promote T-cell proliferation. We initially sought to test
this hypothesis by determining whether increasing IL-7R expression on F5 cells would allow
for their proliferation in response to IL-7.
5.4.1.1 Functional Expression of a Retroviral IL-7R Expression Vector
Full-length murine IL-7Rx cloned into the pMig retroviral expression plasmid (MSCV-Ires-
GFP) was either obtained from Scott Durum (Mig7sd) or prepared independently by Vinay
Mahajan (Mig7vsm). To test expression and function of the IL-7Ra vector, we first
examined retroviral infection of the murine cell line 58 , a variant of the DO-11.10.7 CD4
CD8 mouse hybridoma that lacks TCR a and P chains [172] (Figure 5.10). 24 hours after
infection, infected cells cultured in cytokine-free media showed a strong increased in IL-7RaC
expression that was highly correlated with GFP expression (Figure 5.10a,b). Culture of
infected cells 24 hours with 10 ng/mL IL-7 led to only partial receptor downregulation
(Figure 5.10b). As the introduced vector is not driven by the endogenous IL-7Ra promoter,
and thus not subject to the same transcriptional suppression, surface receptor loss likely
results from endocytic internalization. Stimulation of cytokine-deprived Mig7 infected cells
lead to an increase in Stat5 phosphorylation over uninfected cells that was also correlated
with GFP expression (Figure 5.10c,d), indicating the Mig7 retroviral vector could be
functionally expressed in murine cells.
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Figure 5.10. IL-7Ra Retroviral Expression Vector is Expressed, Functional in a Murine
Lymphocyte Cell Line
(a-b) IL-7Ra surface expression for uninfected (left panel) or Mig7sd infected (right panel,
M01=10) 584 cells after overnight (-16 hour) culture +/- 10 ng/mL IL-7, shown as histograms (a)
or as a function of GFP expression (b). (c-d) As described in (a-b), but staining for intracellular
pStat5.
5.4.1.2 Lack of IL-7R Overexpression Suggests Tight Regulation of Surface IL-7Ra
Having tested the functionality of the IL-7Ra expression vector, we next sought to express
the vector in F5 cells. There is a lack of efficient and reliable methods for the introduction of
foreign genetic material into naive T-cells, and we therefore attempted three different
approaches. We first tried to directly transfect naive F5 cells using the Amaxa
electroporation system (see Methods). Unfortunately, infection rates for the IL-7Ra vector
were <5%, resulted in a severe loss in cell viability, and electroporation even decreased IL-
7Ra expression in control samples that did not include DNA (Figure 5.11).
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Figure 5.11. Naive T-Cell Infection by Electroporation is Inefficient, Compromises Viability
Viability as assessed by DAPI- fraction (top row), GFP+ expressing infected fraction (middle row),
and IL-7Ra surface expression for freshly isolated TCR-tg naive (CD4410) CD8+ T-cells after 16
hours in culture with media +/- 1 ng/mL IL-7 following infection with Mig7sd, a control GFPmax
vector or no vector using the Amaxa cell electroporation system.
As we also observed differences in IL-7 responsiveness between OT1 and F5 in vitro derived
memory-like cells, we next tried to overexpress IL-7Ra in F5 memory cells via retroviral
spin infection of blasting cells during activation. Briefly, cells were activated via either plate
coated uCD3 or PMA/Ionomycin stimulation in the presence of 20 ng/mL IL-2 with two
round of spin infections with either Mig7sd or Mig7vsm virus (MOI=10) at 24 hours and 48
hours after activation, washing cells 24 hours after each round of infection. Cells were then
differentiated in 10ng/mL IL-7 or 40ng/mL IL-15 for three days. Unfortunately, infected F5
in vitro memory cells showed no GFP+ population, or increase in IL-7Ra surface expression
over uninfected controls (Figure 5.12), and did not proliferate in response to IL-7 (not
shown).
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Figure 5.12. No Increase in IL-7Ra for F5 in vitro Memory Cells after Mig7 Spin Infection
IL-7Ra surface expression for F5 TCR-tg CD8+ in vitro memory-like T-cells uninfected (left panels),
Mig7vsm infected (middle panels) or Mig7sd infected (right panels). In vitro memory-like cells were
generated via activation of naive (CD44O) F5 TCR-tg CD8+ T-cells with either (i) plate-coated aCD3
or (ii) PMA/Ionomycin, in the presence of 20 ng/mL IL-2 for 3 days, followed by incubation with
either (i) 40 ng/mL IL-15 or (ii) 1Ong/mL IL-7 for 3 days and overnight rest in cytokine-free media
prior to assessment of IL-7Ra levels. Two rounds of spin infection with retrovirus (MOI=10) were
performed 24 hours and 48 hours after activation, with media exchanges 24 hours after each
infection.
Failing to directly transfect mature T-cells, we subsequently attempted to make bone marrow
chimeras in which F5 bone marrow-derived stem cells retrovirally transduced with IL-7Ra
were adoptively transferred into Rag-/- hosts. While modulation of IL-7Ra expression and
signaling is critical to thymic development, IL-7R overexpression in thymic T-cell precursors
has been shown to produce mature peripheral T-cells with normal phenotypes (Trop S
Blood 2001). To produce chimeras, the stem cell fraction of F5 bone marrow was enriched,
infected and expanded using minor modification of a protocol previously described (Zhang
CC et al 2006). In brief, purified F5 bone marrow stem cells were infected with Mig7sd or
Mig7vsm at 24 hours and 48 hours (MOI~10) and expanded for 7 days. Expanded cells
were then retro-orbitally injected at into sublethally irradiated (600 Rad) Rag-/- hosts (~105
cells/mouse). Bone marrow chimeras were produced for each of the two Migs7d and
Mig7vsm virus preparations, for a total of ~30 mice. Tail bleeds of mice 6 weeks later
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showed -18 mice with significant CD8' peripheral reconstitution, and GFP+ fractions
ranged from 30-70%. Isolation of the lymph node and spleen of one mouse produced from
each of the four virus infection batches confirmed a GFPt mature CD8' T-cell population
in the lymphoid organs (Figure 5.13a). However, examination of IL-7Ra surface expression
in freshly isolated cells or cells rested overnight in the presence of 10 ng/mL of IL-7 or in
cytokine-free media revealed identical surface receptor expression in infected F5 cells
compared to cells from uninfected F5 control mice (Figure 5.13b,c). Complete loss IL-7Ra
surface expression after cytokine treatment also suggested that all receptors expressed were
subject to transcriptional repression, indicating the presence of protein from only the
endogenous gene, and not a combination of endogenous and exogenous expression. As the
Mig7 vector produces a single GFP-fused mRNA transcript, GFP expression without
surface expression suggests additional regulatory mechanisms, such as translational
suppression or other post-transcriptional modifications regulating protein localization.
Despite no apparent increases in total receptor surface expression, we wanted to confirm
whether exogenous IL-7R expression altered F5 cell responses to IL-7. After 5 days of
treatment with lOng/mL of IL-7, pStat5 and pGSK3 levels and CD8 induction in Mig7
infected F5 cells were actually slightly below levels observed in uninfected F5 cells (Figure
5.13d-f). Infected F5 cells also had identical CD5 expression levels to their uninfected
counterparts (Figure 5.13g). Lastly, there was no change in viability with infection (Figure
5.13h), and cells were not able to proliferate (Figure 5.13i).
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Figure 5.13. Transgenic Expression of IL-7Ra Does Not Increase IL-7Ra Surface
Expression orIL-7 Induced Proliferation in F5 Bone Marrow Stem Cell Chimeras
(a) GFP expression showing infection efficiency for CD8+ T-cells isolated from the lymph node and
spleen of Mig7sd-infected F5 bone marrow chimeras 6 weeks after adoptive transfer compared to
those from F5 or OT1 mice. (b-c) IL-7Ra surface expression of naive CD8+ T-cells isolated from
the lymph node and spleen OT1, F5 and Mig7sd-infected F5 bone marrow chimeras sorted on either
the whole population (F57) or the GFP+ fraction (F57 GFP+) for freshly isolated cells or cells
cultured overnight (16 hours) +/- 10g/mL IL-7. Histograms are shown in (b) are quantified in (c).
(d-i) IL-7-induced signaling and responses for naive CD8+ T-cells isolated from the lymph node and
spleen of OT1, F5 and Mig7sd-infected F5 bone marrow chimeras (F57) showing (d) Stat5
phosphorylation (e) GSK3 phosphorylation (f) CD8a surface expression (g) CD5 surface
expression (h) viability, and (i) proliferation as assessed by the KI67+ fraction, all at 5 days.
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Altogether these data suggested that the level of IL-7Rx expression on mature T-cells of a
given TCR specificity might be tightly developmentally regulated. Previous studies using
similar approaches to study overexpression of IL-7Ra via bone marrow chimeras only
examined thymic populations, without commenting on IL-7Ra expression in the mature
population [103, 173, 174]. While IL-7R overexpression on mature peripheral cells has been
achieved, these studies have used mice with an embryonic knock-in of transgenic IL-7Ra
driven off of the CD2 or CD4 promoter/enhancer, allowing it to bypass earlier thymic
developmental checkpoints [15, 173, 175].
5.4.2 Inhibiting OT1 Signaling to F5 Levels Stops Proliferation, Not Viability
Given the difficulties encountered in undertaking gain-of-function studies by overexpressing
IL-7Ra in F5 cells, we adopted an alternate approach, and asked whether lowering IL-7-
induced signaling in OT1 cells to levels achievable by F5 cells abolished proliferation. OT1
cells were treated with 10 ng/mL IL-7 and a dose of Jak or P13K inhibitor sufficient to bring
pGSK3 signaling at 24 hours to levels in untreated F5 cells (Figure 5.14). Reduced signaling
capacity was also reflected by lowering of CD8a induction at 5 days in Jak- or P13K-
inhibited OT1 cells to approximately F5 levels. In uninhibited OT1 cells, ~26% of cells
expressed the nuclear proliferation antigen, Ki67, after 5 days, whereas F5 cells had no
Ki67+ fraction. The OTI proliferating fraction disappeared upon Jak or P13K inhibition of
signaling to F5 levels but had little or no effect on survival. This suggests that even in the
presence of abundant cytokine, F5 IL-7R expression limits the maximum IL-7 signaling
capacity to levels capable to promoting survival, but not proliferation.
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Figure 5.14. F5 CD8+ T-Cell IL-7-Induced Signaling Capacity is Insufficient to Promote
Proliferation
(a-b) Comparison of IL-7 induced responses in OT1 cells with signaling reduced to levels achievable
by F5 cells. (a) Schematic of the signaling inhibition approach to compare OT1 and F5 responses at
the same level of signaling, using inhibition of either Jak by Jak Inhibitor I or P13K by PI-103. (b) 24
hour GSK3 phosphorylation and 5 day CD8a surface expression, viability and Ki67+ proliferating
fraction for untreated OT1 and F5 TCRtg naive (CD440) CD8+ T-cells compared to OT1 cells
treated with 0.0625 paM of Jak Inhibitor I or 1 laM of the P13K inhibitor PI-103.
5.4.3 Distinct Thresholds for Varying Downstream Responses Encoded by the IL-7
Signaling Network
While OT1 signaling at levels achievable by F5 cells was insufficient to promote
proliferation, we wondered precisely what level of IL-7 induced signaling was required for
eliciting proliferation. Varying the dose of Jak Inhibitor I for OT1 cells treated with 10
ng/mL IL-7 revealed a sharp increase in proliferation at 5 days over a very narrow range of
pGSK3 signaling (Figure 5.15). Furthermore, this sharp increase in proliferation occurred at
~75% of the maximum OT1 signaling, which is well above the maximum signaling
obtainable by F5 cells. This was in distinct contrast to the linear increase in CD8at induction,
and quickly saturating viability responses, as a function of signaling. These data suggest that
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the IL-7 signaling network encodes distinct signaling thresholds for different downstream
responses, with the capacity to achieve different responses determined by surface IL-7R
expression.
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Figure 5.15. Distinct Signaling Requirements for IL-7-Induced Viability, Proliferation, CD8a,
Expression
Relationship between 24 hour signaling (GS3K3 phosphorylation) and 5 day responses (viability,
CD8a surface expression, and proliferation (as measured by % Ki67+ cells) for OT1 and F5 TCR-tg
naive (CD44o) CD8+ T-cells treated with 10 ng/mL IL-7. Signaling in OT1 cells was titrated by
varying the dose of Jak Inhibitor I. Responses are normalized to OT1 uninhibited controls.
5.5 Foxol as a Putative Regulator of Basal IL-7R expression
In a recent study, Kerdiles et al (2009) [18] found that Foxol is transcription factor for IL-
7R, and consequently knocking out Foxol expression lead to decreased IL-7R expression in
CD8+ T-cells. Foxol knockout mice also had decreased lymph node population sizes, and
CD8+ T-cells from these mice had decreased expression of Bcl2 and CD62L. As we
observed these same trends in comparing F5 cells to OT1 cells (Figure 4.1b, Figure 5.6a),
we wondered whether there might be also be differences in Foxol expression between these
cells. Indeed, SDS-PAGE of freshly isolate OT1 and F5 cells revealed a -2 fold decrease in
Foxol expression in F5 cells compared to OT1 cells (Figure 5.16). Foxol is a downstream
target of the PI3K/Akt pathway, and Kerdiles et al (2009) [18] also show that inhibition of
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the P13K phosphatase PTEN results in decreased IL-7Ra expression. Intriguingly, our data
examining the sensitivity of OT1 and F5 cells to P13K inhibition suggests higher P13K
activity in F5 cells (Figure 4.12b), which would be consistent with lower PTEN levels in
these cells. These data could suggest an interesting model whereby P13K activity regulates
basal IL-7Ra levels and survival in the absence of cytokine, which in turn regulates the
ability to activate Jak- dependent signaling pathways, including P13K, in the presence of
cytokine.
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Figure 5.16. F5 T-Cells Have Decreased Foxol Expression
Total Foxol expression as measured by SDS-PAGE (left panel) and quantified by densitometry
(right panel) for viable OT1 and F5 TCR-tg naive (CD44o) CD8+ T-cells after rested overnight (-16
hours) in cytokine-free media. Viable cells were isolated by Ficoll-Paque gradient separation after
culture.
5.6 Summary: IL-7R Expression as the Primary Determinant of CD8*
T-Cell IL-7 Responsiveness
Our data indicate that while T-cells share common relationships between IL-7-induced
signaling and responses, their maximum signaling capacity is limited by IL-7R expression.
Furthermore, there exist distinct signaling requirements for inducing survival, proliferation
and CD80c expression. While survival in abundant cytokine conditions only requires low
levels of IL-7R expression and IL-7 induced signaling, proliferation is only observed at much
levels of signaling. This suggests that increased IL-7Raz expression on CD5J T-cells is the
major determinant of their ability to selectively proliferate in response to saturating IL-7,
while all T-cells are able to survive. Different IL-7 dose requirements for T-cell proliferation
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versus survival have been identified for polyclonal T-cell populations [14]. In contrast, our
study extends this work by demonstrating that responses to IL-7 are encoded at the level of
signaling induced, which is determined both by the IL-7 environment and IL-7R expression.
115
116
Chapter 6 Physiological Implications of
Heterogeneous IL-7 Responsiveness
IL-7 provides critical survival signals to T-cells in vivo, but IL-7 signaling is received in the
context of TCR engagement with spMHC as well as additional cytokine and growth factor
signaling. While T-cells in lymphoreplete hosts are normally quiescent, T-cells are able to
proliferate in response to lymphopenia or exogenous IL-7 therapy [2]. In vitro, we observed
that CD5I CD8' T-cells have more robust proliferation responses to IL-7, while CD5" cells
have prolonged survival in cytokine-deprived cultures (Chapter 4). We hypothesized that
variations in the concentration of available IL-7 in t'ivo may also cause the selective
proliferation or persistence of CD5I or CD5'" T-cell populations. We therefore examined in
this chapter the relative ability of CD5hI and CD5" T-cells to survive and proliferate in both
normal lymphoreplete mice, and when IL-7 is elevated during lymphopenia or exogenous
IL-7 treatment. We find that IL-7 levels in lymphoreplete mice promote a homeostatic
balance between CD5hi and CD5" populations, but elevated IL-7 levels during lymphopenia
or IL-7 treatment yield selective proliferation of CD5"' T-cells. These findings suggest that
IL-7 is a significant regulator of both T-cell population size and diversity.
6.1 Homeostasis of CD5 Expression in Lymphoreplete Hosts
The amount of IL-7 in vivo is thought to be limiting, thereby preventing the spontaneous
proliferation of naive T-cells in lymphoreplete animals [2]. If the in vivo level of IL-7 is
indeed highly limiting, our in vitro results suggest that it may favor the relative survival of
CD5"' cells. To test this, we transferred naive B6.Thyl.2* CD8' T-cells into age- and sex-
matched B6.Thy1.1' mice and followed their CD5 profile over three weeks (Figure 6.1).
The number of transferred cells declined steadily with a half-life of -8.4 days (Figure 6.1b).
However, there was no change in their CD5 profiles compared to the naive CD8' T-cells of
the recipient (Figure 6.1a). This suggests that at physiological levels of IL-7, CD5i and
CD5" cells have equivalent population kinetics in vivo. There is little to no proliferation of
naive T-cells in untreated lymphoreplete hosts. Consequently, maintenance of the CD5
profile would require equivalent turnover between CD5I and CD5"' clones. Additionally, this
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suggests that CD5' and CD5"* T-cells are replenished by thymic export of newly developed
cells at equivalent rates. Thus, IL-7 levels in lymphoreplete hosts favor neither CD5 h nor
CD5" expressing T-cells and can be said to maximize the diversity of CD5 expression.
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Figure 6.1. Homeostasis of CD5 Expression in Lymphoreplete Hosts
(a) Comparison of CD5 expression profiles for donor versus recipient naive (CD440) CD8+ T-cells
over 3 weeks for donor C57BL/6.Thyl.2+ CD4410 CD8+ T-cells adoptively transferred into age and
sex-matched C57BL/6.Thyl.1+ recipients. (b) Percent of donor cells amongst naive (CD4410) CD8+
T-cells recovered from recipient spleens at varying times after adoptive transfer as described in (a).
6.2 Selective CD5h T-Cell Proliferation At Elevated IL-7 Levels in vivo
6.2.1 Enhanced Proliferation of CD5h T-Cells During Lymphopenia
IL-7-induced proliferation of T-cells occurs in vivo when there is an excess of IL-7 even in
the absence of foreign antigen, for instance during lymphopenia or exogenous IL-7 therapy
[2]. In the setting of excess IL-7 availability caused by lymphopenia, CD5hi cells have a
greater rate of proliferation than CD5" cells [10, 11], which has so far been attributed to the
greater responsiveness of CD5" cells to cognate spMHC. While our in vitro results suggest
that naive T-cells may also differ in their ability to respond to IL-7, this is difficult to
demonstrate in vivo, as these cells may simultaneously receive different levels of spMHC
signaling through their TCRs. Thus, to determine whether CD5hi T-cells have an intrinsically
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enhanced responsiveness to IL-7 that can impact proliferation in vivo, we exploited the fact
that even within a population of TCR-tg T-cells, there is some variance in CD5 expression.
We sorted naive OT1 cells into CD5I and CD5" populations with a ~2.5-fold difference in
mean CD5 levels (Figure 6.2a) but equivalent TCR expression (Figure 6.2b), and
transferred the cells into syngeneic Rag* hosts. Five days post transfer, on average 85% of
CD5I OT1 cells had undergone division compared to 64% of CD5 OT1 cells (Figure
6.2a). Thus, even in the presence of spMHC, T-cells expressing the same TCR at equivalent
levels can have different rates of IL-7-driven proliferation in vivo. These data suggest that
naive T-cell populations may be comprised of cells with intrinsically different sensitivity to
IL-7 overlaid on their varying spMHC and foreign antigen responsiveness.
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Figure 6.2. Enhanced Proliferation of Intraclonal CD5hi OT1 T-Cells in Lymphopenic Hosts
(a) CD5 expression of OT1 TCR-tg naive (CD441o) CD8+ T-cells sorted into CD5hi and CD5o
expressing fractions (top panels), and their proliferation 5 days after adoptive transfer into syngeneic
Rag-/- hosts, as assessed by CFSE dilution of donor cells recovered from recipient spleens and
quantified as the percent of cells divided (bottom panels). (b) CD5 and TCR surface expression for
OT1 TCR-tg naive (CD44o) CD8+ T-cells gated on CD5hi and CD51o expressing fractions.
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6.2.2 Selective Proliferation of CD5" T-Cells After Exogenous IL-7 Treatment
Having observed differential proliferation of OT1 CD5I and CD5 cells in response to
elevated IL-7 levels during lymphopenia, we next asked whether exogenous IL-7 treatment
in polyclonal lymphoreplete mice had similar effects. We first confirmed that our IL-7
treatment protocol was capable of inducing detectable proliferation. CFSE-labeled naive
Thy1.2* CD8' were adoptively transferred into Thy1.1* congenic mice bearing mini-osmotic
pumps that released PBS or 5 ug IL-7 over 7 days. A fraction of labeled cells recovered from
mice receiving IL-7 underwent 1-2 divisions, while little to no proliferation was observed in
PBS control mice (Figure 6.3). To then identify whether there is heterogeneous
proliferation across the transferred population, sorted naive Thy1.2* CD8' T-cells into
CD5"i and CD5' fractions were individually transferred into congenic mice bearing IL-7-
releasing pumps (Figure 6.4). After 7 days, a greater fraction (35%) of CD5i T-cells
underwent division than CD5' T-cells (7.9%). Again, no proliferation was seen in control
mice that received PBS only (not shown). IL-7 therapy is therefore capable of inducing
selective proliferation of CD5hi T-cells.
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Figure 6.3. Proliferation of CD8+ T-Cells in Lymphoreplete Mice With IL-7 Treatment
Proliferation of donor C57BL/6.Thy1.2+ CD44o CD8+ T-cells adoptively transferred into age and
sex-matched C57BL/6.Thy1.1+ recipients given 5 pg IL-7 by mini-osmotic pump over seven days, as
assessed by CFSE dilution of donor cells recovered from recipient spleens and quantified as the
percent of cells divided.
120
B6 CD5hi and CD51o j140
0 120-
CDS CD5 [3 B6 CD5h 00
l0 hi QB6 CD51o o
o 0
CD5 CD51o CD~hi
B6 Recipient + 5ug IL7, 7 days
B6 CD51o B6 CD5hi 4a
7.9 35.5 30
Z2&1L
CFSE CFSE CD51o CD5hi
Figure 6.4. Enhanced Proliferation of CD5hi T-Cells in Lymphoreplete Mice With IL-7
Treatment
CD5 expression of C57BL/6.Thyl.2+ naive (CD44o) CD8+ T-cells sorted into CD5hi and CD5'o
expressing fractions and their proliferation 7 days after adoptive transfer into lymphoreplete
C57BL/6.Thyl.1+ hosts given 5 pg IL-7 by mini-osmotic pump over seven days, as assessed by
CFSE dilution of donor cells recovered from recipient spleens and quantified as the percent of cells
divided.
6.2.3 Upwards Shift in the Distribution of CD5 Expression Upon IL-7 Treatment
While IL-7 treatment induces proliferation of mature peripheral cells, it may also alter the
rates of T-cell turnover or thymic export of newly developed cells [106]. To determine how
these combined effects affect the overall resulting peripheral T-cell population, we examined
the surface expression profiles of CD8+ T-cells in mice receiving IL-7 treatment. We
observed significant shifts towards higher CD5 expression in the total CD8+ population of
young mice receiving IL-7 versus PBS over 7 days (Figure 6.5a). Greater IL-7 signaling in
T-cells upon exogenous IL-7 addition was also reflected by an increase in surface CD8a
expression (Figure 6.5b), and there was a significant increase in cell numbers in the lymph
node and spleen over PBS treated mice (Figure 6.5c). Interestingly, we also observed an
increase in the CD44I expressing population in IL-7 treated mice (Figure 6.5d). However, it
was unclear whether this resulted from selective proliferation of the CD44I population or an
increase in CD44 expression by proliferating CD440 cells. We observed both of these effects
in vitro (Figure 4.8-9), and conversion to a CD44hi memory-like phenotype has been
reported for cells undergoing LIP [34]. Nevertheless, CD8+ cells gated on the CD44'
fraction still show an increase in CD5 and CD8 with IL-7 treatment (Figure 6.5e,f), though
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the shift in CD5 is less significant. These results therefore demonstrate that exogenous IL-7
therapy has the potential to skew the naive T-cell repertoire towards higher CD5 expression,
in part by inducing selective proliferation of CD5"' cells.
6.2.4 No Shift in CD5 Expression Distribution in IL-7 Depleted Mice
At low concentrations of cytokine in vitro, CD5hi cells have a reduced ability to survive
compared to CD5O T-cells. We hypothesized that enhanced survival of CD5" T-cells might
also occur in vivo under conditions of IL-7 deficiency and shift the CD8' T-cell repertoire to
lower CD5 expression levels. To test this idea, lymphoreplete B6 mice were injected i.p. with
1mg of the IL-7 depleting antibody M25 or an isotype control antibody every alternate day
for 14 days. In contrast to IL-7 treatment, mice receiving IL-7-depleting antibodies showed
no difference in their distribution of CD5, CD44 or CD8a expression compared to isotype-
treated controls (Figure 6.6a-b,d). However, M25-treated mice did show a slight decrease in
overall CD8' lymph nodes and spleen cell numbers (Figure 6.6c). Extrapolating from our in
vitro signaling studies (Figure 5.9), the lack of a decrease in CD8X expression implies that
IL-7 signaling is already at extremely low levels in lymphoreplete animals. Antibody deletion
of IL-7 may therefore be insufficient to inhibit IL-7 signaling to levels where mild
differences in survival between CD5hi and CD5" clones can be observed on these time
scales. In this case, differences might only be observed on longer timescales with greater
doses of IL-7 blocking antibodies or in hosts deficient in IL-7 production. Alternatively, the
presence of self-peptide stimulation in vivo, which was excluded in our in vitro survival studies,
may equalize CD5h and CD5" T-cell turnover in vivo in cytokine-starved conditions.
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Figure 6.5. IL-7 Treatment Shifts the CD5 Expression Profile of the Naive T-Cell Repertoire
(a-d) Comparison of the (a) CD5 and (b) CD8a surface expression, (c) total cell numbers and (d)
CD44 surface expression for CD8+ T-cells recovered from the lymph nodes or spleen of
lymphoreplete C57BL/6 mice given PBS vs. 5 pg IL-7 by mini-osmotic pump over 7 days. (a-b) As
described for (a-b) except for cells gated on the CD440 expressing fraction.
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Figure 6.6. IL-7 Depletion May be Insufficient for Observing Shifts in CD8+ T-Cell CD5
Expression
(a-d) Comparison of the (a) CD5 and (b) CD8a surface expression, (c) total cell numbers and (d)
CD44 surface expression for CD8+ T-cells recovered from the lymph nodes or spleen of
lymphoreplete C57BL/6 mice given injections of 1mg of the IL-7-binding antibody M25 vs. an
isotype control antibody every alternate day for 14 days.
6.3 In vivo IL-7 Levels Suggest Mechanism for Maintaining
Homeostasis
6.3.1 IL-7R Expression in vivo Suggest Physiological Range of Cytokine Levels
We sought to determine if the physiological range of IL-7 concentrations at steady state in
vivo is tuned to maintain the homeostatic diversity of CD5 expression in CD8* T-cells.
Measurement of IL-7 levels in serum isolated from the blood of OT1, F5 and B6 mice by
ELISA confirmed previous reports [76] that IL-7 serum levels are close to or below the
detection limit of 1 pg/mL (Figure 6.7). However, serum levels of IL-7 may not reflect the
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local availability of IL-7 in lymphoid organs [5, 176, 177], in part because IL-7 is sequestered
by binding to the extracellular matrix [77]. We therefore took an alternate approach, and
used IL-7RX and CD8x expression on freshly isolated CD8' cells as an indicator of the
amount of effective cytokine signaling received in lymphoid organs in vivo. We first examined
IL-7Rax expression of freshly isolated OT1 and F5 cells and compared them to their IL-7Ra
levels 24 hours after treatment with varying concentrations of IL-7 in vitro (Figure 6.8a).
This suggested that equivalent in vivo cytokine concentrations in these mice correspond to in
vitro IL-7 concentrations of approximately 0.01-0.1 ng/mL. Interestingly, at this range of IL-
7 concentrations in vitro, both cells had equal viability (Figure 6.8b), but neither received
sufficient IL-7 signaling to proliferate (Figure 6.8c). This suggests that the homeostatic
balance between CD5hi and CD5'" T-cells in vivo may be achieved by maintaining IL-7 at a
level sufficient to promote equal survival among T-cells without inducing selective
proliferation (Figure 6.9).
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Figure 6.7. Serum IL-7 Concentrations At or Below the Limit of Detection
IL-7 concentration in the serum fraction of blood isolated from C57BL/6, OT1 TCR-tg or F5 TCR-
tg mice as measured by ELISA, in comparison to the reported limit of detection for this
measurement technique.
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Figure 6.8. IL-7Ra Expression Indicate in vivo Cytokine Levels Promote Neither Selective
Survival Nor Proliferation
(a) IL-7Rat expression of OT1 and F5 TCR-tg naive (CD4410) CD8+ T-cells rested overnight in
cytokine-free media and treated 24 hours with varying IL-7 concentrations ranging from 0.0001-100
ng/mL, compared to the IL-7Ra expression of freshly isolated cells, indicating effective in tivo
cytokine concentrations reflect in vitro IL-7 concentrations of 0.01-0.1 ng/mL. (b-c) 24 hour viability
(b) and 5 day proliferation (%Ki67+ fraction) (c) for OT1 and F5 TCR-tg naive (CD441o) CD8+ T-
cells treated with varying IL-7 concentrations in vitro as described in (a), showing that at the
proposed effective in vivo IL-7 concentration range, both cells survive, but do not proliferate.
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Figure 6.9: Model for IL-7-Mediated Regulation of the Diversity of CD5 Expression in vivo
Model of skewing of ratio of relative CD5hi versus CD5o CD8+ T-cell abundance with varying IL-7
concentrations in tivo. At IL-7 concentrations in normal lymphoreplete hosts, the diversity of CD5
expression is maximized, while selective proliferation of CD5hi subsets at high [IL-7] shifts towards
high CD5 expression and selective survival of CD5O subsets at low [IL-7] shifts towards low CD5
expression.
6.3.2 In vivo Bioassay Revealing Variations in IL-7 Levels Across Hosts
While we were able to estimate the in vitro correlate of in vivo IL-7 concentrations for OT1
and F5 mice, it was not clear how this related to the IL-7 concentration in normal B6
lymphoreplete mice. To compare the relative IL-7 levels between different mice, we
adoptively transferred 2C TCR-tg Rag1 / Thy1.1* T-cells into B6, Rag'-, OT1, 2C and F5
hosts (Figure6.10a) and examined the relative IL-7Rx and CD8a expression on the
transferred cells in the recipient spleens after 18 hours as a surrogate measure of IL-7 levels
in vivo (Figure 6.10b-c). While this assay avoids problems inherent to comparing resident
populations across TCR-tg mice which differ in their TCR specificity and basal IL-7R
expression, it implicitly assumes that access to spMHC signaling is equivalent for donor cells
bearing the same TCR across hosts.
Low IL-7Ra and high CD8a expression of donor cells in Rag' mice indicated relatively
high IL-7 levels in these mice compared to OT1, 2C, F5 and B6 recipients that bear full
CD8' T-cell compartments (Figure 6.10b). Our assay indicates that IL-7 levels are similar
among OT1, 2C, F5 and B6 mice, albeit with subtle differences in the order: F5 > 2C > B6
> OT1. These data additionally suggest that the effective in vivo cytokine concentration in B6
mice also corresponds to in vitro IL-7 concentrations of 0.01-0.lng/mL observed to support
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survival but not proliferation. However, Rag-/- mice have relatively elevated IL-7 levels,
presumably sufficient to promote selective proliferation of CD5' clones. Donor cell IL-7Ra
expression showed a strong correlation with the number of CD8+ T-cells in the spleens of
the recipient mice (Figure 6.10c), supporting the notion that in vivo IL-7 levels scale
approximately with the number of T-cells consuming IL-7 [4, 5]. Altogether, these data
support a model whereby physiological IL-7 levels are optimally regulated to maintain the
diversity of CD5 expression in the naive CD8+ T-cell population by supporting T-cell
survival but not selective proliferation (Figure 6.9). Increasing IL-7 levels have the capacity
to cause selective proliferation of CD5hI T-cells; conversely, depleting IL-7 may favor
selective persistence of CD5 T-cells.
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Figure 6.10. Bioassay Indicating Variations in IL-7 Levels Between Mice Scaling with
Population Size
(a-c) Bioassay for in vivo IL-7 levels in which 106 Thy1.1+ 2C TCR-tg naive (CD44)o) CD8+ T-cells
were transferred into Thy1.2+ B6, OT1 TCR-tg Rag-, 2C TCR-tg Rag-/, F5 TCR-tg Rag- or Rag-
hosts (a), and the relative IL-7 levels between hosts were inferred from the IL-7Ra and CD8a
expression of Thyl.1+ donor cells (b). IL-7Ra expression of donor cells showed a strong linear
correspondence with number of CD8+ T-cells recovered from the recipient spleens (c).
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6.3.3 Alternate Interpretation of Varied Rates of LIP in Different TCR-tg Hosts
Our IL-7 bioassay suggests that there are variations in effective cytokine levels across
different TCR-tg mice. Interestingly, CD5hI CD8' TCR-tg T-cells are found to proliferate
when adoptively transferred into certain syngeneic TCR-tg Rag' hosts only when the
recipient CD8* T-cells have lower CD5 expression [10] (Figure 6.11). While this was
interpreted as being due to the enhanced ability of donor CD5i T-cells to compete for
spMHC, our results suggest that these differences could also be impacted by variations in the
in vivo IL-7 levels between different TCR-tg hosts. For instance, OT1 cell proliferation after
adoptive transfer scales in the order Rag'> F5 > 2C > OT1, and our assay indicates in vivo
IL-7 availability also increases in the same order (Figure 6.10b). 2C cell proliferation across
hosts also scales in the same order, but these cells have lower proliferation than OT1 cells,
potentially because their reduced receptor expression compared to OT1 cells (data not
shown) leads to reduced signaling in the same environment. This suggests that both the cell-
intrinsic ability to respond to IL-7 and extrinsic variations in IL-7 availability can shape the
naive T-cell pool.
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Figure 6.11: In vivo IL-7 Availability May Potentiate Variations in LIP Across TCR-tg Hosts
Schematic of results from Ge et al (2004) [10], demonstrating the average number of divisions of
CFSE-labeled donor naive (CD440) CD8+ T-cells 30 days after adoptive transfer into recipient mice
for donor cells isolated from OT1, F5 or 2C TCR-tg mice and transferred into OT1, F5 or 2C TCR-
tg and Rag' recipients. Also shown is the relative donor cell proliferation capacity in response to IL-
7 stimulation alone, and the relative estimated IL-7 levels, demonstrating how variations in IL-7
levels of the host and intrinsic IL-7 responsiveness of the donor may contribute to observed
differences in proliferation, as opposed to TCR avidity differences between host & donor alone.
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6.3.4 Implications of in vivo IL-7 Heterogeneity For the Co-receptor Tuning Model
Diversity in the levels of CD5, CD8X and IL-7Ra expressed by naive T-cells in niro has been
largely explained in the context of heterogeneous extrinsic signals from both spMHC and
IL-7 [2, 5, 7, 15, 24]. In what they have termed the 'co-receptor tuning' model, CD8a
expression is regulated by mutual feedback between the IL-7Ra and TCR signaling
pathways: IL-7Ra signaling induces the transcription of CD8x to increase TCR signaling,
which negatively feeds back to reduce IL-7 signaling [24]. Reduced CD8aX co-receptor
expression on CD5hi T-cells is then proposed to 'tune down' excessive spMHC-induced
TCR signaling (Figure 6.12a). The 'co-receptor tuning' model is supported in part by a
positive correlation of IL-7RX, and inverse correlation of CD8a, with CD5 expression for a
panel of freshly isolated TCR-tg cells (2C, F5 and female HY Rag/ mice). Indeed, we also
observe these trends for OT1, 2C and F5 mice, however at more modest levels (data not
shown). While feedback between IL-7R and TCR signals may dampen TCR signals in CD5"
cells (Figure 6.12b), observed trends in CD5, CD8u and IL-7Ra expression may also be
explained by differences in IL-7 availability in these mice (Figure 6.12c). Indeed, our data
suggests that OT1, 2C and F5 mice have decreasing numbers of CD8' cells and conversely
increasing levels of available IL-7 (Figure 6.10b), which could partly explain the
progressively higher levels of CD8a in these mice.
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Figure 6.12: Variations in IL-7 Levels Across TCR-tg Hosts May Partially Account for
Correlations in CD8, IL-7R, CD5 Attributed to Co-Receptor Tuning
(a) Schematic of co-regulation of TCR and IL-7R induced signaling according to the CD8
coreceptor tuning model [24]. IL-7 transcriptionally increases CD8a expression to promote TCR-
self peptide-MHC engagement, but TCR signaling then feeds back to impair IL-7R signaling. Low
CD8 expression on CD5hi IL-7Ro cells resulting from this mutual feedback is proposed to 'tune
down' excessive TCR-spMHC signaling. (b-c) Relationship between CD5, CD8a and IL-7Ra for a
panel of TCR-tg mice observed in iivo versus at varying levels of IL-7 in vitro. The observed in vivo
trends could result from spMHC signaling leading to non-linear feedback to CD8 expression
assuming the same in idvo IL-7 levels across hosts (b). Alternatively, trends may be accounted for
solely by differences in the in vivo IL-7 levels between hosts from which cells are isolated (c).
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6.4 Summary: IL-7 as a Critical Controller of the Homeostasis of CD5
Expression
Altogether, these data suggest that variations in IL-7 responsiveness across the T-cell
repertoire are present and functional in 'ivo even in presence of spMHC stimulation. IL-7
levels in lymphoreplete hosts are such that the homeostatic diversity of CD5 expression is
maintained by promoting neither selective survival nor proliferation of CD5' and CD5"' T-
cell subsets. Conversely, the relative in iivo abundance of T-cell clones is shifted towards
favoring high CD5 expressing clones when IL-7 is elevated during lymphopenia or IL-7
treatment. This suggests an important role for IL-7 in controlling both the size and the
composition of the T-cell pool, and adds the selection of certain T-cell subsets as an
additional consideration for the design of IL-7 therapies. Our studies also suggest a putative
reinterpretation of previous studies presented in support of TCR-mediated differences in
LIP and surface expression profiles across TCR-tg mice in which extrinsic variations in the
IL-7 environment potentiate responses. This reinforces the notion that both cell-intrinsic
variations in IL-7 responsiveness, and cell-extrinsic variations in the cytokine environment,
play critical roles in shaping T-cell responses.
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Chapter 7 Quantitative Analysis of Heterogeneous
IL-7 Depletion Amongst CD8* T-Cells
Increased IL-7R expression on CD5"' CD8 T-cells imparts a signaling advantage that allows
for enhanced proliferation in response to elevated IL-7 levels in vitro (Chapter 4) and in vivo
(Chapter 6). However, one putative disadvantage of higher receptor expression is higher
depletion of IL-7 from the environment, which may limit long-term survival when faced
with limiting cytokine reserves. While previous chapters have focused on characterizing the
effect of varying IL-7 environments on IL-7 responses, this chapter focuses on
characterizing the ability of cells to modulate the IL-7 environment. We find that T-cells
have heterogeneous capacities to deplete IL-7 that scales with their receptor expression.
Furthermore, T-cells require sustained signaling to support viability, IL-7R(X suppression and
CD8X induction. Fast IL-7 depletion for high IL-7R expressing populations therefore poses
a potential survival disadvantage in IL-7 limited conditions. This reinforces the concept that
the naive T-cell pool is shaped by a complex interplay between heterogeneities in both the
ability to consume, and respond to, available IL-7.
7. 1 Sustained IL-7 Signaling Required for Complete Survival,
Receptor Suppression, CD8 induction
IL-7 is highly localized to its sites of production, which include the bone marrow, thymus,
lymph nodes, spleen and liver [2]. T-cells cycle between these IL-7 rich regions and the
relatively IL-7 depleted circulatory system. The transient receipt of cytokine signals during
cycling is believed to play a major role in directing T-cell trafficking to and/from lymphoid
organs via the modulation of the expression of the CCR7 chemokine receptor [18, 178]. To
gain a better understanding of the consequences of this cycling behavior, we sought to
characterize the differences in T-cells responses to the transiently pulsed versus sustained
presence of IL-7.
A range of T-cell residence times in and out of the secondary lymphoid organs have been
reported. During normal homeostasis, T-cells can spend up to 24-48 hours in lymphoid
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organs, while transitions times between blood and lymph node vary highly, peaking at -24
hours [16, 17, 179]. As a model of the behavior of T-cells which have just entered lymph
nodes versus those that have recently exited into circulation, we compared OTI and F5 T-
cells treated continuously with varying levels of IL-7 with those receiving a 1 hour 'pulse' of
cytokine followed by washing and culture in cytokine-free media for the remaining culture
time (Figure 7.1). Cells under pulsed cytokine treatment had reduced viability (Figure 7.1a)
and CD8u induction (Figure 7.1b) and incomplete surface IL-7RaX suppression (Figure
7.1c) at 24 hours compared to cells left in the presence of cytokine. This effect was more
apparent after 48 hours in culture. Increasing the pulse time from 1 to 4 hours only slightly
decreased the effect of cytokine removal compared to sustained IL-7 presence (not shown).
Lack of differences between pulsed and sustained IL-7 treatments at high doses (>10
ng/mL) likely reflects difficulty in completely washing off large amounts of cytokine bound
to surface IL-7R, as well potential recycling to the media of cytokine already internalized.
Interestingly, this net difference in responses between pulsed and sustained dosing
conditions is slightly greater for OT1 cells than F5 cells. For instance, at 0.1 ng/mL IL-7,
CD8aX induction is greater for OT1 than F5 cells under sustained signaling, but both cells
have approximately equivalent CD8X levels in the pulsed condition (Figure 7.1c).
T-cells therefore require re-encounter with cytokine on time scales <24 hours in order to
support complete viability and CD8a induction, and the net effect of cytokine deprivation
may be heterogeneous across clones. These time scales are in accordance with the proposed
T-cell cycling times outside the lymph nodes peaking at -24 hours. Furthermore, re-
upregulation of receptor surface expression over these time scales is in line with the
proposed 'altruistic' model of IL-7 sharing whereby cells that have just entered the lymph
node from the circulation have increased receptor expression (Figure 2.6). Cells most
needing survival signals therefore have improved capacity to compete for, and signal in
response to, limiting cytokine reserves.
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(a-c) (a) Viability, (b) IL-7Ra surface expression and (c) CD81 surface expression at 24 hours (left
panels) or 48 hours (right panels) for OT1 and F5 TCR-tg naive (CD4410) CD8+ T-cells rested
overnight (-16 hours) in cytokine-free media and then treated with varying IL-7 concentrations
ranging from 0.0001-10 ng/mL without replacement either for the complete duration of the culture
('sustained') or for only the first hour of culture ('pulsed').
7. 2 Heterogeneous IL-7 Depletion Scales with IL-7R Expression
In the proposed 'altruistic' model, IL-7 is optimally utilized to support the maximum T-cell
population by scaling receptor expression with the relative need for IL-7 signaling [5, 24]
(Figure 2.6). However, these studies discuss heterogeneity in IL-7R expression amongst
naive T-cells originating only from extrinsic differences in the spatiotemporal presentation of
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IL-7. Furthermore, they do not directly quantify ligand depletion to determine whether it is
truly optimally utilized amongst all T-cells. We therefore sought to directly measure IL-7
depletion, and characterize the consequences of the observed heterogeneities in basal IL-7R
expression amongst naive T-cells on their relative rates of IL-7 depletion.
To measure rates of IL-7 depletion, OT1 and F5 cells were cultured at varying densities (1x,
2x, or 3x 3.3x105 cells/mL) in the presence of 0.1 ng/mL IL-7. IL-7 remaining in the
supernatant of cell-containing and cell-free cultures after 24 or 48 hours was quantified by
ELISA, and cell viability and IL-7Ra expression was determined by flow cytometry (Figure
7.2). IL-7 depletion from the media was both time- and cell density-dependent, but OT1
cells gave rise to significantly greater IL-7 depletion from the media (Figure 7.2a).
Furthermore, while F5 cells at all densities maintained complete receptor downregulation
throughout the full 48 hours in culture, OT1 cells already showed re-upregulated receptor
expression that varied with cell density by 24 hours (Figure 7.2b). Despite differences in the
rates of ligand depletion from the media, cells across all conditions maintained ~100%
viability over the two days examined (Figure 7.2c). Quantifying the ligand depletion over
24 hours in lx cell density conditions reveals ~2 fold increase in ligand depletion in OT1
cells over F5 cells (Figure 7.2d). However, depletion is approximately equivalent on a per-
receptor basis (Figure 7.2e). Nevertheless, both cells have equal viabilities on these
timescales (Figure 7.2c), and in previous experiments we have shown that the IL-7 dose of
0.1 ng/mL used is insufficient for signaling a proliferation response for OT1 cells (Figure
4.16). T-cells therefore have heterogeneous capacities to deplete IL-7 from their
environment that scales with receptor expression, and greater consumption does not
necessarily lead to an enhanced phenotypic response.
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Figure 7.2: IL-7 Consumption Scales with IL-7Ra Expression
(a-c) OT1 and F5 TCR-tg naive (CD446) CD8+ T-cells rested overnight (~ 16 hours) in cytokine-
free media, and then viable cells were plated at either 1x, 2x or 3x (3.3x10 5) cells/mL density and
then treated with 0.1 ng/mL of IL-7. After 24 or 48 hours in culture, (a) IL-7 remaining in the media
was measured by ELISA and (b) IL-7Ra surface expression and (c) viability were measured by flow
cytometry. (d-e) IL-7 molecules consumed after 24h for OT1 and F5 T-cells cultured at 1ix density,
either (d) per cell and (e) per receptor.
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7. 3 Early IL-7 Depletion Compromises Late Survival
While OT1 cells depleted more IL-7 than F5 cells when treated with 0.1 ng/mL IL-7, it did
not increase their relative viability over the 2-day time scales examined, nor induce them to
proliferate. As we have observed that complete viability responses require the sustained
presence of cytokine (Section 7.1), we hypothesized that this early 'over-consumption' of
cytokine might compromise viability over longer time scales when cells are faced with
limited IL-7. To test this hypothesis, we extended culture times to 9 days, and compared
daily behavior in intermediate IL-7 doses (0.1 ng/mL) to those in abundant cytokine
conditions (10 ng/mL IL-7) and in cytokine-free cultures (Figure 7.3).
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Figure 7.3: High IL-7R Expression and IL-7 Consumption Poses Survival Disadvantage
When IL-7 is Limited
Viability (top row), IL-7Ra surface expression (middle row) and CD8x surface expression (bottom
row of panels) over 9 days for OT1 and F5 naive (CD44o) CD8+ T-cells rested overnight in
cytokine-free media and treated with 0 ng/mL IL-7 (left column), 0.1 ng/mL IL-7 (middle column)
or 10 ng/mL IL-7 (right column).
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At high concentrations of cytokine, there appears to be no effect of differences in IL-7
uptake, as both OT1 and F5 cells maintain ~100% survival over the full 9 days at high
cytokine conditions. However, at an intermediate cytokine dose, we reveal the consequences
of greater early IL-7 consumption by OT1 cells: while both cell types survive equivalently for
the first -5 days, OT1 cells rapidly die off in the days thereafter. Early IL-7 depletion from
OT1 cultures in reflected in the upregulation of receptor after 2 days in culture, whereas F5
cells only start to re-express receptor after 7 days. Receptor is not fully re-expressed, though
comparison with cytokine-free cultures reveals this is not due to presence of residual
cytokine. Rather, this may reflect overall decreases in protein expression and/or metabolism
after removal of cells from their in vio environment, including stimulation by spMHC.
Differences in the duration of signaling between OT1 and F5 cells at 0.1ng/mL are also
apparent in their CD8a profiles: while OT1 has greater initial CD8aX expression, it is
surpassed by F5 later in culture. CD8a expression for OT1 cells also begins to decrease later
in culture at 10 ng/mL IL-7, which may result from differences in cytokine levels which only
becomes functionally apparent at later time points when starting within initially high cytokine
doses. Overall, these data suggest that increased IL-7R expression leads to greater ligand
consumption than is required to support early survival, which poses a survival disadvantage
in limiting cytokine conditions.
7. 4 Summary: IL-7R Expression Drives Heterogeneous IL-7
Consumption
Our data reveals that while heterogeneous IL-7R expression among T-cells drives their
differential responses to the IL-7 environment, it also determines their capacity to alter that
environment via cytokine consumption. IL-7 consumption scales with IL-7R expression,
thus CD5hiIL-7R h T-cells more quickly deplete their IL-7 environment. However, T-cells
require periodic stimulation with IL-7 to support prolonged survival. Thus, under IL-7
limited conditions, early 'overconsumption' of cytokine by IL-7Rh T-cells poses a survival
disadvantage for T-cells later in culture. Differential use and demand for cytokine resources
across the T-cell repertoire calls for re-examination of the notions that IL-7 levels in vizo
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scale with the number of cells consuming IL-7, and that IL-7 levels are optimally regulated
to support the maximum population size.
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Chapter 8 Conclusions and Discussion
8.1 Intrinsic Heterogeneity in Cytokine Responsiveness Across the
CD8* T-Cell Repertoire
T-cells have been increasingly divided into numerous functionally distinct sub-populations
such as naive, effector, memory and regulatory cells based on defined sets of surface marker
expression. Functional differences between T-cells within sub-populations have been
thought to arise from genetically distinct TCRs with varying avidity for self or foreign
antigens. Stochastic heterogeneity in protein levels has also been reported to result in
significant diversification of activation responses even among individual naive T-cell clones
[180]. However, variability in these responses is limited by expression of opposing signaling
co-regulators. While stochastic fluctuations in protein state can be transmitted from mother
to daughter, they result in transient heritability in cell fate [181]. In contrast, here we have
described an additional novel layer of functional heterogeneity in T-cells that appears distinct
from non-genetic cell-to-cell variability within cell populations [182, 183]. Our data suggests
that in the context of homeostatic survival and proliferation, even modest differences in
surface IL-7Rx expression levels among naive T-cells have predictable functional
consequences that are robustly heritable.
While IL-7 has a well-documented role in promoting T-cell survival and proliferation,
responses have been generally been in examined in the context spMHC signaling. Here we
have shown that even in the absence of TCR-spMHC engagement, IL-7 can promote both
CD8' T-cell survival and proliferation (Chapter 4). Furthermore, while all T-cells examined
could survive in response to IL-7, their IL-7 induced proliferation capacities were correlated
with their CD5 and IL-7R expression levels. As CD5 expression is thought to reflect the
avidity of TCR-spMHC interactions [6-9], the enhanced LIP of CD5hi T-cell clones has been
previously attributed to their enhanced spMHC signaling [10, 11]. However, our data
suggests differential IL-7R expression and resulting responsiveness to IL-7 may also
potentiate proliferation.
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The TCR-independent IL-7-induced proliferation characterized in this thesis is reduced in
magnitude compared to the combined stimulation with spMHC-expression dendritic cells in
vitro [184] or during LIP in lymphopenic mice (see, for example, [10]). TCR stimulation with
spMHC is not sufficient for proliferation, as cells die the absence of cytokine stimulation
[64]. Similarly, while IL-7 can support complete T-cell survival over short time scales in nitro,
spMHC signaling is required for long-term survival in tivo [1, 2]. This suggests that functional
differences in survival and proliferation in vi'o result from a complex interplay between TCR
and IL-7R signals. The idea that IL-7 requirements and/or responsiveness may vary with
TCR affinity, and that IL-7 may potentiate spMHC signaling is almost a decade old [185],
though only recently have potential mechanisms been proposed [78]. One putative
mechanism of synergy supported by recent work suggests that TCR signaling may maintain
IL-7R surface expression for more sustained IL-7 signaling (Park J.H. et al, unpublished
results). However, these studies still generally assume equal TCR-independent IL-7 signaling
capacities. Deconvolution of the contribution of heterogeneous IL-7R versus TCR signaling
to responses will require systems for the combined quantitative presentation of both spMHC
and IL-7 and precise measurements of their downstream signaling and responses.
Subsequent determination of the key modes of response regulation encoded within the
TCR- and IL-7R- signaling network will greatly benefit from the development of
mathematical models to interpret and guide experimental designs (Discussed further in
Chapter 9).
In addition to their enhanced responsiveness to IL-7, CD5h T-cells also selectively
proliferated in response to IL-2 and IL-15 stimulation (Figure 4.7). CD5 may therefore
serve as a marker for globally enhanced responsiveness of T-cells to homeostatic cytokines.
IL-2 and IL-15 are classically thought to be more specific to effector and memory T-cell
populations [1]. However, recent proposals suggest that naive T-cells can also proliferate
robustly to these cytokines, but their in vi'o cell responses are limited via cytokine production
and localization [1]. One putative underlying mechanism for heightened cytokine
responsiveness may reside in CD5I T-cells having already undergone division, or be primed
to divide, upon their isolation. LIP is known to induce naive T-cell conversion to a
'memory-like' phenotype [34]. Indeed, we observed that OT1 mice have a 'memory-like'
CD44hi subpopulation of CD8' T-cells that presumably arises from LIP (Figure 4.1). CD44
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expression is increased even among the CD44'" subpopulation compared to CD5'" F5 mice.
This CD44"l population has more robust cytokine-induced proliferation, although we still
observe preferential cytokine-induced proliferation for CD5I cells under stringent sorting
for CD44'" T-cells (Figure 4.10b). CD5hi T-cells also have increased cell size compared to
CD5" cells (Figure 4.15), and there is thought to be a critical cell size requirement to initiate
division [186]. This increase in cell size may also be supported by 'priming' by homeostatic
signals in ito and may potentiate the observed cytokine responses. Altogether, these data
suggest that prior in vivo cytokine and spMHC interactions may have complex effects on
global cytokine responsiveness that we observe both in vitro and in vivo. It will also be
interesting for future studies to look across a panel of IL-2 family cytokine receptor to see
whether their increased expression is also the mechanism for enhanced responsiveness in
CD5 h T-cells, as we have shown for IL-7. As IL-2 and IL-15 have multiple shared receptor
components under feedback control, mathematical modeling of receptor dynamics will also
undoubtedly be useful for understanding their signaling control of heterogeneous T-cell
responses (Discussed further in Chapter 9).
In addition to differences in cytokine responsiveness, our studies reveal an intrinsic
difference in the rate of cell death amongst T-cell clones that also correlates with their CD5
expression (Section 4.2). While T-cells survive equally in the presence of saturating levels of
cytokine, CD5' T-cells having prolonged survival when withdrawn from both TCR and IL-
7R stimuli. CD5" clones have a survival advantage despite their lower Bcl2 expression
(Figure 5.6) and a smaller cell size (Figure 4.15) that would indicate reduced anti-apoptotic
survival signaling and basal metabolism respectively. It therefore remains uncertain whether
prolonged survival results from differential utilization of death pathways, compensatory
differences in other Bcl-2 family members regulating apoptosis [1], or the relative ability of
these cells support metabolism under conditions of starvation through mechanisms such as
autophagy [187, 188]. Interestingly, in vivo adoptive transfer experiments suggest that IL-7
levels in replete mice are sufficient to maintain equal turnover between clones with different
CD5 expression (Figure 6.1). Furthermore, even in the presence of IL-7 depleting
antibodies, we were not able to observe in vivo differences in survival on short time scales
,nor decreases in IL-7 induced signaling (Figure 6.6), suggesting IL-7 is already highly
limiting. In lymphoreplete mice, equal turnover may therefore be maintained by balancing
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the requirement for homeostatic signals with the ability to compete for these signals. In
other words, CD5"I T-cells have a shorter half-life in the absence of homeostatic signals
compared to CD5'" T-cells, but their higher IL-7R expression and TCR avidity may allow
them greater access to limiting IL-7 and/or spMHC to make up for their basal survival
deficiency. Discerning whether homeostasis is maintained primarily by IL-7 levels, or a
balance of IL-7 and access to spMHC, will require better tools to measure local IL-7
abundance and TCR and IL-7R signaling. Mathematical models which are able to capture
and dissect the subtle quantitative effects of variations in homeostatic availability and cell
responsiveness may be useful in discriminating the primary mechanisms controlling the
homeostatic diversity of CD5 expression.
The presiding model for regulation of the naive T-cell pool posits that T-cell diversity results
from competition for a correspondingly diverse pool of cognate spMHCs [1-3], while IL-7
availability limits the overall size of the naive T-cell population [5, 185]. This model has
recently been supported by several computational models of the regulation of T-cell
population and size in both normal hosts, and during peripheral reconstitution following
thymus transplantation in DiGeorge syndrome [166, 168, 169]. However, these studies
implicitly assume equal turnover in the absence of signaling, and ability to respond to non-
TCR-dependent stimuli. Our demonstration of heterogeneous abilities amongst naive T-cells
to respond to IL-7 and survive in the absence of TCR-and IL-7R signaling therefore
suggests a new model whereby IL-7 plays a critical role in regulating both the size and
diversity of the T-cell repertoire. Revisions of these previous mathematical models to include
heterogeneities in cytokine-dependent responses across T-cell of differing specificity may
help reconcile differences in current conceptual models for how T-cell repertoires are
established and maintained (discussed further in Chapter 9).
8.2 IL-7R as the Primary Regulator of IL-7 Responses
We found that CD5 expression is a stable marker of predictable correlated differences in
TCR-independent T-cell survival and proliferation capacities in response to IL-7 stimulation
(Chapter 4). However mechanistically, increased IL-7Ra expression on CD5hi T-cells
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appears to be the major determinant of their increased responsiveness to IL-7 (Chapter 5).
Receptor proximal signaling scaled linearly with loss of IL-7R from the cell surface following
IL-7 binding and internalization (Figure 5.7), indicating receptor expression limits the
maximum achievable upstream signaling capacity. However, T-cells with different IL-7R
expression had conserved relationships between their receptor-proximal signaling and
downstream responses, including survival, proliferation and CD8o induction (Figure 5.9).
There are several different mechanisms by which IL-7 sensitivity could vary across individual
T-cells (discussed in detail in Chapter 3), including differential expression of proteins such
as the Jak-Stat inhibitor SOCS1, or altered receptor trafficking dynamics. However,
downstream changes in the signaling network impacting feedback to signal durations would
be reflected in differences in the relationship between early signals and late responses in T-
cells, which we fail to observe (Figure 5.9). Thus, while there may be additional subtle
network-wide changes affecting IL-7 responses, our data suggest that heterogeneous IL-7R
expression is sufficient to give rise to the observed variation in IL-7 sensitivity across T-cell
clones.
Our data suggest that even the modest differences in IL-7Rx expression observed across the
naive T-cell pool can give rise to large differences in the functional responses to IL-7
(Chapter 4). Our detailed analysis of signal-response relations in the IL-7R signaling
network revealed that this broadening of responses results from distinct signaling
relationships for varying downstream responses (Figure 5.15). Survival rapidly saturates as a
function of signaling, with signaling even by low IL-7R expressing cells supporting complete
survival. In contrast, CD8aX induction scales linearly with receptor expression and increased
continuously with IL-7 treatment. Variations in proliferation were the most dramatic
differences in IL-7 induced response between T-cells, with only cells expressing a critical
level of IL-7R capable of proliferating in the presence of abundant cytokine. The underlying
signaling relationships suggest this is due to a sharp increase in proliferation over a narrow
range in signaling, with a critical signaling threshold lying well above that required for
survival. Different IL-7 dose requirements for T-cell proliferation vs. survival have been
identified [14]. In contrast, our study indicates that responses to IL-7 are encoded at the level
of signaling induced, which is determined both by the IL-7 environment and IL-7R
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expression. Determination of the molecular mechanisms underlying varying responses will
require both continued identification of the critical downstream effectors of IL-7 induced
signaling and further analysis of how the network topology can give rise to distinct signal-
response relationships (discussed in detail in Chapter 3).
Identifying conserved dynamic signal-response relationships between T-cells required an
alternative approach for titrating signaling which could remove the effects of varying
receptor-mediated ligand depletion between cells (Section 5.3.1). If instead of modulating
signaling by inhibiting the initial receptor-proximal signaling events we had taken the more
traditional approach of varying the cytokine dose, very different signaling relationships
would have been identified, with significant interclonal divergence at low ligand doses
(Figure 5.8). Previous investigations into the Stat signaling requirements for survival and
proliferation in polyclonal T-cell populations have not taken these effects into consideration
[14], and future studies into the signaling differences between T-cell clones will need to take
precautions to discriminate whether less sustained signaling arises from altered intracellular
signaling, or extracellular resources. This can be achieved both by careful experimental
design, and use of mechanistic models of receptor trafficking that can capture these
dynamics effects [189].
While IL-7 can induce proliferation in CD5hI T-cells, not all cells proliferate (e.g. Figure 4.2).
Similar to our observations for CD5 (Figure 4.6), there are variations in IL-7R expression
even within TCR-tg T-cell populations. Furthermore, IL-7R is expressed at relatively low
levels on T-cells - estimates range from -1000-3000 receptors/cell - and signaling induces
strong negative feedback to IL-7R expression [1, 184]. Stochastic fluctuations in receptor
expression, or among its downstream regulators - combined with local heterogeneities in IL-
7 concentration around an individual T-cell - may therefore result in only a subset of cells
sustaining sufficient signaling strengths and/or durations in order to initiate proliferation
response. Similar effects have been attributed to heterogeneities amongst cells undergoing
apoptosis [181, 190]. Recent work indicates that receptor suppression plays a strong role in
restricting proliferation, as expression of a non-repressible form of IL-7Ra. in OT1 T-cells at
the same levels as uninhibited endogenous IL-7Ra induced robust proliferation among the
entire T-cell population [191]. This reinforces the need to examine cell responses on an
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individual cell basis, and indicates that functionally discrete T-cell subpopulations are not
required to give rise to the distinct behavioral responses observed within naive T-cell
populations.
Our data indicates that heterogeneous surface IL-7R receptor levels are controlled at the
level of gene expression (Figure 5.2), and are intrinsic to an individual T-cell. IL-7R levels
may therefore be imprinted during development, and these set expression levels then
determine mature peripheral T-cell cytokine responses. Initial attempts to identify
methylation or other epigenetic modifications of the IL-7Ra promoter revealed no
significant differences between T-cells [184]. IL-7R may therefore not be the direct target of
imprinting, and rather its expression regulated by the net effect of network-wide changes
affecting one or more regulators of IL-7R expression. One potential candidate regulator of
IL-7R expression levels is the transcription factor Foxol, whose deletion in lymphocytes
results in significant loss or IL-7R expression [18]. Indeed, we observe significantly lower
expression of Foxol in IL-7R'" F5 cells compared to IL-7R"I OT1 cells (Figure 5.16). F5
cells also show the same traits of decreased Bcl2 (Figure 5.6) and CD62L (Figure 4.1)
expression, and reduced thymocyte numbers [10] observed for mice with Foxol KO T-cells
[18]. Our data also indicated that F5 cells have increased P13K signaling activity (Figure
4.14), and P13K is a known negative regulator of Foxol activity [192, 193]. Regulation of
Foxol therefore offers a possible connection between decreased IL-7R expression and
increased P13K dependent survival in the absence of cytokine.
IL-7R expression is tightly controlled in a cell-type and stage-specific manner during thymic
development. For both DP and mature activated T-cells, downregulation of IL-7R is
proposed to remove these rapidly expanding populations from competition for IL-7 with
less abundant DN T-cell and relatively quiescent naive T-cell fractions [5]. IL-7 signaling is
also thought to be critical for CD8' vs. CD4 lineage selection [194] and IL-7R expression is
proposed to identify effector subsets destined for memory cell formation [195-197]. While
negative feedback to IL-7R expression is thought to be critically important for maximizing
naive T-cell populations [15], all variations in IL-7R expression were attributed to extrinsic
spatiotemporal variations in access to IL-7 [5]. Thus while the importance of modulating IL-
7R expression throughout the developmental lifespan of T-cell is well recognized, our work
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reveals an underappreciated role for IL-7R in controlling interclonal differences in the ability
of naive T-cells to respond and compete for cytokine signals.
8.3 Intrinsic Versus Extrinsic Regulation of IL-7R, CD5, CD8
Diversity in CD5, CD8u and IL-7Ra expression amongst naive T-cells in viio has been
largely attributed to extrinsic heterogeneities in the local spMHC and IL-7 environments [7,
15, 24]. However, our data suggest that basal CD5 and IL-7R levels are maintained by
intrinsic mechanisms, and that their expression patterns can then be further altered via
extrinsic heterogeneities in the signaling environment. Conversely, basal CD8x levels appear
to be relatively equal amongst T-cells, though heterogeneous signaling down intrinsically
different IL-7R- and TCR-mediated pathways results in more widely varied expression when
subject to homeostatic signaling in yvo.
Based on the requirement of naive T-cells to engage spMHC for the maintenance of their
CD5 levels in vivo [7], CD5 expression has been interpreted as a surrogate measure for the
strength of spMHC-induced signaling in the periphery [7, 8, 10, 11]. In this thesis we have
present several lines of evidence that differences in basal CD5 levels among naive T-cell
clones are stably maintained as T-cells undergo activation/differentiation or after withdrawal
from spMHC signals (Figure 4.3). These findings suggest that measured differences in CD5
levels are maintained by both extrinsic and intrinsic mechanisms. The degree of induction of
CD5 levels above baseline may reflect spMHC signals received in the periphery [7], with the
baseline CD5 level indicating the strength of thymic selection [8]. Similarly, while the broad
distribution of IL-7R expression among naive T-cells in vivo was attributed solely to the
heterogeneity in the spatiotemporal presentation of IL-7 between T-cells cycling in and out
of IL-7 rich lymphoid organs [5], our data suggest intrinsic differences in basal IL-7R
expression also underlie these differences.
While we find that IL-7R expression is sufficient to explain the heterogeneous IL-7
responsiveness of mature T-cells (Chapter 4), the correlation between CD5 and IL-7R levels
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may have developmental connections. One hypothesis is that imprinting of CD5 and IL-7R
arises from a one-time epigenetic remodeling event during thymic selection. Spatiotemporal
variability in the spMHC repertoire encountered by T-cells undergoing selection can give rise
to thymic selection of the same TCR into different lineages even within the same TCR
transgenic mouse [9]. It is therefore conceivable that stochastic variations in TCR:spMHC
interactions variation also effect epigenetic remodeling events involved in any particular
lineage commitment. CD5 expression is thought to reflect the strength of cognate spMHC
interactions during thymic selection [9], and underlying remodeling events controlling CD5
expression may also predispose IL-7R expression levels. As discussed above (Section 8.2),
these may not directly target IL-7R or CD5, but rather be the result of many subtle network-
wide changes across indirect regulators of IL-7R and CD5. The unique developmental
history of spMHC interactions of an individual T-cell clones might therefore determine its
homeostatic capacity as a mature T-cell.
A recent study has suggested that mutual feedback between TCR and IL-7R signaling
pathways underlies correlations between IL-7R, CD5 and CD8oa expression among mature
naive T-cells [24]. In what is termed the 'co-receptor tuning' model, IL-7Ra signaling
induces the transcription of CD8a to increase TCR signaling, which negatively feeds back to
reduce IL-7R signaling (Figure 2.7). Reduced CD8a co-receptor expression on CD5 h T-
cells is then proposed to 'tune down' excessive spMHC-induced TCR signaling. Lack of IL-
7-induced Stat5 signaling in freshly isolated CD5hi male HY TCR-tg CD8' T-cells has been
used to support this model. However, we did not find comparable signaling defects in naive
OT1 or polyclonal CD5hi CD8' T-cells (Figure 5.6d), which may reflect differences in their
thymic development compared to male HY T-cells, which are selected on agonist ligands.
The 'co-receptor tuning' model is also supported by a positive correlation of IL-7RX, and
inverse correlation of CD8ax, with CD5 expression for a panel of freshly isolated TCR-tg
cells. Indeed, we also observe these trends for OT1, 2C and F5 mice, however at more
modest levels (data not shown). While feedback between IL-7R and TCR signals may
dampen TCR signals in CD5"' cells, observed trends in CD5, CD8aX and IL-7Ra expression
may also be explained by differences in IL-7 availability in these mice. Our data suggests that
OT1, 2C and F5 mice have decreasing numbers of CD8' cells and conversely increasing
levels of available IL-7, which could partly explain the progressively higher levels of CD8a
in these mice (Section 6.3.4).
Altogether, these data suggest that observed variations in IL-7R, CD5 and CD8 expression
amongst naive T-cells are a complex function of both intrinsic heterogeneities in expression
with possible developmental connections, and extrinsic heterogeneities in the homeostatic
signaling environment that vary both locally within hosts and between different animals.
Determining the underlying relationships giving rise to these correlated differences and
functional responses will require accurate quantification of the local IL-7 and spMHC
environment the resulting TCR and IL-7R signaling across TCR specificities and host
environments for individual T-cell clones. Analysis of these subtle variations will
undoubtedly benefit from coupling of these data with mathematical systems modeling
(discussed in Chapter 9).
8.4 IL-7R as an Important Regulator of the IL-7 Environment
Our data suggests that while high IL-7R expression imparts enhanced IL-7 induced signaling
capacity (Chapter 5), it also leads to more rapid depletion of IL-7 from the environment
(Figure 7.2). This is potentially disadvantageous under limiting cytokine environments, as
cells require periodic contact with cytokine to survive (Figure 7.1), and rapid early depletion
compromises late survival responses (Figure 7.3). The observation of heterogeneous
manipulation of the IL-7 environment by T-cells has several important consequences for
previous models for how IL-7 resources are distributed amongst the naive T-cell population
i vivo.
It has been hypothesized that signaling feedback to IL-7R expression ensures optimal
sharing of limited cytokine resources between T-cells by scaling receptor expression with the
need for cytokine signals [5, 15] (Fig 2.6). That is, cells deprived of cytokine for the longest
periods of time (i.e. those re-entering the lymph nodes from circulation) re-upregulate their
receptor and bind ligand preferentially over those cells that recently received cytokine signals
and downregulated receptor expression (i.e. cells already residing in the lymph nodes). The
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broad distribution of IL-7R expression seen in ro is also attributed to this cycling behavior.
While our studies confirm that the dynamics of receptor expression are in line with this type
of homeostatic cycling behavior (Section 7.1), it suggest that there also exist heterogeneous
abilities to compete for cytokine even amongst cells simultaneously encountering cytokine-
rich regions (Section 7.2). Furthermore, cells with higher receptor expression are capable of
'over-consuming' cytokine beyond what is required to support certain responses, such as
viability. This potentially non-optimal use of cytokine would deplete the cytokine
environment for all cells, limiting overall population size below that which is theoretically
achievable (Section 7.3). Thus, while IL-7 levels have been generally believed to scale
inversely with the number of cell consuming IL-7 [4, 5], our studies suggest it scales more
closely with the total receptor expression amongst the IL-7 consuming pool.
While consequences of unequal competition between T-cells have not been previously
characterized within the naive T-cell population, there have been studied in the context of
competition between different T-cell subpopulations. Overexpression of transgenic IL-7Rx
throughout thymic development was found to decrease overall thymic cellularity [103]. As
DP cells normally silence IL-7R expression, reduced cell numbers were thought to result
from depletion of limiting IL-7 by the relatively abundant DP cells, which then deprive DN
and SP cells of IL-7. Similarly, activated cells are proposed to downregulate IL-7R
expression and become reliant on other cytokines such as IL-2 for pro-survival signaling, so
that the rapidly expanding population does not compete for IL-7 with the naYve T-cell
population [15]. While immunohistochemistry is not sensitive enough to directly confirm
whether these populations do in fact compete in vivo [2], our results suggests that
heterogeneous expression can result in different capacities to deplete the IL-7 environment.
Furthermore, it demonstrates that this competition may be important not only between
functionally distinct T-cell populations, but also within T-cell subpopulations.
Our in vitro studies of depletion differ from in ivo environments in several potentially
important ways. First, at least for CD4' cells, strong TCR-spMHC binding affinity may
enhance the ability of cells to compete for IL-7: TCR engagement signals to IL-7 production
in dendritic cells and higher TCR binding keeps cells in proximately to this localized source
of IL-7 [76]. However, our in vitro depletion measurements do not take into account the
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effects of TCR engagement. Our experimental model also looks at a potentially extreme
example of differences in consumption by beginning with cells with complete receptor
upregulation. However, we still observe heterogeneities in IL-7R expression in freshly
isolated cells (Figure 5.1), so differences in consumption rates may be comparatively
smaller, but still present. Lastly, we look explicitly at cell responses when faced with a single
limiting dose of IL-7, but in vivo, IL-7 is continually replenished. The relative homeostatic
rates of IL-7 uptake at the pseudo-steady-state concentrations of IL-7 in lymph nodes will
therefore depend highly on the rate of receptor and ligand recycling to the surface when
receptor is partially suppressed. As IL-7 signaling influences migration [18], measurements of
total consumption also needs to take into consideration the distribution of T-cells in the
periphery. Accounting for all these effects will require advancements in the ability to
experimentally monitor IL-7 levels and cycling times in z7o.
Whilst IL-7 conditions in normal replete mice do not appear to favor CD5hi or CD5'('
populations, there must remain a balance between total IL-7 production and consumptions
by the naYve T-cell population. Despite 'overconsumption' of IL-7 by OT1 cells, there is a
paradoxical greater naYve T-cell population size in OT1 TCR-tg mice than in F5 TCRtg mice.
One possibility is that although OT1 T-cells consume more IL-7, IL-7 levels in these
relatively lymphopenic mice (which lack other IL-7 consuming populations such as B-cells)
may still allow OT1 T-cells to proliferate and expand their population whereas F5 cells
cannot. Expanded cell populations may also gain memory-like phenotypes with more
reliance upon other cytokines, such as IL-15, whose expression may not be as limiting. As
most TCR-tg mice fail to attain the steady state population sizes of replete mice [10], it is
also possible that their IL-7 production rates differ (due to TCR stimulated feedback, as
discussed above) and/or that the cytokine pool does not become limiting. In the latter case,
the naive T-cell population size achievable by F5 cells may represent the maximum steady
state population capacity in the absence of peripheral expansion. LastyN, as IL-7R signaling is
also a key regulator of migration in and out of the lymphoid organs [18], altered rates of
cycling due to different IL-7R expression may skew the fraction of the population occupying
these sites and bias estimates of total population size.
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Altogether, these data highlight the importance of IL-7R expression in the regulation of both
the ability of T-cells to respond to IL-7 and to impact their IL-7 environment.
Deconvolution of the relative effects of receptor expression, feedback to receptor
expression and rates of IL-7 production, and lymphoid trafficking in controlling the
homeostatic levels of IL-7, and cell numbers and diversity, would likely highly benefit from
rigorous quantitative experiments in combination with mathematical systems modeling
(discussed in Chapter 9).
8.5 Physiological and Therapeutic Implications
Competition between T-cells for limited extraneous resources in the form of spMHC
presented on dendritic cells and cytokines produced by stromal cells is believed to set the
limits on the numbers and diversity of a T-cell population. The pro-survival cytokines are
currently believed to regulate total cell numbers while spMHC regulates the structural (TCR)
diversity of the T-cell repertoire [2]. This general model has been supported by several
mathematical models [166, 168, 169], however, these studies typically implicitly assume equal
reliance on non-TCR specific resource, and equal turnover in the absence of TCR signals.
Rather, our demonstration of heterogeneities IL-7R signaling and basal survival among naive
T-cells suggest that IL-7 does not strictly control population size alone, and suggests that the
diversity of naive T-cell repertoire is shaped by a complex interplay between TCR and IL-7R
signaling.
The 'competition-diversity paradox' describes how competition for survival factors would
ultimately result in the domination of the repertoire by T- cell clones with the best ability to
compete for (or respond to) homeostatic signals [12, 13]. Yet despite CD5I T-cells having
both increased TCR-spMHC avidity and increased ability to respond to IL-7, our in t'ivo
studies indicate that normal replete mice maintain a homeostatic balance between CD5I and
CD5" T-cells (Figure 6.1). Avoidance of dominance of the T-cell repertoire by CD5I clones
according to the competition-diversity paradox may rely on the basal differences in survival
when deprived of homeostatic signals. One putative model is that a T-cell's greater ability to
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compete for resources, via higher spMHC:TCR affinity and IL-7Ra expression in CD5hi
cells, is balanced by a greater demand for available spMHC and IL-7 resources. Our findings
suggest that T-cell survival and proliferation is balanced at a state of stable equilibrium
associated with an IL-7 level that does not promote selective proliferation or persistence of
CD5 or CD5'" cells [4, 5]. This steady state may arise by balancing the overall size of the T-
cell population consuming IL-7 with its production. Maintaining this limiting optimal IL-7
level may allow for avoidance of the competition-diversity paradox. However, exogenous IL-
7 therapy temporarily disrupts homeostasis, shifting the environment to one in which CD5"i
T-cells have a selective advantage. However, it is plausible that once IL-7 therapy is stopped,
the expanded T-cell population would then deplete remaining IL-7 at an increased rate due
to higher basal IL-7R expansion and consumption of the expanded CD5hI T-cells. This may
eventually lead to IL-7 depleted conditions where CD5'" T-cells have a survival advantage,
returning the overall population to homeostasis. Confirming if, and how, populations return
their basal homeostatic diversity of CD5 expression after IL-7 treatment has stopped will
require longer in vivo experiments examining the dynamics of both population size and CD5
distributions. Moreover, determining precisely how subtle heterogeneities in IL-7R
expression and TCR avidity integrate to influence the size and diversity of the T-cell
repertoire during normal homeostasis and under cytokine therapies will likely require
rigorous quantitative models describing the balance of production, consumption and access
to homeostatic resources among cells with varying survival and proliferation capacities
(discussed in Chapter 9).
A number of studies have shown that the T-cell population is expanded by thymic-
dependent and independent mechanisms in both normal and lymphopenic mice following
infusion of IL-7 [106, 185]. IL-7 administered in combination with immunization also
enhances T-cell responses and promotes memory cell generation [112, 113]. This work has
sparked much interest in the therapeutic use of IL-7 to help restore compromised immune
systems following chemotherapy or viral attack, and as an adjuvant for vaccines and cancer
immunotherapies [113, 114, 198]. Two rhIL-7 Phase I clinical trials have recently been
completed in adult patients with refractory cancer [126, 127]. In both trials, CD8' and CD4*
T-cells showed an IL-7 dose-dependent increase in population size and a concomitant
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increase in the diversity of TCR VP usage which they attributed to predominant expansion
of the more 'diverse' recent thymic emigrant (RTE) population [127]. However, it is unclear
whether this increase in TCR V diversity translates to functional ability to respond to new
antigenic challenges. Our study demonstrates an additional mechanism by which IL-7 affects
the diversity of the T-cell repertoire: regulating the diversity of TCR-spMHC avidities,
indicated by CD5 expression, via correlated differences in their IL-7R expression and IL-7
responsiveness. While TCR V diversity increases with IL-7 therapy, our model suggests
that the homeostatic diversity of CD5 expression amongst T-cell clones is maximized at
physiological IL-7 levels (Figure 6.9).
Our studies also add an important consideration to the design of potential IL-7 therapies.
Although in normal replete mice we saw no survival advantage between CD5I and CD5"
cells, IL-7 treatment can result in the preferential expansion of CD5"I T-cells (Figure 6.4).
Preferential expansion of more autoreactive CD5hI T-cells in response to increased IL-7,
either systemically or at local sites of inflammation, has been proposed to contribute to
development and progression of autoimmune disorders [19, 20]. Yet selective expansion of
self-reactive T-cells may prove to be desirable for the use of IL-7 as an adjuvant in cancer
immunotherapies [113, 199]. Enhanced IL-7R signaling has also been proposed to
contribute to T-cell leukemogenesis [21]. Thus while IL-7 therapies may expand overall T-
cell numbers, they may have the unintended consequence of preferentially expanding
undesirable T-cell population subsets. Given the increasing interest in IL-7 based therapies,
further investigation of the intrinsic differences in the signaling networks across T-cell
populations will help us understand the clinical impact of skewing the T-cell repertoire
toward a CD5hIL-7Rhi or CD5'IL-7R'" phenotype.
The potential therapeutic promise of IL-7 therapies for expanding or enhancing the function
of T-cell populations combined with the potential detrimental effects of skewing of the T-
cell repertoire calls for careful design of therapeutic dosing strategies. While the
aforementioned rhIL-7 clinical trials observed an IL-7 dose-dependent increase in the
population size of the T-cell repertoire, at high cytokine doses, receptor suppression
appeared to limit overall responses [127]. Determining the optimal IL-7 dose size and timing
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to maximize beneficial therapeutic effects can be guided by mathematical models that
capture the dynamic feedback between receptor suppression, population size and
composition and the cytokine environment. Furthermore, characterizing the key
physicochemical parameters regulating these processes may help guide the design of IL-7
mutants with improved therapeutic efficiency (discussed in Chapter 9).
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Chapter 9 Perspectives on Future Work
Chapter 8 highlighted many outstanding questions surrounding how heterogeneities in IL-7R
signaling across naive T-cells arise developmentally and are manifested in vivo in the context
of TCR and other cytokine signaling. Of particular importance are questions relating to how
IL-7 therapies currently in clinical trials might impact the T-cell repertoire, and whether they
can be further optimized. In the following sections we discuss in detail particular areas that
are ripe for future exploration and potentially addressable by a combination of quantitative
experimental and mathematical modeling approaches.
9.1 IL-7 Signaling Cross-Talk with TCR & Other Related Cytokines
It is becoming increasingly evident that there are multiple mechanisms of both cell-intrinsic
and cell-extrinsic crosstalk between TCR and IL-7R signaling. Moreover, multiple cytokines
present in vivo within the T-cell niche have partially overlapping roles with IL-7 and affect IL-
7R expression [1]. Chapter 3 discusses many of the interactions that may give rise to non-
intuitive cellular responses under stimulation with multiple cytokine and/or TCR cues. Here
we offer a few specific questions that directly follow from the conclusions of this thesis that
might be of particular interest for future studies, and some initial perspectives on how they
might be addressed.
9.1.1 Relationships Between IL-2, IL-15 & IL-7 Signaling
Is the heterogeneous responsiveness of CD5hI and CD5'" T-cells to IL-2 and IL-15
controlled at the level of receptor expression? Do these related cytokines share
common signal-response relationships with IL-7?
In vivo, the pro-survival cytokines IL-2 and IL-15 are thought to have partially overlapping
roles with IL-7 [1], and are proposed to partially account for maintenance of the small T-cell
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population still present in IL-7-deficient mice [64]. WXhile the focus of this thesis was to
characterize responses to IL-7, many of the same mechanisms regulating cell responses to
IL-7 may also apply generally across IL-2 family cytokines [200]. Indeed, we observed that
in addition to their increased responsiveness to IL-7, CD5I T-cells also had more robust
proliferation responses to IL-2 and IL-15 (Figure 4.7). IL-2-based therapies have found use
in treating a diversity of disease conditions [201], and manipulation of IL-15 levels has been
proposed for vaccine adjuvants [202] or autoimmune therapies [203]. It will be critical to
study whether these and other related cytokines have similar abilities to shift the diversity of
TCR affinities across the T-cell repertoire as we have observed for IL-7.
This thesis offers a potential 'roadmap' to characterizing signal-response relationships of T-
cells to other cytokines. First, while we have established differential responsiveness to IL-2
and IL-15 across CD8' T-cells of different CD5 expression, it is unclear whether this
enhanced sensitivity is determined primarily by their receptor expression, as we have
observed for IL-7. Future work should therefore begin by characterizing the receptor
expression and proximal signaling dynamics as we've undertaken for IL-7 (Chapter 4). In
contrast to negative signaling feedback to receptor expression for IL-7, IL-2 signaling causes
upregulation of the IL-2-specific IL-2RX/CD25 receptor chain [22]. IL-15 poses further
complexities, as its unique a chain is thought to transpresented, though signaling can still
originate from IL-15Rx on the cell surface [204, 205]. An Fc/IL-15Ra fusion can be pre-
complexed with IL-15 to mimic transpresentation for signaling studies (R&D systems) [206].
Furthermore, both IL-2 and IL-15 have an additional shared receptor component, IL-
2RP/CD122. These complexities highlight the need for precise measurements of multiple
receptor components over time to fully characterize whether differences in signaling and
responses are determined by receptor expression dynamics. Mechanistic ODE-based models
of receptor-ligand dynamics will likely be useful in quantitatively relating signaling and
receptor dynamics [189].
Our initial signaling profiles for IL-7 indicated that Stat5 and P13K were the dominant
upstream signaling pathways and their individual measurements were sufficient to predict
responses (Section 5.3.2). However, in many systems, predicting responses often requires
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network-wide activity measurements across multiple signaling pathways (see for example
[207, 208]). In the particular case of IL-2 and IL-15 stimulation, MvAPK pathway signaling is
likely to play a significant regulatory role in addition to Jak/Stat and PI3K/Akt signaling
[22]. Nevertheless, it will be interesting to see to what extent viability, proliferation and
CD8x induction responses to IL-2 and IL-15 can be individually predicted from their Stat5
or pGSK3 phosphorylation levels as we've observed for IL-7, and whether this signal-
response relationship is common among all three cytokines. Where discrepancies exist,
additional dynamic measurements of MAPK pathways components may improve response
predictions. These studies will likely benefit from statistical modeling techniques which
determine a hierarchy of predictive power amongst multiple signals, and can be used to
identify critical underlying regulatory relationships [25]. As all of these cytokines can be
simultaneously present in vivo, and share both downstream signaling pathways and receptor
components, models built on dynamic data under an array of combined cytokine
stimulations will be useful for deconvoluting overall systems behavior in complex cytokine
environments present in ivo.
9.1.2 IL-7R Control in the Context of Other Cytokines
Do alterations in IL-7R expression induced by other cytokines translate directly to
IL-7 signaling capacity and responses?
We found that IL-7R expression was the primary determinant of responsiveness to IL-7
among T-cells. However we, and others [15], have observed that multiple cytokines
influence IL-7R expression. IL-4, IL-6, IL-2, IL-15 and IFNy all decrease IL-7R surface
protein expression, while TNFa increases expression (Figure 9.1). While each of these
cytokines have unique roles in T-cell development and function [200], they may also alter
responses to IL-7 either directly via receptor expression or via downstream signaling
crosstalk (Chapter 3). Furthermore, manipulation of receptor expression with other
cytokines might be an alternative approach to studying variations in IL-7R expression.
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Figure 9.1: IL-7R Expression is Influenced by Multiple Cytokines
IL-7Ra surface expression of F5 TCR-tg naive (CD4410) CD8+ T-cells rested overnight (~16 hours)
in cytokine-free media and then treated with lOng/mL of IL-2, IL-4, IL-6, IL-7, IL-15, IFNy, TNFa
or medium alone.
We were unable to increase IL-7R expression on F5 cells via infection of bone marrow stem
cells with retroviral IL-7RQ, presumably because of tight development controls on
expression (Section 5.4.1). However, it might be possible to pre-treat F5 cells with TNFa to
increase IL-7R expression, followed by treatment with IL-7, to see whether this leads to
sufficient signaling for proliferation. As TNFa induces cell death pathways [209] whereas
IL-7 induces pro-survival signaling, these studies will also be informative as to how T-cells
balance pro- and anti- apoptotic signaling via their receptor dynamics. Pre-treatment or
simultaneous stimulation with a variety of cytokines types and doses and IL-7 could
therefore be used in a similar way to varying inhibitor treatments to titrate IL-7 signaling
responses. As highlighted in the previous section, a variety of mechanistic and statistical
modeling approaches might be useful to deconvoluting effects that result from either
manipulation of receptor levels or influencing downstream pathway activation. There studies
would help inform a more complete understanding of how IL-7 responses are regulated via
other cytokines present in vivo.
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9.1.3 Interactions Between TCR and IL-7R Signaling
What is the effect of spMHC stimulation on IL-7-induced downstream signaling
activity and responses and vice versa?
Work in this thesis has focused on IL-7 responses in the absence of TCR stimulation, yet it
is increasingly clear that T-cell survival and proliferation is controlled by integration of both
TCR and IL-7R signals. Park et al. (2007) have proposed a model whereby mutual feedback
between these pathways balance overall homeostatic signaling [24]. In contrast, others
suggest that cytokine signaling primes T-cells for more robust TCR-pMHC interactions [78].
The ability to carefully study the mechanisms of integrated signaling control of cellular
responses to TCR and IL-7R stimulation has been hindered in several ways. Of foremost
difficulty is directly quantifying and comparing low-affinity spMHC:TCR interactions,
especially across TCR specificities [210]. While an increasing number of estimates of binding
affinities have been made, it is not always clear these directly relate to the multivalent
interactions of T-cells with spMHC on antigen presenting cell surfaces [210, 211]. There are
also likely dynamic changes in the local spMHC and cytokine environment during these cell-
cell interactions whose effects are not accounted for in artificial spMHC presentation
systems. Lastly, there is in many cases a lack of reliable probes to monitor signaling activity
on a single-cell basis by flow cytometry, immunohistochemistry, or live cell imaging. Despite
these limitations, discussed here are a few simple studies that might provide some initial
insight into TCR-IL-7R interactions.
There exist several TCR-tg T-cell systems for which a library of peptides of varying TCR
affinity has been identified. For instance, the 2C TCR system has been highly characterized
[46]. Naturally occurring self-peptides that mediate both positive selection and peripheral
homeostasis have also been identified for the 2C and OT1 TCR systems [47, 212]. While the
exact affinity of these peptide-TCR interactions have not all been measured, in many cases,
their affinities can be rank ordered. New peptide-exchange systems [213] allow for simple
and quick presentation of a diversity of pMHC complexes either on artificial surfaces, on
antigen presenting cells, or as MHC tetramers [214]. Another method for quantitatively
varying TCR signaling is to take a similar approach to our cytokine signaling titration
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(Figure 5.8), and use the same peptide input stimulation but vary the dose of inhibitor to
receptor-proximal signaling events (see for example [215, 216])
As a first step, future studies could profile T-cell survival, proliferation and CD8aX induction
responses in vitro using one of the aforementioned spMHC presentation systems for varying
TCR signaling in combination with varying cytokine signaling. This data should reveal in
what treatment regimes there is divergent behavior from spMHC or IL-7 signaling alone,
and the minimal individual and combined requirements for homeostasis. Monitoring critical
IL-7R and TCR signaling pathway components such as Stat5 and Erk respectively and
downstream effectors of survival such as Bcl2 will provide an initial indication of IL-
7R/TCR signaling pathway crosstalk. These pathways offer the additional advantage of
having good flow cytometry-validated antibodies for their detection (BD Bioscience
PhosFlow System), allowing for single-cell analysis of signaling even in the context of co-
culture systems for spMHC presentation. Simply assaying IL-7 signaling in the presence and
absence of stimulation by positively selecting spMHC will help resolve discrepancies
between the TCR signaling mediated inhibition of IL-7 signaling reported by Park et al
(2007) [24] that was not observed in our studies.
9.1.4 Predictive Models of Signaling Control of T-Cell Responses
Can we predict survival and proliferation responses as a function of combined
spMHC and cytokine signaling?
We may not be able to fully mimic in vitro all the components present within in vivo T-cell
environments. However, work by our lab and other suggest that signaling assays of network
activity may be more robustly predictable of cellular responses than the particular cell
treatment (combination of cytokines and spMHC), which will undoubtedly present other
contextual stimulatory cues (see for example [207]). We can gain significant understanding of
cellular control by undertaking a 'cue-signal-response-analysis': examining how a constrained
set of stimulatory cues (or treatments) give rise to signaling pathway activation and then are
translated into responses. However, in translating these relationships to complex in vivo
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environments containing other potentially unknown cues, signal-response relationships are
more likely to be preserved than cue-response relationships. This suggests that even with our
limited ability to directly mimic in ri'o environments, systematic profiling of T-cell signaling
and responses under a wide range of cytokine and TCR stimulations might inform a useful
model for predicting in ivo cellular outcomes based on their signaling state when isolated
from their in vivo environments.
We have the experimental methodology to extend the study of control of T-cell homeostasis
from one cue (IL-7) to many cues (multiple cytokines and/or spMHC complexes). However,
discerning critical regulatory relationships from this expanded data set comprising multiple
stimulations, downstream signals and response requires more sophisticated data analysis and
visualization tools that the one component analysis framework we have largely employed in
this thesis. Many of these tools have been developed in our lab and successfully applied to a
wide array of cell systems, including a T-cell hybridoma system under varying levels of
activating stimuli [208]. We might similarly be able to use a comprehensive and quantitative
data set for primary T-cells under combined stimulation to help understand & predict how
T-cells resolve their complex cytokine and TCR environment into functional responses.
Using these models to infer mechanisms for integrated signaling control in vivo will require
murine models from which we can either quantitatively measure the homeostatic
environment or independently control access to either spMHC or IL-7. We've observed
potential variations in IL-7 levels across TCR-tg hosts (Section 6.3.2), enforcing the need to
compare survival and proliferation responses of T-cells with specificities within identical
hosts. In vivo levels of IL-7 in a single host can then be manipulated via infusion of cytokine
or cytokine-neutralizing antibodies as we've described in Chapter 7. In may be possible to
compare relative homeostatic capacities of a given T-cell specificity across varying spMHC
stimulations in vivo by genetically varying TCR expression or using 'single' spMHC mice [48,
49, 217]. Cells can then be assayed for their resulting signaling network following adoptive
transfer into each host environment. Thus, whereas models derived from in vitro stimulation
data can help derive relationships between signals and responses, these in Pivo studies can
clarify the physiological relationships between stimulatory cues and signaling. These coupled
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approaches may help define the roles of spMHC versus IL-7 signals in regulating
homeostatic T-cell survival and proliferation responses.
9.2 Optimization of Therapeutic IL-7 Dosing Strategies
IL-7 is currently being administered in multiple clinical trials aimed at treating a wide variety
of pathological diseases including cancer, HIV, and a variety of autoimmune diseases, and
has shown early promise in restoring compromised immune systems and as an adjuvant in
vaccines [218]. However, significant questions remain as to how to optimize therapeutic
dosing strategies for IL-7. Early cytokine immunotherapy trials evoked adverse
immunological reactions that were partially attributed overdosing, and these studies have
hindered the rapid development and approval of related therapies [129-131]. This highlights
the need for careful design of cytokine therapies during initial stages of development and
early clinical trials. Human clinical have shown dose-dependent expansion of the T-cell pool,
but total expansion achievable was limited in both size and duration [126, 127]. However,
the therapeutic capacity of cytokines may be altered by genetic mutations affecting
receptor/ligand binding and resulting trafficking properties [219], or using cytokines pre-
complexed or directly fused to antibodies [220-223]. Here we highlight several questions
relating to IL-7 dosing strategies and potential ways to begin addressing them with
quantitative modeling, protein engineering and in t'ivo studies.
9.2.1 Examination of Receptor Feedback-Limited Dosing
Does receptor suppression limit the net population expansion during IL-7 therapy?
In one of the first human clinical trial of IL-7 therapy, a cohort of adults with refractory
cancer was subjected to varying doses of IL-7 injected every other day for two weeks [127].
Clinicians observed a dose-dependent increase in the CD4' and CD8' lymphocyte
populations which peaked at -300% and ~400% of initial population size respectively at 21
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days after the initiation of treatment. However, the percentage of cycling cells, as well as
intracellular Bcl2 levels, peaked after only 7 days into the treatment, and coincided with loss
of IL-7R expression at both the surface protein and mRNA levels. Investigators interpreted
loss in IL-7R expression as a self-limiting mechanism preventing further cell expansion with
continued IL-7 treatment. However, at lower doses of IL-7, despite reduced total expansion
than with high doses, cells did not completely lose receptor expression. Furthermore, IL-7R
expression increased after cessation of IL-7 treatment in all cases. This implies that either
using lower IL-7 doses over longer durations, or higher doses at less frequent intervals may
allow for continued and/or periodic re-expression of receptor, allowing cells to continue to
be receptive to IL-7 stimulation. Authors also observed that several weeks after treatment
was halted, growth in the lymphocyte population ceased, and in some cases population sizes
began to fall. This might indicate the initial stage of a return to a lower homeostatic
population size. However, patients were not monitored sufficiently long to confirm whether
they re-establish their baseline population sizes prior to treatment or maintain a net increase
in lymphocyte numbers.
Determining IL-7 dosing parameters for promoting an optimal sustained increase in
population size begs for a rigorous quantitative analysis of different therapeutic strategies -
both dose size and duration/frequency - and how they are impacted by negative feedback to
receptor expression. In particular, a simple mathematical differential equation model relating
receptor trafficking dynamics and signaling to survival, proliferation and receptor
suppression [189] would greatly benefit the interpretation of both in vitro and in vivo studies.
Such a model would need to be informed by measured kinetic rates of receptor dynamics
and empirical signal-response relationships similar to those derived in this thesis. However, it
could then be used to evaluate in silico a much wider array of IL-7 treatment regimes than is
feasible with in vico studies to determine critical parameters controlling population dynamics
as a function of treatment dose and time. The capacity of the model to predict population
size outcomes could then be evaluated for a more restricted set of treatment regimes in
mouse models. These in vivo studies could also monitor CD5 expression profiles throughout
and after treatment, in particular to determine whether CD5 and population size returns to
initial homeostatic states after exogenous IL-7 is depleted. If true, this would suggest that
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while IL-7 therapy may accelerate population recovery in the short term, populations will
eventually return to the initial size governed by rates of IL-7 production.
9.2.2. Improving the Therapeutic Design of IL-7
Can IL-7 be rendered more efficacious by altering its receptor binding properties
and/or pre-complexing with antibody?
Work in our lab has shown that the receptor binding properties of cytokines can be altered
via genetic mutation, which impacts cell signaling and responses as well as rates of cytokine
recycling and degradation [219, 224-228]. The overall impact of changing binding properties
on cell behavior is often non-intuitive, but can be their design can be guided, and effects
interpreted, by the use of mathematical models [219]. Development of these models require
quantitative dynamic data to determine kinetic rate parameters, and our group has developed
experimental methodology to independently determine rates of ligand binding,
internalization, uptake, degradation and recycling. Models of behavior with wild type IL-7
can therefore be constructed using data in this thesis and supplemented with additional
measurements using either radioactive isotope or fluorescent labeling of IL-7. Sensitivity
analysis of ligand binding parameters would then inform hypotheses as to whether cell
behavior and/or ligand depletion may be significantly altered via mutation. IL-7 with
mutations that meet desired biophysical parameters can be isolated using yeast-two-hybrid
screening approaches [229]. It may therefore be possible to develop recombinant mutant IL-
7 that is more therapeutically efficacious than wild type IL-7.
Another approach to altering the in vivo activity and persistence of cytokines is to pre-
complex them or fuse them directly to antibodies and/or soluble receptor components [221-
223]. IL-7:aIL-7mAb complexes have been shown to elicit more robust B- and T-cell
expansion and more potent CD8' T-cell antigen-specific activation responses [230]. IL-2:IL-
2 antibody complexes and IL-15 pre-associated with IL-15Ra have similarly increased
biological activity [206, 220, 231]. There is some debate over the mechanisms of increased
activity for cytokine-antibody complexes [220, 222]. Antibody complexation may increase in
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vi'o half-lives of cytokines by reducing cell-mediated-degradation and clearance [232]. They
may also directly affect receptor-binding properties [232]. Soluble isoforms of IL-7R first
identified in humans [233, 234], and just recently observed in mice [235] have also been
proposed to have similar action to cytokine mAbs. However, presence of the Fc portion of
antibodies is required for the full activity of some IL-7/mAb complexes, suggesting
additional cellular interactions unique to antibody complexation [230]. Mathematical
modeling might provide a useful tool for critically evaluating these possible mechanisms in a
quantitative framework. Extending the model to include extracellular soluble antibodies
and/or receptors would be a simple extension of the prospective model described in the
previous section. Similar to the studies described above, we may also be able to use this
model to inform whether changes in the antibody-ligand binding properties might further
enhance the efficacy of antibody-cytokine complexes and how their dosing might be
optimized.
9.2.3 Modeling Homeostasis with IL-7R Heterogeneity
What are the implications of heterogeneous IL-7R signaling capacities for current
models for the development and reconstitution of the T-cell pool?
Several mathematics models have recently been published which describe how the size and
diversity of the T-cell pool is initially established, maintained during normal homeostasis,
and how it recovers following periods of lymphopenia [166, 168, 169]. These models reach
similar conclusions: T-cell population diversity is regulated by TCR specificity, while IL-7
places limitations on the total population size achievable. However, these models made the
implicit assumptions that T-cell turnover and 'demand' for non-TCR-dependent recourses
such as IL-7, and sensitivity to these cytokines, is equal across TCR specificities. As we've
demonstrated that heterogeneities in both cytokine responses and cytokine- and spMHC-
deprived survival vary across the T-cell repertoire, these models need to be revised. Future
work could involve the simple extension of these models to include additional variation in
reliance on cytokine signaling, and basal turnover rates, that co-vary with TCR sensitivity.
Determining whether these models allow for establishment of steady state diversity in
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TCR:spMHC avidity (CD5 expression) and population size would help determine whether
feedback between TCR and IL-7R pathways is in fact required for homeostasis. It would
also allow for more detailed evaluation of how IL-7 resources are shared among the T-cell
pool and how population sizes scale with the availability of IL-7. These revised models
would be very useful in furthering our understanding of which factors influence the
development and maintenance of immune function and advise the further development of
cytokine therapies.
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Methods
M.1 Mice
C57BL/6J (136) mice, B6 TAP-/ mice and B6.CD90.1/Th 1.1 congenic mice
(B6.PLThyla/Cy) were purchased from the Jackson Laboratory. OT1, 2C and F5 TCR-tg
mice were backcrossed onto the B6.Ragl/ background for >20 generations. Age- and sex-
matched mice, between 6 and 16 weeks of age, were used for experiments. Mice were
maintained in the MIT animal facilities and used according to the guidelines of the
Institutional Committee on Animal Care.
M.2 T-Cell Purification and in vitro Culture
CD8' T-cells were purified from single cell suspensions of lymph nodes or spleen using an
EasySep mouse CD8' T-cell enrichment kit (Stem Cell Technologies). For enrichment of the
naYve (CD44"') lymphocyte fraction, T-cells were either (1) stained with phycoerythrin-
conjugated anti-CD44 and the stained fraction removed using anti-phycoerythrin
microbeads (Miltenyi Biotech) or (2) stained with anti-CD44 and removed using fluorescent
cell sorting. For all experiments involving sorting on CD5 expression, viable CD8*CD44'" T-
cells expressing the maximum 20% and the minimum 20% levels of CD5 were sorted into
CD5I and CD5" fractions. Purified T-cells were cultured in complete RPMI-1640 medium
containing 10% FCS (see Culture Media) at 37'C and 5% CO 2. Cells were assayed either
immediately following isolation, or where indicated, cells were rested overnight (-16 hours)
in medium without cytokine to eliminate any TCR and cytokine signaling prior to treatment.
Unless otherwise indicated, cells were cultured at densities of 2-3.5x10 5 cells/mL.
M.3 Culture Media
Unless otherwise indicated, cells were grown in RPMI-1640 with glutamine (VWR), 10%
charcoal/dextran stripped FBS (HyClone), penicillin (100 U/ml), streptomycin (100ug/ml),
nonessential amino acids (lx), HEPES (10 mM), sodium pyruvate (1 mM), and 50 uM $-
mercaptoethanol (all VWR).
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M.4 Peptides, Cytokines & Inhibitors
Recombinant murine IL-7, IL-2, IL-I5, IL-4, IL-6, IL-9, TGFa, and IFNy (all Peprotech,
H20 with 5% BSA stock) were added to culture media at concentrations ranging from
0.0001 to 100 ng/mL. The P13K inhibitors LY2904002 (0.1-200 pM), PI-103 (0.01-10 tM)
and the Jak family inhibitor, Jak Inhibitor I (0.004-2 tM) (all Calbiochem, DMSO stock)
were added to cultures for 30 minutes prior to cytokine addition at the indicated
concentrations. RTY (RTYTYEKL), ISF (ISFKFDHL) and SII (SIINKEKL) peptides (MIT
Biopolymers facility, H2 0 stock) were added to cultures at the concentrations indicated
simultaneously with cytokines.
M.5 In vitro Memory Cell Generation
OT1 and F5 memory-like T-cells were generated via slight modification of protocols
previously described [35]. In brief, OT1 and F5 cells were activation by one of two methods,
as indicated: (1) cells were cultured in on plate-coated anti-CD3 antibody (BD Biosciences)
for 3 days in the presence of 20 ng/mL mIL-2 (Peprotech), or (2) cells were cultured in
media containing 25ng/mL PMA + 500ng/mL ionomycin for 24 hours, washed 3x with
media, and cultured in media containing 20 ng/mL IL-2 for 2 days. Following activation and
blasting, cells were then washed 3x in cytokine-free media, and culture in either 5ng/mL IL-
7 or 40ng/mL IL-15. Cell responses to cytokines were then measured following cell culture
overnight in media without cytokines after washing 3x with cytokine-free media.
M.6 Antibodies
The following antibodies were used (clone names in parentheses): Bcl-2 (3F11), Stat5 (89),
pStat5 Y694 (47), Ki67 (B56), Mouse IgG1,K isotype (MOPC-21) (all BD Biosciences),
pGSK3 (37F11), GSK3 (9315), P-Actin (8H1OD10) (all Cell Signaling Technologies), IL-
7Rx/CD127 (SB/199), CD5 (53-7.3), CD44 (IM7), CD69 (H1.2F3), CD62L (MEL-14),
TCR, CD8ax (53-6.7), CD25 (PC61), CD122 (TM-bl),Thy1.1/CD90.1 (OX-7),
Thy1.2/CD90.2 (30-H12), mouse IgG2x,K isotype (MOPC-173), Rat IgG2x,K isotype
(RTK2758) and Rat IgG2,K isotype (RTK4530) (all Biolegend). Optimal antibody dilutions
were determined by titration.
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M.7 CFSE staining
T-cells were suspended at 1x10 cells/ml in 2mL serum-free RPMI media containing 5mM
CFSE (carboxyfluorescein diacetate succinimidyl diester; Invitrogen) and incubated at 37oC
for 5 minutes. Staining was stopped by addition of 10mL of serum-containing media and
placing cells on ice for 5 minutes. Cells were washed twice prior to in vitro culture or adoptive
transfer.
M.8 Flow Cytometry: Live Cell Detection of Surface Epitopes
Cells were washed in PBS containing 0.5% BSA and resuspended in PBS containing 0.5%
BSA, 0.1% NaN 3 and 2.5 Ig/mL Fc BlockTIM for 10 minutes at 4'C. Fluorescently-tagged
antibodies were added to a final concentration of 1.25ug/mL for 40 minutes at 4'C.
Nonspecific background fluorescence was determined by staining with isotype-matched
antibodies. Cells were washed twice with PBS containing 0.5% BSA and 0.1% NaN3 and
kept on ice prior to multi-parameter flow cytometric detection on FACS LSRII (Becton
Dickinson). Cell viabilities were determined by adding 1.5 mM DAPI (Invitrogen) to the
final resuspension.
M.9 Flow Cytometry: Detection of Cell Surface & Intracellular
Antigens
For detection of intracellular signaling, Live/Dead Fixable Blue Dead Cell Stain (Invitrogen)
was added to cells for 10 minutes before the end of culture. Cells were placed on ice and
washed lx with ice-cold PBS. Cells were fixed by resuspending in with 4% formaldehyde for
10 minutes. Cells were then permeabilized by resuspending in ice-cold 90% MeOH for >2
hours at -20'C. Cells were washed twice and then resuspended in PBS with 0.5% BSA and
2.5 tg/mL Fc BlockT (2.4G2) (BD Biosciences) for 10 minutes at 4'C. One of two
protocols was then followed depending on the nature of the antibodies used for staining:
Primary conjugated antibodies only (pStat5, pErk, Ki67):
Fluorescently-tagged antibodies against intracellular and cell surface antigens were added for
40 minutes at room temperature. Final concentrations for antibodies against cell surface
antigens were 1.25ug/mL (typically 1:200 dilution for Biolegend antibodies) unless otherwise
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indicated. For intracellular antigens, final concentrations of 1 ug/mL (typically 1:20 dilution
for BD Phosflow antibodies) were used unless otherwise indicated. Cells were then washed
twice and resuspended in PBS containing 0.5% BSA and kept on ice prior to multi-
parameter flow cytometric detection on FACS LSRII (Becton Dickinson).
Primary conjugated and unconjugated antibodies (pGSK3, Bcl2, Akt):
Unconjugated primary antibodies against intracellular antigens were added for 40 minutes at
room temperature. Unless otherwise indicated, primary antibodies were added at Sug/mL
(typically 1:20 dilution Cell Signaling Technologies). Cells were washed twice with PBS
containing 0.5% BSA, and resuspended in secondary antibodies and antibodies against cell
surface antigens in PBS with 0.5% BSA and 2.5 pg/mL Fc BlockTA' for 40 minutes at room
temperature. Final concentrations for antibodies against cell surface antigens were
1.25ug/mL (typically 1:200 dilution for Biolegend antibodies) unless otherwise indicated.
Secondary antibodies were added at 2ug/mL (typically 1:500 dilution for Invitrogen
antibodies) unless otherwise noted. Nonspecific background fluorescence was determined by
staining with isotype-matched antibodies and/or secondary antibody staining only as
indicated. Cells were washed twice with PBS containing 0.5% BSA and kept on ice prior to
multi-parameter flow cytometric detection on FACS LSRII (Becton Dickinson).
M.10 Flow Cytometry Analysis
All flow cytometry analysis was performed using FlowJo software (Treestar). In nearly all
cases, cell gatings were performed in the following order: (1) FSC/SSC for non-debris
populations (2) FCS-A vs. FSC-H for non-doublet population (3) CD8' fraction (4) PI- or
DAPI- viable cell fraction (5) additional markers.
M.11 Western Blot Analysis of Total Protein Expression
T-cells were cultured in cytokine-free media for 16 hours, and viable T-cells were isolated by
Ficoll-Paque Plus gradient separation (GE Healthcare). T-cells were lysed in RIPA lysis
buffer (Thermo Scientific) containing PhosStop Phosphotase Inhibitor, Complete Mini
Protease Inhibitor (Roche) and 0.1 M PMSF. Lysates equivalent to 6x0 cells were subjected
to SDS-PAGE (Invitrogen). Western blots transferred onto nitrocellulose were probed with
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primary antibodies against Stat5 (1:1000, Becton Dickinson), f-actin (1:10000) and GSK3
(1:1000) (both Cell Signaling Technologies) in Licor blocking buffer (Licor Biosciences)
overnight at 4oC, washed 3x with PBS with 0.1% Tris (PBS-T) for 10minutes, probed with
Infrared secondary antibodies (1:10000 Licor Biosciences), washed 3x with PBS with 0.1%
Tris (PBS-T) for 10minutes and imaged on the LICOR Odyssey Infrared Imaging system
(Licor Biosciences).
M.12 Glucose Uptake
Glucose uptake was measured as previously described [14] with minor modifications. T-cells
were cultured for 24 hours in presence or absence of 10 ng/mL IL-7. Viable cells were
isolated by Ficoll-Paque Plus gradient separation. T-cells (8.5x10) were incubated for 30
minutes in serum- and glucose-free RPMI 1640 media. Glucose uptake was initiated by
adding labeled 2-deoxy-D[1- 3H] glucose (Amersham Pharmacia Biosciences) to a final
concentration of 0.1mM (4 pCi/mL). Cells were incubated for 45 minutes at 37"C, washed
3x in cold glucose- and serum-free RPMI 1640 media and solubilized in 525 pIL of 1% SDS.
Radioactivity in 470 pL of the sample was measured by liquid scintillation.
M.13 Adoptive Transfer Assays
For all experiments involving adoptive transfer of T-cells, purified naive CD8' T-cells were
resuspended in Hank's buffered salt solution and injected retro-orbitally into age- and sex-
matched recipients. Unless otherwise indicated, ~1x10 6 cells were injected in -100uL.
M.14 In vivo IL-7 Addition
In vivo addition of IL-7 or PBS was done by subcutaneous implantation of mini-osmotic
pumps which release 0.5 pIL/hr over 7 days (#1007D, Alzet). Prior to implantation, pumps
were filled with 100 pL of PBS or PBS containing 5 pg of IL-7 (Peprotech). Pumps were
implanted into a 2 cm long subcutaneous pocket inside a 0.5 mm mid-scapular incision over
the right flank and closed using a wound clip with application of a Betadine* antiseptic on
the incisions site. Lymph nodes and spleen were harvested after 7 days.
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M.15 In vivo IL-7 Depletion
In vivo IL-7 depletion was achieved by i.p. injection of 1mg anti-IL-7 antibody M25 or the
mouse IgG2b isotype MPC- 11 ( BioXCel) every other day for two weeks (days 0, 2, 4, 6, 8,
10, 12). Lymph nodes and spleen were harvested after 14 days.
M.16 Bioassay for Comparison of in vivo IL-7 Levels Across Mice
Purified Thyl.1' 2C TCR-tg naive CD8* T-cells (-10) were adoptively transferred into
syngeneic Thyl.2* mice and the relative IL-7 levels in vi*o in different recipients were
determined by comparing IL-7Ra and CD8X expression on the Thy1.1* donor cells
recovered from the recipient spleens and lymph nodes after 18 hours. A minimum of three
mice of each genotype (B6, OT1 Rag', 2C Rag', F5 Rag-, Rag') were examined for each
experiment.
M.17 Plasmids & Virus Production
Coding sequence for the full-length mIL-7R was cloned into the pMIG vector (MSCV-
IRES-GFP) by Vinay Mahajan, designated Mig7vsm. A second supposedly identical
construct was also obtained from the Scott Durum's lab, designated Mig7sd. For production
of virus, 293FT / cells were transfected with 2 ug transfer vector, lug MLV gag-pol and lug
VSVg expression vectors using Fugene 6 (Roche) per the manufacturer's protocols. Medium
was changed 24 h after transfection. After 48 h, media was collected, passed through a
0.45uM filter and ultracentrifuged to concentrate virus. To titer the virus and demonstrate all
constructs were expressed on surface of murine cells, 584 cells [172] were transfected with
retrovirus supernatants and 4ug/mL polybrene for 24 hours and surface IL-7Rx and GFP
expression subsequently measured by flow cytometry. Virus titers were determined to be
approximately -7x10 4 /uL (Mig7sd) and 5x10 4 /uL (Mig7vsm).
M.18 Amaxa Transfection of Naive T-Cells
106 F5 T-cells freshly isolated from lymph nodes were transfected with pMaxGFP (2.5ug),
Mig7sd (4ug) or Mig7vsm (4ug) vectors by electroporation using the Amaxa T-Cell
Nucleofactor Kit (VPA-1006, Lonza) as per the manufacturer's directions. Transfected cells
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were rested for 24 hours in media with or without 10 ng/mL for 24 hours prior to cell
surface staining and detection by flow cytometry.
M.19 Spin Infection of in vitro Memory Cells
Memory cells were generated as described in Section M.5 with the following changes. At
24h and 48h after activation (plating on anti-CD3 or addition of PMA/Ionomvcin), Mig7sd
or Mig7vsm was added to cells at an MOI of 10. The culture plate was sealed with saran
wrap and spun at 10OOg for 90 minutes. Cells were placed back in culture at 37'C and 5%
CO2, and cells were washed 3x with media and resuspended in fresh media (with IL-2 as
indicated) 24 hours after each infection.
M.20 F5 Retroviral IL-7R a Overexpressing Bone Marrow Chimeras
Purified F5 bone marrow stem cells were isolated according to procedures previously
described (Zhang CC et al Nature med 2006). In brief, bone marrow was isolated from the
femur and tibia of F5 mice and made into single cell suspensions. The stem cell fraction was
enriched by depleting cells with the following surface markers by magnetic separation
(MACS): Ter119 (erythroid), CD11b (macrophage), Gr1 (myeloid), CD8 (T lymphoid),
CD19 (B lymphoid), DX5 (NK cells), using ~1uL antibody per 4x10 6 total cells. Purified
cells were plated at low density (10000 cells/150uL ) in a U-bottom 96-well plate in
stemspan serum-free medium (StemCell Technologies) supplemented with 10ug/mL heparin
(Sigma), 10ng/mL mouse SCF, 20ngmL mouse TPO, 20ng/mL mouse IGF-2 (all from
R&D systems) and 10ng/mL human FGF-1 (Invitrogen), (STIF medium) with 100ng/mL
Flag Angptl2. Cells were infected with Mig7sd, Mig7vsm or an empty control vector (MOI-
=10) with 4ug/mL polybrene at 2 and 3 days after cell isolation. After 7 days in culture, cells
were washed and resuspended in HBSS, and checked for the presence of GFP* expressing
fractions. Expanded cells were then retroorbitally injected into sublethally irradiated (600
Rad) Rag- hosts (~10' cells/mouse). Bone marrow chimeras were produced for each of the
two Migs7d and Mig7vsm virus preparations, for a total of ~30 mice. Tail bleeds of mice 6
weeks later showed ~18 mice with significant CD8' peripheral reconstitution, and GFP*
fractions ranged from 30-70%. Mature cells were then isolated from the lymph nodes and
spleen 8 weeks after adoptive transfer for analysis.
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M.21 Pulsed versus Sustained Signaling Treatments
Purified naive (CD44'") OT1 and F5 T-Cells were rested overnight in cytokine-free media.
Cells were resuspended in media with varying concentrations of IL-7 (0,0.0001-100ng/mL)
at ~5x10 4 cells/150uL in a 96-well plate. After 1 or 4 hours in culture, 'pulsed' treatment
samples were washed 3x with 200uL of cytokine-free media and resuspended in 200uL of
cvtokine-free media for the remainder of culture (24 or 48 hours). 'Sustained' samples did
not received media changes, but were centrifuged and resuspended alongside pulsed samples
during washings.
M.22 In vitro IL-7 Depletion Measurements
T-cells were rested overnight in cytokine free media and then suspended at Ox, 1x, 2x, or 3x
3.3x105 cells/mL and cultured with O.lng/mL of IL-7 for 24h. After 24 hours, supernatant
media was collected and IL-7 remaining in cell containing versus cell free cultures measured
by ELISA (R&D Systems). IL-7Ra surface expression and viability of cells in cultures were
assayed by flow cytometry.
M.23 Statistical Analysis
Prism software was used for statistical analyses. P-values were calculated with two-tailed
Student's t-test. P-values of less than 0.05 were considered significant.
M.24 Mathematical Modeling Analysis
Ordinary differential equation models were executed using the Matlab software package (The
Mathworks).
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Appendix
A.1 Model Reaction Schemes for Chapter 3
The model reaction schemes and parameter values used to generate the plots for the figures
presented in Chapter 3 are outlined below. These schemes are manifestly idealized in a
highly simplified manner with many major approximations and assumptions. Some aspects
of the network topology are not fully characterized and many of the system parameters are
undetermined or poorly defined, so model results represent merely a reasonably
conceptualized set of outcomes. These models should therefore not be considered
simulations of true system function, but rather theoretical explorations of the modulation of
system behavior that could arise from effects of various network interaction processes. In
each case, simplifying assumptions and parameter values have been selected to highlight the
key effects explored in that particular figure. We believe that these explorations raise
interesting and potentially significant hypotheses that could motivate more in-depth and
detailed modeling and quantitative experimental efforts in this system.
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Figure 3.2
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Figure 3.3
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Figure 3.4
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Figure 3.5
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Figure 3.6
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Figure 3.7
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Figure 3.8
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k~synthnaive non-altruistic activated = 10min-'
k~synthatruistic activated = 1min
k_in_synth = 0.00 1
IL7_prod =0.005 nM min-
Cell-prod = 108 L' mn-
k_expand = 0.0015 min-
k-sig-deg = 0.003min-'
k death = 0.002min~
k death activated = 0.000004 in-
k in death = 0.001
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